WO2006138257A2 - Single molecule arrays for genetic and chemical analysis - Google Patents
Single molecule arrays for genetic and chemical analysis Download PDFInfo
- Publication number
- WO2006138257A2 WO2006138257A2 PCT/US2006/022895 US2006022895W WO2006138257A2 WO 2006138257 A2 WO2006138257 A2 WO 2006138257A2 US 2006022895 W US2006022895 W US 2006022895W WO 2006138257 A2 WO2006138257 A2 WO 2006138257A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- array
- spaced apart
- discrete spaced
- concatemers
- target
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/682—Signal amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Electro-optical investigation, e.g. flow cytometers
- G01N15/1404—Fluid conditioning in flow cytometers, e.g. flow cells; Supply; Control of flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Electro-optical investigation, e.g. flow cytometers
- G01N15/1434—Electro-optical investigation, e.g. flow cytometers using an analyser being characterised by its optical arrangement
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/151—Modifications characterised by repeat or repeated sequences, e.g. VNTR, microsatellite, concatemer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/30—Oligonucleotides characterised by their secondary structure
- C12Q2525/313—Branched oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/125—Rolling circle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/50—Detection characterised by immobilisation to a surface
- C12Q2565/513—Detection characterised by immobilisation to a surface characterised by the pattern of the arrayed oligonucleotides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/778—Nanostructure within specified host or matrix material, e.g. nanocomposite films
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/789—Of specified organic or carbon-based composition in array format
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/789—Of specified organic or carbon-based composition in array format
- Y10S977/79—Of specified organic or carbon-based composition in array format with heterogeneous nanostructures
- Y10S977/791—Molecular array
- Y10S977/792—Nucleic acid array, e.g. human genome array
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/84—Manufacture, treatment, or detection of nanostructure
- Y10S977/88—Manufacture, treatment, or detection of nanostructure with arrangement, process, or apparatus for testing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/84—Manufacture, treatment, or detection of nanostructure
- Y10S977/882—Assembling of separate components, e.g. by attaching
Definitions
- the present invention relates to methods and compositions for high-throughput analysis of populations of individual molecules, and more particularly, to methods and compositions related to fabrication of single molecule arrays and applications thereof, especially in high-throughput nucleic acid sequencing and genetic analysis.
- Such arrays play a key role in most currently available, or emerging, large-scale genetic analysis and proteomic techniques, including those for single nucleotide polymorphism detection, copy number assessment, nucleic acid sequencing, and the like, e.g. Kennedy et al (2003), Nature Biotechnology, 21: 1233-1237; Gunderson et al (2005), Nature Genetics, 37: 549-554; Pinkel and Albertson (2005), Nature Genetics Supplement, 37: Sl 1-S17; Leamon et al (2003), Electrophoresis, 24: 3769-3777; Shendure et al (2005), Science, 309: 1728-1732; Cowie et al (2004), Human Mutation, 24: 261-271; and the like.
- compositions of the invention in one form include random arrays of a plurality of different single molecules disposed on a surface, where the single molecules each comprise a macromolecular structure and at least one analyte, such that each macromolecular structure comprises a plurality of attachment functionalities that are capable of forming bonds with one or more functionalities on the surface.
- the analyte is a component of the macromolecular structure, and in another aspect, the analyte is attached to the macromolecular structure by a linkage between a unique functionality on such structure and a reactive group or attachment moiety on the analyte.
- compositions of the invention include random arrays of single molecules disposed on a surface, where the single molecules each comprise a concatemer of at least one target polynucleotide and each is attached to the surface by linkages formed between one or more functionalities on the surface and complementary functionalities on the concatemer.
- compositions of the invention include random arrays of single molecules disposed on a surface, where the single molecules each comprise a concatemer of at least one target polynucleotide and at least one adaptor oligonucleotide and each is attached to such surface by the formation of duplexes between capture oligonucleotides on the surface and the attachment oligonucleotides in the concatemer.
- compositions of the invention include random arrays of single molecules disposed on a surface, where each single molecule comprises a bifunctional macromolecular structure having a unique functionality and a plurality of complementary functionalities, and where each single molecule is attached to the surface by linkages between one or more functionalities on the surface and complementary functionalities on the bifunctional macromolecular structure, the unique functionality having an orthogonal chemical reactivity with respect to the complementary functionalities and being capable of forming a covalent linkage with an analyte.
- such single molecules are disposed in a planar array randomly distributed onto discrete spaced apart regions having defined positions.
- the discrete spaced apart regions each have an area that permits the capture of no more than a single molecule and each is surrounded by an inter-regional space that is substantially free of other single molecules.
- the invention includes an array of polymer molecules comprising: (a) a support having a surface; and (b) a plurality of polymer molecules attached to the surface, wherein each polymer molecule has a random coil state and comprises a branched or linear structure of multiple copies of one or more linear polymeric units, such that the polymer molecule is attached to the surface within a region substantially equivalent to a projection of the random coil on the surface and randomly disposed at a density such that at least thirty percent of the polymer molecules are separately detectable.
- substantially equivalent in reference to the above projection means a substantially circular region with a diameter equal to the root mean square of the end-to-end distance of such linear polymer, hi another embodiment, for linear or branched polymers, "substantially equivalent” means a substantially circular region having a diameter that is one half or less than the total length of the polymer; or in another embodiment one tenth or less; or in another embodiment, one hundredth or less.
- the invention includes an array of polynucleotide molecules comprising: (a) a support having a surface; and (b) a plurality of polynucleotide molecules attached to the surface, wherein each polynucleotide molecule has a random coil state and comprises a concatemer of multiple copies of a target sequence such that the polynucleotide molecule is attached to the surface within a region substantially equivalent to a projection of the random coil on the surface and randomly disposed at a density such that at least thirty percent of the polynucleotide molecules have a nearest neighbor distance of at least fifty nm.
- the invention provides an array of single molecules comprising: (a) a support having a planar surface having a regular array of discrete spaced apart regions, wherein each discrete spaced apart region has an area of less than 1 ⁇ m 2 and contains reactive functionalities attached thereto; and (b) a plurality of single molecules attached to the surface, wherein each single molecule comprises a macromolecular structure and at least one analyte having an attachment moiety , such that each macromolecular structure comprises a unique functionality and a plurality of attachment functionalities that are capable of forming linkages with the reactive functionalities of the discrete spaced apart regions, and such that the analyte is attached to the macromolecular structure by a linkage between the unique functionality and the attachment moiety of the analyte, wherein the plurality of single molecules are randomly disposed on the discrete spaced apart regions such that at least a majority of the discrete spaced apart regions contain only one single molecule.
- the invention provides an array of polynucleotide molecules comprising: (a) a support having a surface with capture oligonucleotides attached thereto; and (b) a plurality of polynucleotide molecules attached to the surface, wherein each polynucleotide molecule comprises a concatemer of multiple copies of a target sequence and an adaptor oligonucleotide such that the polynucleotide molecule is attached to the surface by one or more complexes formed between capture oligonucleotides and adaptor oligonucleotides, the polynucleotide molecules being randomly disposed on the surface at a density such that at least a majority of the polynucleotide molecules have a nearest neighbor distance of at least fifty nm.
- the surface is a planar surface having an array of discrete spaced apart regions, wherein each discrete spaced apart region has a size equivalent to that of the polynucleotide molecule and contains the capture oligonucleotides attached thereto and wherein substantially all such regions have at most one of the polynucleotide molecules attached.
- the invention further includes, a method of making an array of polynucleotide molecules comprising the following steps: (a) generating a plurality of polynucleotide molecules each comprising a concatemer of a DNA fragment from a source DNA and an adaptor oligonucleotide; and (b) disposing the plurality of polynucleotide molecules onto a support having a surface with capture oligonucleotides attached thereto so that the polynucleotide molecules are fixed to the surface by one or more complexes formed between capture oligonucleotides and adaptor oligonucleotides and so that the polynucleotide molecules are randomly distributed on the surface at a density such that a majority of the polynucleotide molecules have a nearest neighbor distance of at least fifty nm, thereby forming the array of polynucleotide molecules.
- the invention provides a method of determining a nucleotide sequence of a target polynucleotide, the method comprising the steps of: (a) generating a plurality of target concatemers from the target polynucleotide, each target concatemer comprising multiple copies of a fragment of the target polynucleotide and the plurality of target concatemers including a number of ⁇ fragments that substantially covers the target polynucleotide; (b) forming a random array of target concatemers fixed to a surface at a density such that at least a majority of the target concatemers are optically resolvable; (c) identifying a sequence of at least a portion of each fragment in each target concatemer; and (d) reconstructing the nucleotide sequence of the target polynucleotide from the identities of the sequences of the portions of fragments of the concatemers.
- the step of identifying includes the steps of (a) hybridizing one or more probes from a first set of probes to the random array under conditions that permit the formation of perfectly matched duplexes between the one or more probes and complementary sequences on target concatemers; (b) hybridizing one or more probes from a second set of probes to the random array under conditions that permit the formation of perfectly matched duplexes between the one or more probes and complementary sequences on target concatemers; (c) ligating probes from the first and second sets hybridized to a target concatemer at contiguous sites; (d) identifying the sequences of the ligated first and second probes; and (e) repeating steps (a through (d) until the sequence of the target polynucleotide can be determined from the identities of the sequences of the ligated probes.
- the invention includes kits for making random arrays of the invention and for implementing applications of the random arrays of the invention, particularly high-throughput analysis of one or more target polynucleotides.
- the present invention provides a significant advance in the microarray field by providing arrays of single molecules comprising linear and/or branched polymer structures that may incorporate or have attached target analyte molecules.
- such single molecules are concatemers of target polynucleotides arrayed at densities that permit efficient high resolution analysis of mammalian-sized genomes, including sequence determination of all or substantial parts of such genomes, sequence determination of tagged fragments from selected regions of multiple genomes, digital readouts of gene expression, and genome-wide assessments of copy number patterns, methylation patterns, chromosomal stability, individual genetic variation, and the like.
- Figs. IA-I I illustrate various embodiments of the methods and compositions of the invention.
- Figs. 2A-2B illustrate methods of circularizing genomic DNA fragments for generating concatemers of polynucleotide analytes.
- Fig. 3 is an image of a glass surface containing a disposition of concatemers of E. coli fragments.
- Fig. 4 is an image of concatemers derived from two different organisms that are selectively labeled using oligonucleotide probes.
- Fig. 5 is an image of concatemers of DNA fragments that contain a degenerated base, each of which is identified by a specific ligation probe.
- Fig. 6 is an image of concatemers of DNA fragments that contain a segment of degenerate bases, pairs of which are identified by specific probes.
- Fig. 7 is a scheme for identifying sequence differences between reference sequences and test sequences using enzymatic mismatch detection and for constructing DNA circles therefrom.
- Fig. 8 is another for identifying sequence differences between a reference sequence and a test sequence using enzymatic mismatch detection and for constructing DNA circles therefrom.
- the practice of the present invention may employ, unless otherwise indicated, conventional techniques and descriptions of organic chemistry, polymer technology, molecular biology (including recombinant techniques), cell biology, biochemistry, and immunology, which are within the skill of the art.
- Such conventional techniques include polymer array synthesis, hybridization, ligation, and detection of hybridization using a label. Specific illustrations of suitable techniques can be had by reference to the example herein below. However, other equivalent conventional procedures can, of course, also be used.
- Such conventional techniques and descriptions can be found in standard laboratory manuals such as Genome Analysis: A Laboratory Manual Series (VoIs.
- the invention provides random single molecule arrays for large-scale parallel analysis of populations of molecules, particularly DNA fragments, such as genomic DNA fragments.
- single molecules of the invention comprise an attachment portion and an analyte portion.
- the attachment portion comprises a macromolecular structure that provides for multivalent attachment to a surface, particularly a compact or restricted area on a surface so that signals generated from it or an attached analyte are concentrated. That is, the macromolecular structure occupies a compact and limited region of the surface.
- Macromolecular structures of the invention may be bound to a surface in a variety of ways. Multi-valent bonds may be covalent or non-covalent.
- Non-covalent bonds include formation of duplexes between capture oligonucleotides on the surface and complementary sequences in the macromolecular structure, and adsorption to a surface by attractive noncovalent interactions, such as Van der Waal forces, hydrogen bonding, ionic and hydrophobic interactions, and the like.
- Multi-valent covalent bonding may be accomplished, as described more fully below, by providing reactive functionalities on the surface that can reactive with a plurality of complementary functionalities in the macromolecular structures.
- An analyte portion may be attached to a macromolecular structure by way of a unique linkage or it may form a part of, and be integral with, the macromolecular structure.
- Single molecules of the invention are disposed randomly on a surface of a support material, usually from a solution; thus, in one aspect, single molecules are uniformly distributed on a surface in close approximation to a Poisson distribution. In another aspect, single molecules are disposed on a surface that contains discrete spaced apart regions in which single molecules are attached. Preferably, macromolecular structures, preparation methods, and areas of such discrete spaced apart regions are selected so that substantially all such regions contain at most only one single molecule. Preferably, single molecules of the invention, particularly concatemers, are roughly in a random coil configuration on a surface and are confined to the area of a discrete spaced apart region.
- the discrete space apart regions have defined locations in a regular array, which may correspond to a rectilinear pattern, hexagonal pattern, or the like.
- a regular array of such regions is advantageous for detection and data analysis of signals collected from the arrays during an analysis.
- single molecules confined to the restricted area of a discrete spaced apart region provide a more concentrated or intense signal, particularly when fluorescent probes are used in analytical operations, thereby providing higher signal-to-noise values.
- Single molecules of the invention are randomly distributed on the discrete spaced apart regions so that a given region usually is equally likely to receive any of the different single molecules. In other words, the resulting arrays are not spatially addressable immediately upon fabrication, but may be made so by carrying out an identification or decoding operation.
- the identities of the single molecules are discernable, but not known.
- there are subsets of discrete spaced apart regions that receive single molecules only from corresponding subsets for example, as defined by complementary sequences of capture oligonucleotides and adaptor oligonucleotides.
- Macromolecular structures of the invention comprise polymers, either branched or linear, and may be synthetic, e.g. branched DNA, or may be derived from natural sources, e.g linear DNA fragments from a patient's genomic DNA.
- macromolecular structures comprise concatemers of linear single stranded DNA fragments that can be synthetic, derived from natural sources, or can be a combination of both.
- target sequence refers to either a synthetic nucleic acid or a nucleic acid derived from a natural source, such as a patient specimen, or the like.
- target sequences are part of a concatemer generated by methods of the invention, e.g.
- target sequences are synthetic or derived from natural sources, they are usually replicated by various methods in the process of forming macromolecular structures or single molecules of the invention. It is understood that such methods can introduce errors into copies, which nonetheless are encompassed by the term "target sequence.”
- macromolecular structures may be selected to satisfy a variety of design objectives in particular embodiments. For example, in some embodiments, it may be advantageous to maintain an analyte molecule as far from the surface as possible, e.g. by providing an inflexible molecular spacer as part of a unique linkage. As another example, reactive functionalities may be selected as having a size that effectively prevents attachment of multiple macromolecular structures to one discrete spaced apart region. As still another example, macromolecular structures may be provided with other functionalities for a variety of other purposes, e.g. enhancing solubility, promoting formation of secondary structures via hydrogen bonding, and the like.
- macromolecular structures are sufficiently large that their size, e.g. a linear dimension (such as a diameter) of a volume occupied in a conventional physiological saline solution, is approximately equivalent to that a discrete spaced apart region.
- sizes may range from a few thousand nucleotides, e.g. 10,000, to several hundred thousand nucleotides, e.g. 100-200 thousand.
- such macromolecular structures are made by generating circular DNAs and then replicating them in a rolling circle replication reaction to form concatemers of complements of the circular DNAs.
- macromolecular structures of the invention are single stranded polynucleotides comprising concatemers of a target sequence or fragment.
- polynucleotides may be concatemers of a target sequence and an adaptor oligonucleotide.
- source nucleic acid (1000) is treated (1001) to form single stranded fragments (1006), preferably in the range of from 50 to 600 nucleotides, and more preferably in the range of from 300 to 600 nucleotides, which are then ligated to adaptor oligonucleotides (1004) to form a population of adaptor-fragment conjugates (1002).
- Source nucleic acid (1000) may be genomic DNA extracted from a sample using conventional techniques, or a cDNA or genomic library produced by conventional techniques, or synthetic DNA, or the like.
- Treatment (1001) usually entails fragmentation by a conventional technique, such as chemical fragmentation, enzymatic fragmentation, or mechanical fragmentation, followed by denaturation to produce single stranded DNA fragments.
- Adaptor oligonucleotides (1004), in this example, are used to form (1008) a population (1010) of DNA circles by the method illustrated in Fig. 2A.
- each member of population (1010) has an adaptor with an identical primer binding site and a DNA fragment from source nucleic acid (1000).
- the adapter also may have other functional elements including, but not limited to, tagging sequences, attachment sequences, palindromic sequences, restriction sites, functionalization sequences, and the like.
- classes of DNA circles may be created by providing adaptors having different primer binding sites.
- a primer and rolling circle replication (RCR) reagents may be added to generate (1011) in a conventional RCR reaction a population (1012) of concatemers (1015) of the complements of the adaptor oligonucleotide and DNA fragments, which population can then be isolated using conventional separation techniques.
- RCR may be implemented by successive ligation of short oligonucleotides, e.g. 6-mers, from a mixture containing all possible sequences, or if circles are synthetic, a limited mixture of oligonucleotides having selected sequences for circle replication.
- Concatemers may also be generated by ligation of target DNA in the presence of a bridging template DNA complementary to both beginning and end of the target molecule.
- a population of different target DNA may be converted in concatemers by a mixture of corresponding bridging templates.
- Isolated concatemers (1014) are then disposed (1016) onto support surface (1018) to form a random array of single molecules. Attachment may also include wash steps of varying stringencies to remove incompletely attached single molecules or other reagents present from earlier preparation steps whose presence is undesirable or that are nonspecifically bound to surface (1018).
- Concatemers (1020) can be fixed to surface (1018) by a variety of techniques, including covalent attachment and non-covalent attachment.
- surface (1018) may have attached capture oligonucleotides that form complexes, e.g.
- capture oligonucleotides may comprise oligonucleotide clamps, or like structures, that form triplexes with adaptor oligonucleotides, e.g. Gryaznov et al, U.S. patent 5,473,060.
- surface (1018) may have reactive functionalities that react with complementary functionalities on the concatemers to form a covalent linkage, e.g. by way of the same techniques used to attach cDNAs to microarrays, e.g.
- DNA molecules e.g. several hundred nucleotides or larger, may also be efficiently attached to hydrophobic surfaces, such as a clean glass surface that has a low concentration of various reactive functionalities, such as -OH groups. Concatemers of DNA fragments may be further amplified in situ after disposition of a surface.
- concatemer may be cleaved by reconstituting a restriction site in adaptor sequences by hybridization of an oligonucleotide, after which the fragments are circularized as described below and amplified in situ by a RCR reaction.
- Fig. IB illustrates a section (1102) of a surface of a random array of single molecules, such as single stranded polynucleotides.
- Such molecules under conventional conditions (a conventional DNA buffer, e.g. TE, SSC, SSPE, or the like, at room temperature) form random coils that roughly fill a spherical volume in solution having a diameter of from about 100 to 300 nm, which depends on the size of the DNA and buffer conditions, in a manner well known in the art, e.g. Edvinsson, "On the size and shape of polymers and polymer complexes," Dissertation 696 (University of Uppsala, 2002).
- a conventional DNA buffer e.g. TE, SSC, SSPE, or the like
- a random coil polymer such as single stranded DNA
- a root mean square of the end-to-end distance is roughly a measure of the diameter of the randomly coiled structure.
- Such diameter referred to herein as a "random coil diameter”
- Additional size measures of macromolecular structures of the invention include molecular weight, e.g. in Daltons, and total polymer length, which in the case of a branched polymer is the sum of the lengths of all its branches.
- polynucleotides Upon attachment to a surface, depending on the attachment chemistry, density of linkages, the nature of the surface, and the like, single stranded .
- polynucleotides fill a flattened spheroidal volume that on average is bounded by a region (1107) defined by dashed circles (1108) having a diameter (1110), which is approximately equivalent to the diameter of a concatemer in random coil configuration.
- macromolecular structures e.g. concatemers, and the like, are attached to surface (1102) within a region that is substantially equivalent to a projection of its random coil state onto surface (1102), for example, as illustrated by dashed circles (1108).
- An area occupied by a macromolecular structure can vary, so that in some embodiments, an expected area may be within the range of from 2-3 times the area of projection (1108) to some fraction of such area, e.g. 25-50 percent.
- an expected area may be within the range of from 2-3 times the area of projection (1108) to some fraction of such area, e.g. 25-50 percent.
- probes e.g. fluorescently labeled oligonucleotides, specifically directed to components of a macromolecular structure or concatemer.
- the size of diameter (1110) of regions (1107) and distance (1106) to the nearest neighbor region containing a single molecule are two quantities of interest in the fabrication of arrays.
- a variety of distance metrics may be employed for measuring the closeness of single molecules on a surface, including center-to-center distance of regions (1107), edge-to-edge distance of regions (1007), and the like. Usually, center-to-center distances are employed herein.
- the selection of these parameters in fabricating arrays of the invention depends in part on the signal generation and detection systems used in the analytical processes. Generally, densities of single molecules are selected that permit at least twenty percent, or at least thirty percent, or at least forty percent, or at least a majority of the molecules to be resolved individually by the signal generation and detection systems used. In one aspect, a density is selected that permits at least seventy percent of the single molecules to be individually resolved.
- a density is selected such that at least a majority of single molecules have a nearest neighbor distance of 50 run or greater; and in another aspect, such density is selected to ensure that at least seventy percent of single molecules have a nearest neighbor distance of 100 nm or greater.
- a density is selected such that at least a majority of single molecules have a nearest neighbor distance of 200 nm or greater; and in another aspect, such density is selected to ensure that at least seventy percent of single molecules have a nearest neighbor distance of 200 nm or greater.
- a density is selected such that at least a majority of single molecules have a nearest neighbor distance of 300 nm or greater; and in another aspect, such density is selected to ensure that at least seventy percent of single molecules have a nearest neighbor distance of 300 nm or greater, or 400 nm or greater, or 500 nm or greater, or 600 nm or greater, or 700 run or greater, or 800 nm or greater.
- a density is selected such that at least a majority of single molecules have a nearest neighbor distance of at least twice the minimal feature resolution power of the microscope.
- polymer molecules of the invention are disposed on a surface so that the density of separately detectable polymer molecules is at least 1000 per ⁇ m 2 , or at least 10,000 per ⁇ m 2 , or at least 100,000 per ⁇ m 2 .
- inter-regional areas are inert in the sense that concatemers, or other macromolecular structures, do not bind to such regions.
- blocking agents e.g. DNAs unrelated to concatemer DNA, other polymers, and the like.
- source nucleic acids (1000) are fragmented and adaptored (1002) for circularization (1010), after which concatemers are formed by RCR (1012).
- Isolated concatemers (1014) are then applied to surface (1120) that has a regular array of discrete spaced apart regions (1122) that each have a nearest neighbor distance (1 124) that is determined by the design and fabrication of surface (1120).
- arrays of discrete spaced apart regions (1122) having micron and submicron dimensions for derivatizing with capture oligonucleotides or reactive functionalities can be fabricated using conventional semiconductor fabrication techniques, including electron beam lithography, nano imprint technology, photolithography, and the like.
- the area of discrete spaced apart regions (1122) is selected, along with attachment chemistries, macromolecular structures employed, and the like, to correspond to the size of single molecules of the invention so that when single molecules are applied to surface (1120) substantially every region (1122) is occupied by no more than one single molecule.
- the likelihood of having only one single molecule per discrete spaced apart region may be increased by selecting a density of reactive functionalities or capture oligonucleotides that results in fewer such moieties than their respective complements on single molecules.
- a single molecule will "occupy" all linkages to the surface at a particular discrete spaced apart region, thereby reducing the chance that a second single molecule will also bind to the same region.
- substantially all the capture oligonucleotides in a discrete spaced apart region hybridize to adaptor oligonucleotides a single macromolecular structure.
- a discrete spaced apart region contains a number of reactive functionalities or capture oligonucleotides that is from about ten percent to about fifty percent of the number of complementary functionalities or adaptor oligonucleotides of a single molecule.
- the length and sequence(s) of capture oligonucleotides may vary widely, and may be selected in accordance with well known principles, e.g.
- the lengths of capture oligonucleotides are in a range of from 6 to 30 nucleotides, and in another aspect, within a range of from 8 to 30 nucleotides, or from 10 to 24 nucleotides.
- Lengths and sequences of capture oligonucleotides are selected (i) to provide effective binding ofmacromolecular structures to a surface, so that losses of macromolecular structures are minimized during steps of analytical operations, such as washing, etc., and (ii) to avoid interference with analytical operations on analyte molecules, particularly when analyte molecules are DNA fragments in a concatemer.
- sequences and lengths are selected to provide duplexes between capture oligonucleotides and their complements that are sufficiently stable so that they do not dissociate in a stringent wash.
- a discrete spaced apart region may contain more than one kind of capture oligonucleotide, and each different capture oligonucleotide may have a different length and sequence.
- sequences of capture oligonucleotides are selected so that sequences of capture oligonucleotide at nearest neighbor regions have different sequences.
- sequences of capture oligonucleotide at nearest neighbor regions have different sequences.
- a rectilinear array such configurations are achieved by rows of alternating sequence types.
- a surface may have a plurality of subarrays of discrete spaced apart regions wherein each different subarray has capture oligonucleotides with distinct nucleotide sequences different from those of the other subarrays.
- a plurality of subarrays may include 2 subarrays, or 4 or fewer subarrays, or 8 or fewer subarrays, or 16 or fewer subarrays, or 32 or fewer subarrays, or 64 of fewer subarrays.
- a surface may include 5000 or fewer subarrays.
- capture oligonucleotides are attached to the surface of an array by a spacer molecule, e.g. polyethylene glycol, or like inert chain, as is done with microarrays, in order to minimize undesired affects of surface groups or interactions with the capture oligonucleotides or other reagents.
- the area of discrete spaced apart regions (1 122) is less than 1 ⁇ m 2 ; and in another aspect, the area of discrete spaced apart regions (1 122) is in the range of from 0.04 ⁇ m 2 to 1 ⁇ m 2 ; and in still another aspect, the area of discrete spaced apart regions (1122) is in the range of from 0.2 ⁇ m 2 to 1 ⁇ m 2 . In another aspect, when discrete spaced apart regions are approximately circular or square in shape so that their sizes can be indicated by a single linear dimension, the size of such regions are in the range of from 125 nm to 250 nm, or in the range of from 200 nm to 500 nm.
- center-to-center distances of nearest neighbors of regions (1122) are in the range of from 0.25 ⁇ m to 20 ⁇ m; and in another aspect, such distances are in the range of from 1 ⁇ m to 10 ⁇ m, or in the range from 50 to 1000 nm.
- regions (1120) may be arranged on surface (1018) in virtually any pattern in which regions (1122) have defined locations, i.e. in any regular array, which makes signal collection and data analysis functions more efficient.
- Such patterns include, but are not limited to, concentric circles of regions (1122), spiral patterns, rectilinear patterns, hexagonal patterns, and the like.
- regions (1122) are arranged in a rectilinear or hexagonal pattern.
- DNA circles prepared from source nucleic acid (1200) need not include an adaptor oligonucleotide.
- source nucleic acid (1200) is fragmented and denatured (1202) to form a population of single strand fragments (1204), preferably in the size range of from about 50 to 600 nucleotides, and more preferably in the size range of from about 300 to 600 nucleotides, after which they are circularized in a non-template driven reaction with circularizing ligase, such as CircLigase (Epicentre Biotechnologies, Madison, WI), or the like.
- concatemers are generated by providing a mixture of primers that bind to selected sequences. The mixture of primers may be selected so that only a subset of the total number of DNA circles (1206) generate concatemers. After concatemers are generated (1208), they are isolated and applied to surface (1210) to form a random array of the invention.
- single molecules of the invention comprise an attachment portion and an analyte portion such that the attachment portion comprises a macromolecular structure that provides multivalent attachment of the single molecule to a surface.
- macromolecular structures may be concatemers made by an RCR reaction in which the DNA circles in the reaction are synthetic.
- An analyte portion of a single molecule is then attached by way of a unique functionality on the concatemer.
- Synthetic DNA circles of virtually any sequence can be produced using well- known techniques, conveniently, in sizes up to several hundred nucleotides, e.g. 200, and with more difficulty, in sizes of many hundreds of nucleotides, e.g. up to 500, e.g. Kool, U.S.
- Synthetic DNA circles (1300) that comprise primer binding sites (1301) are combined with primer (1302) in an RCR reaction (1306) to produce concatemers (1308).
- all circles have the same sequence, although different sequences can be employed, for example, for directing subsets of concatemers to preselected regions of an array via complementary attachment moieties, such as adaptor sequences and capture oligonucleotides.
- Primer (1302) is synthesized with a functionality (1304, designated as "R") at its 5' end that is capable of reacting with a complementary functionality on an analyte to form a covalent linkage.
- R a functionality
- exemplary functionalities include amino groups, sulfhydryl groups, and the like, that can be attached with commercially available chemistries (e.g. Glen
- Concatemers (1308) are applied to surface (1310) to form an array (1314), after which analytes (1312) having an attachment moiety are applied to array (1310) where a linkage is formed with a concatemer by reaction of unique functionalities, R (1311) and attachment moiety (1312).
- concatemers (1308) may be combined with analytes (1312) so that attachment moieties and unique functionalities can react to form a linkage, after which the resulting conjugate is applied to array (1310).
- concatemers (1308) can be linked to a sufhydryl group on an analyte using N- succinimidyl 3-(2-pyridyldithio)propionate (SPDP), succinimidyloxycarbonyl- ⁇ -methyl- ⁇ -(2- pyridyldithio)toluene (SMPT), succinimidyl-4-(N-maleimidomethyl)cyclohexane- 1 -carboxylate (SMCC), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), N-succinimidyl(4- iodoacetyl)aminobenzoate (SLAB), succinimidyl 6-((iodoacetyl)amino)hexanoate (SIAX), and like reagents.
- SPDP N- succinimidyl 3-(2-pyridyldithio)propionate
- SMPT succini
- Suitable complementary functionalities on analytes include amino groups, sulfhydryl groups, carbonyl groups, which may occur naturally on analytes or may be added by reaction with a suitable homo- or heterobifunctional reagent.
- Analyte molecules may also be attached to macromolecular structures by way of non-covalent linkages, such as biotin-streptavidin linkages, the formation of complexes, e.g. a duplexes, between a first oligonucleotide attached to a concatemer and a complementary oligonucleotide attached to, or forming part of, an analyte, or like linkages.
- Analytes include biomolecules, such as nucleic acids, for example, DNA or RNA fragments, polysaccharides, proteins, and the like.
- macromolecular structures of the invention may comprise branched polymers as well as linear polymers, such as concatemers of DNA fragments.
- Exemplary branched polymer structures are illustrated in Figs. IF and IG.
- a branched DNA structure is illustrated that comprises a backbone polynucleotide (1400) and multiple branch polynucleotides (1402) each connected to backbone polynucleotide (1400) by their 5' ends to form a comb-like structure that has all 3' ends, except for a single 5' end (1404) on backbone polynucleotide (1400), which is derivatized to have a unique functionality.
- such unique functionality may be a reactive chemical group, e.g. a protected or unprotected amine, sulfhydryl, or the like, or it may be an oligonucleotide having a unique sequence for capturing an analyte having an oligonucleotide with a complementary sequence thereto.
- such unique functionality may be a capture moiety, such as biotin, or the like.
- Such branched DNA structures are synthesized using known techniques, e.g. Gryaznov, U.S. patent 5,571,677; Urdea et al, U.S. patent 5,124,246; Seeman et al, U.S.
- a dentrimeric structure is illustrated that comprises oligonucleotide (1406), which is derivatized with multiple tri-valent linking groups (1408) that each have two functionalities (1410, designated by "R") by which additional polymers (1407), e.g. polynucleotides, can be attached to form a linkage to oligonucleotide (1406) thereby forming macromolecular structure (1409), which, in turn, if likewise derivatized with multivalent linkers, can form a nucleic acid dendrimer.
- Trivalent linkers (1408) for use with oligonucleotides are disclosed in Iyer et al, U.S. patent 5,916,750, which is incorporated herein by reference.
- dendrimeric or branched structures (1411) can be attached to array (1420) as described above for linear polynucleotides, after which analytes (1430) can be attached via unique functionalities (1410).
- unreacted unique functionalities (1422) may be capped using conventional techniques.
- dendrimeric or branched structures (1411) may be combined with analytes (1430) first, e.g. in solution, so that conjugates are formed, and then the conjugates are disposed on array (1420).
- the analyte is a polynucleotide (1440) with a free 3' end, as shown in Fig. II, such end may be extended in an in situ RCR reaction to form either concatemers of target sequences or other sequences for further additions.
- polynucleotide analytes may be extended by ligation using conventional techniques.
- macromolecular structures comprise concatemers of polynucleotide analytes, i.e. target sequences, which are extracted or derived from a sample, such as genomic DNA or cDNAs from a patient, an organism of economic interest, or the like.
- Random arrays of the invention comprising such single molecules are useful in providing genome-wide analyses, including sequence determination, SNP measurement, allele quantitation, copy number measurements, and the like.
- fragmentation is carried out in at least two stages, a first stage to generate a population of fragments in a size range of from about 100 kilobases (Kb) to about 250 kilobases, and a second stage, applied separately to each 100-250Kb fragment, to generate fragments in the size range of from about 50 to 600 nucleotides, and more preferably in the range of from about 300 to 600 nucleotides, for generating concatemers for a random array.
- the first stage of fragmentation may also be employed to select a predetermined subset of such fragments, e.g. fragments containing genes that encode proteins of a signal transduction pathway, or the like.
- fragments are generated from at least 10 genome-equivalents of DNA; and in another aspect, fragments are generated from at least 30 genome-equivalents of DNA; and in another aspect, fragments are generated from at least 60 genome-equivalents of DNA.
- Genomic DNA is obtained using conventional techniques, for example, as disclosed in Sambrook et al., supra, 1999; Current Protocols in Molecular Biology, Ausubel et al, eds.(John Wiley and Sons, Inc., NY, 1999), or the like.
- Important factors for isolating genomic DNA include the following: 1) the DNA is free of DNA processing enzymes and contaminating salts; 2) the entire genome is equally represented; and 3) the DNA fragments are between about 5,000 and 100,000 bp in length. In many cases, no digestion of the extracted DNA is required because shear forces created during lysis and extraction will generate fragments in the desired range. In another embodiment, shorter fragments (1-5 kb) can be generated by enzymatic fragmentation using restriction endonucleases.
- 10-100 genome-equivalents of DNA ensure that the population of fragments covers the entire genome.
- carrier DNA e.g. unrelated circular synthetic double- stranded DNA
- fragments may be derived from either an entire genome or it may be derived from a selected subset of a genome.
- Many techniques are available for isolating or enriching fragments from a subset of a genome, as exemplified by the following references that are incorporated by reference: Kandpal et al (1990), Nucleic Acids Research, 18: 1789-1795; Callow et al, U.S. patent publication 2005/0019776; Zabeau et al, U.S. patent 6,045,994; Deugau et al, U.S. patent 5,508,169; Sibson, U.S. patent 5,728,524; Guilfoyle et al, U.S.
- an initial fragmentation of genomic DNA can be achieved by digestion with one or more "rare" cutting restriction endonucleases, such as Not I, Asc I, Bae I, CspC I, Pac I, Fse I, Sap I, Sfi I, Psr I, or the like.
- the resulting fragments can be used directly, or for genomes that have been sequenced, specific fragments may be isolated from such digested DNA for subsequent processing as illustrated in Fig. 2B.
- Genomic DNA (230) is digested (232) with a rare cutting restriction endonuclease to generate fragments (234), after which the fragments (234) are further digested for a short period (i.e.
- biotinylated primers (241) specific for the ends of desired fragments can be annealed to a capture oligonucleotide for isolation; or alternatively, such fragments can be annealed to a primer having a capture moiety, such as biotin, and extended with a DNA polymerase that does not have strand displacement activity, such as Taq polymerase Stoffel fragment.
- primer extension from a genomic DNA template is used to generate a linear amplification of selected sequences greater than 10 kilobases surrounding genomic regions of interest.
- the reverse primer may be biotinylated for capture to streptavidin beads which can be heated to melt any double stranded homoduplexes from being captured. All attached molecules will be single stranded and representing one strand of the original genomic DNA.
- the products produced can be fragmented to 0.2-2 kb in size, or more preferably, 0.3-0.6 kb in size (effectively releasing them from the solid support) and circularized for an RCR reaction.
- genomic DNA 200
- denatured 202
- single stranded DNA fragments (204) are first treated with a terminal transferase (206) to attach a poly dA tails (208) to 3-prime ends.
- ligation 212 of the free ends intra-molecularly with the aid of bridging oligonucleotide (210).
- Duplex region (214) of bridging oligonucleotide (210) contains at least a primer binding site for RCR and, in some embodiments, sequences that provide complements to a capture oligonucleotide, which may be the same or different from the primer binding site sequence, or which may overlap the primer binding site sequence.
- capture oligonucleotides may vary widely, In one aspect, capture oligonucleotides and their complements in a bridging oligonucleotide have lengths in the range of from 10 to 100 nucleotides; and more preferably, in the range of from 10 to 40 nucleotides.
- duplex region (214) may contain additional elements, such as an oligonucleotide tag, for example, for identifying the source nucleic acid from which its associated DNA fragment came.
- circles or adaptor ligation or concatemers from different source nucleic acids may be prepared separately during which a bridging adaptor containing a unique tag is used, after which they are mixed for concatemer preparation or application to a surface to produce a random array.
- the associated fragments may be identified on such a random array by hybridizing a labeled tag complement to its corresponding tag sequences in the concatemers, or by sequencing the entire adaptor or the tag region of the adaptor.
- Circular products (218) may be conveniently isolated by a conventional purification column, digestion of non-circular DNA by one or more appropriate exonucleases, or both.
- DNA fragments of the desired sized range e.g. 50-600 nucleotides
- CircLigase as single stranded DNA ligase that circularizes single stranded DNA without the need of a template. CircLigase is used in accordance with the manufacturer's instructions (Epicentre, Madison, WI).
- a preferred protocol for forming single stranded DNA circles comprising a DNA fragment and one or more adapters is to use standard ligase such as T4 ligase for ligation an adapter to one end of DNA fragment and than to use CircLigase to close the circle, as described more fully below.
- An exemplary protocol for generating a DNA circle comprising an adaptor oligonucleotide and a target sequence using T4 ligase.
- the target sequence is a synthetic oligo TIN (sequence : 5'- " NNNNNNNNGCATANCACGANGTCATNATCGTNCAAACGTCAGTCCANGAATCNAGATCC ACTTAGANTGNCGNNNNNNNN- ⁇ 'XSEQ ID NO: 1).
- the adaptor is made up of 2 separate oligos.
- the adaptor oligo that joins to the 5' end of TIN is BR2-ad (sequence : 5'-
- TATCATCTGGATGTTAGGAAGACAAAAGGAAGCTGAGGACATTAACGGAC-S') (SEQ ID NO: 2) and the adaptor oligo that joins to the 3' end of TIN is UR3-ext (sequence : 5'- ACCTTCAGACCAGAT-3 ') (SEQ ID NO: 3)
- UR3-ext contains a type Hs restriction enzyme site (Acu I : CTTCAG) to provide a way to linearize the DNA circular for insertion of a second adaptor.
- BR2-ad is annealed to BR2-temp (sequence 5'-NNNNNNNGTCCGTTAATGTCCTCAG-S') (SEQ ID NO: 4) to form a double-stranded adaptor BR2 adaptor.
- UR3-ext is annealed to biotinylated UR3- temp (sequence 5'-[BIOTIN]ATCTGGTCTGAAGGTNNNNNNN-3') (SEQ ID NO: 5) to form a double-stranded adaptor UR3 adaptor.
- 1 pmol of target TIN is ligated to 25 pmol of BR2 adaptor and 10 pmol of UR3 adaptor in a single ligation reaction containing 5OmM Tris-Cl, pH7.8, 10% PEG, ImM ATP, 50 mg/L BSA, 1OmM MgCl 2 , 0.3 unit/ ⁇ l T4 DNA ligase (Epicentre Biotechnologies, WI) and 10 mM DTT) in a final volume of 10 ul.
- the ligation reaction is incubated in a temperature cycling program of 15°C for 11 min, 37°C for 1 min repeated 18 times. The reaction is terminated by heating at 70°C for 10 min.
- BR2 adaptors are removed by capturing the ligated products with streptavidin magnetic beads (New England Biolabs, MA).
- 3.3 ul of 4x binding buffer (2M NaCl, 80 mM Tris HCl pH7.5) is added to the ligation reaction which is then combined with 15 ⁇ g of streptavidin magnetic beads in Ix binding buffer (0.5M NaCl, 20 mM Tris HCl pH7.5). After 15 min incubation in room temperature, the beads are washed twice with 4 volumes of low salt buffer (0.15M NaCl, 20 mM Tris HCl pH7.5).
- Elution buffer (10 mM Tris HCl pH7.5) is pre-warmed to 70 deg, 10 ⁇ l of which is added to the beads at 70°C for 5 min. After magnetic separation, the supernatant is retained as primary purified sample.
- This sample is further purified by removing the excess UR3 adaptors with magnetic beads pre-bound with a biotinylated oligo BR-rc-bio (sequence : 5'- [BIOTIN]CTTTTGTCTTCCTAACATCC-S') (SEQ ID NO: 6) that is reverse complementary to BR2-ad similarly as described above.
- the concentration of the adaptor-target ligated product in the final purified sample is estimated by urea polyacrylamide gel electrophoresis analysis.
- the circularization is carried out by phosphorylating the ligation products using 0.2unit/ ⁇ l T4 polynucleotide kinase (Epicentre Biotechnologies) in 1 mM ATP and standard buffer provided by the supplier, and circularized with ten-fold molar excess of a splint oligo UR3-closing-88 (sequence 5'- AGATGATAATCTGGTC-S 1 ) (SEQ ID NO: 7) using 0.3 unit/ ⁇ l of T4 DNA ligase (Epicentre Biotechnologies) and ImM ATP.
- the circularized product is validated by performing RCR reactions as described below.
- single molecules comprise concatemers of polynucleotides, usually polynucleotide analytes, i.e. target sequences, that have been produce in a conventional rolling circle replication (RCR) reaction.
- RCR rolling circle replication
- Guidance for selecting conditions and reagents for RCR reactions is available in many references available to those of ordinary skill, as evidence by the following that are incorporated by reference: Kool, U.S. patent 5,426,180; Lizardi, U.S. patents 5,854,033 and 6,143,495; Landegren, U.S. patent 5,871,921; and the like.
- RCR reaction components comprise single stranded DNA circles, one or more primers that anneal to DNA circles, a DNA polymerase having strand displacement activity to extend the 3' ends of primers annealed to DNA circles, nucleoside triphosphates, and a conventional polymerase reaction buffer. Such components are combined under conditions that permit primers to anneal to DNA circles and be extended by the DNA polymerase to form concatemers of DNA circle complements.
- An exemplary RCR reaction protocol is as follows: In a 50 ⁇ L reaction mixture, the following ingredients are assembled: 2-50 pmol circular DNA, 0.5 units/ ⁇ L phage ⁇ 29 DNA polymerase, 0.2 ⁇ g/ ⁇ L BSA, 3 mM dNTP, IX ⁇ 29 DNA polymerase reaction buffer (Amersham). The RCR reaction is carried out at 3O 0 C for 12 hours. In some embodiments, the concentration of circular DNA in the polymerase reaction may be selected to be low (approximately 10-100 billion circles per ml, or 10-100 circles per picoliter) to avoid entanglement and other intermolecular interactions.
- concatemers produced by RCR are approximately uniform in size; accordingly, in some embodiments, methods of making arrays of the invention may include a step of size-selecting concatemers.
- concatemers are selected that as a population have a coefficient of variation in molecular weight of less than about 30%; and in another embodiment, less than about 20%.
- size uniformity is further improved by adding low concentrations of chain terminators, such ddNTPs, to the RCR reaction mixture to reduce the presence of very large concatemers, e.g. produced by DNA circles that are synthesized at a higher rate by polymerases.
- concentrations of ddNTPs are used that result in an expected concatemer size in the range of from 50-250 Kb, or in the range of from 50-100 Kb.
- concatemers may be enriched for a particular size range using a conventional separation techniques, e.g. size-exclusion chromatography, membrane filtration, or the like.
- macromolecular structures comprise polymers having at least one unique functionality, which for polynucleotides is usually a functionality at a 5' or 3' end, and a plurality of complementary functionalities that are capable of specifically reacting with reactive functionalites of the surface of a solid support.
- Macromolecular structures comprising branched polymers, especially branched polynucleotides, may be synthesized in a variety of ways, as disclosed by Gryaznov (cited above), Urdea (cited above), and like references.
- branched polymers of the invention include comb-type branched polymers, which comprise a linear polymeric unit with one or more branch points located at interior monomers and/or linkage moieties.
- Branched polymers of the invention also include fork-type branched polymers, which comprise a linear polymeric unit with one or two branch points located at terminal monomers and/or linkage moieties.
- Macromolecular structures of the invention also include assemblies of linear and/or branched polynucleotides bound together by one or more duplexes or triplexes. Such assemblies may be self- assembled from component linear polynucleotide, e.g. as disclosed by Goodman et al, Science, 310: 1661-1665 (2005); Birac et al, J. MoI. Graph Model, (April 18, 2006); Seeman et al, U.S. patent 6,255,469; and the like, which are incorporated herein by reference.
- linear polymeric units of the invention have the form: "--(M-L) n -" wherein L is a linker moiety and M is a monomer that may be selected from a wide range of chemical structures to provide a range of functions from serving as an inert non-sterically hindering spacer moiety to providing a reactive functionality which can serve as a branching point to attach other components, a site for attaching labels; a site for attaching oligonucleotides or other binding polymers for hybridizing or binding to amplifier strands or structures, e.g. as described by Urdea et al, U.S. Pat. No. 5,124,246 or Wang et al, U.S. Pat. No.
- M is a straight chain, cyclic, or branched organic molecular structure containing from 1 to 20 carbon atoms and from 0 to 10 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur.
- M is alkyl, alkoxy, alkenyl, or aryl containing from 1 to 16 carbon atoms; heterocyclic having from 3 to 8 carbon atoms and from 1 to 3 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; glycosyl; or nucleosidyl.
- M is alkyl, alkoxy, alkenyl, or aryl containing from 1 to 8 carbon atoms; glycosyl; or nucleosidyl.
- L is a phosphorus(V) linking group which may be phosphodiester, phosphotriester, methyl or ethyl phosphonate, phosphorothioate, phosphorodithioate, phosphoramidate, or the like.
- linkages derived from pho sphoramidite or hydrogen phosphonate precursors are preferred so that the linear polymeric units of the invention can be conveniently synthesized with commercial automated DNA synthesizers, e.g. Applied Biosystems, Inc.
- n may vary significantly depending on the nature of M and L. Usually, n varies from about 3 to about 100. When M is a nucleoside or analog thereof or a nucleoside-sized monomer and L is a phosphorus(V) linkage, then n varies from about 12 to about 100. Preferably, when M is a nucleoside or analog thereof or a nucleoside-sized monomer and L is a phosphorus(V) linkage, then n varies from about 12 to about 40. Polymeric units are assembled by forming one or more covalent bridges among them.
- bridges are formed by reacting thiol, phosphorothioate, or phosphorodithioate groups on one or more components with haloacyl- or haloalkylamimo groups on one or more other components to form one or more thio- or dithiophosphorylacyl or thio- or dithiophosphorylalkyi bridges.
- the assembly reaction may involve from 2 to 20 components depending on the particular embodiment; but preferably, it involves from 2 to 8 components; and more preferably, it involves from 2 to 4 components.
- the haloacyl. or haloalkylamino groups are haloacetylamino groups; and more preferably, the haloacetylamino groups are bromoacetylamino groups.
- the acyl or alkyl moieties of the haloacyl- or haloalkylamino groups contain from 1 to 12 carbon atoms; and more preferably, such moieties contain from 1 to 8 carbon atoms.
- the reaction may take place in a wide range of solvent systems; but generally, the assembly reaction takes place under liquid aqueous conditions or in a frozen state in ice, e.g. obtained by lowering the temperature of a liquid aqueous reaction mixture.
- Typical aqueous conditons include 4 ⁇ M of reactants in 25 mM NaCl and 15 mM phosphate buffer (pH 7.0).
- the thio- or dithiophosphorylacyl- or thio- or dithiophosphorylalkylamino bridges are preferred because they can be readily and selectively cleaved by oxidizing agents, such as silver nitrate, potassium iodide, and the like.
- the bridges are cleaved with potassium iodide, KI 3 , at a concentration equivalent to about a hundred molar excess of the bridges.
- a KI 3 is employed at a concentration of about 0. IM.
- a 3'-haloacyl- or haloalkylamino (in this example, haloacetylamino) derivatized oligonucleotide 1 is reacted with a 5'- phosphorothioate derivatized oligonucleotide 2 according to the following scheme:
- Compound 1 can be prepared by reacting N-succinimidyl haloacetate in N,N-dimethylformamide (DMF) with a 3'-aminodeoxyribonucleotide precursor in a sodium borate buffer at room temperature. After about 35 minutes the mixture is diluted (e.g. with H 2 O), desalted and, purified, e.g. by reverse phase HPLC.
- DMF N,N-dimethylformamide
- purified e.g. by reverse phase HPLC.
- the Y- aminodeoxyribonucleotide precursor can be prepared as described in Gryaznov and Letsinger, Nucleic Acids Research, 20:3403-3409 (1992). Briefly, after deprotection, the 5' hydroxyl of a deoxythymidine linked to a support via a standard succinyl linkage is phosphitylated by reaction with chloro-(diisopropylethylamino)-methoxyphosphine in an appropriate solvent, such as dichloromethane/diisopropylethylamine.
- the 5'-phosphitylated thymidine is reacted with a 5'-trityl-O-3'-amino-3'-deoxynucleoside to form a nucleoside-thymidine dimer wherein the nucleoside moieties are covalently joined by a phosphoramidate linkage.
- the remainder of the oligonucleotide is synthesized by standard phosphoramidite chemistry. After cleaving the succinyl linkage, the oligonucleotide with a 3' terminal amino group is generated by cleaving the phosphoramidate link by acid treatment, e.g.
- 5'-monophosphorothioate oligonucleotide 2 is formed as follows: A 5' monophosphate is attached to the 5' end of an oligonucleotide either chemically or enzymatically with a kinase, e.g. Sambrook et al, Molecular Cloning: A Laboratory Manual, 2nd Edition (Cold Spring Harbor Laboratory, New York, 1989).
- a monophosphate is added by chemical phosphorylation as described by Thuong and Asscline, Chapter 12 in, Eckstein, editor, Oligonucleotides and Analogues (IRL Press, Oxford, 1991) or by Horn and Urdea, Tetrahedron Lett., 27:4705 (1986) (e.g. using commercially available reagents such as 5' Phosphate-ON.TM. from Clontech Laboratories (Palo Alto, Calif.)).
- the 5'-monophosphate is then sulfurized using conventional sulfurizing agents, e.g.
- Monophosphorodithioates are prepared by analogous procedures, e.g. Froehler et al, European patent publication 0 360 609 A2; Caruthers et al, International application PCT/US 89/02293; and the like.
- Compound 3 can be prepared by reacting N- succinimidyl haloacetate in N,N-dimethylformamide (DMF) with a 5'-aminodeoxyribonucleotide precursor in a sodium borate buffer at room temperature, as described above for the 3 '-amino oligonucleotide.
- DMF N,N-dimethylformamide
- 5'-aminodeoxynucleosides are prepared in accordance with Glinski et al, J. Chem. Soc. Chem. Comm., 915-916 (1970); Miller et al, J. Org. Chem.
- oligonucleotide 4 can be prepared as described by Thuong and Asscline (cited above). Oligonucleotides 1 and 4 and 2 and 3 may be reacted to form polymeric units having either two 5' termini or two 3' termini, respectively.
- Reactive functionalities for the attachment of branches may be introduced at a variety of sites.
- amino functionalities are introduce on a polymeric unit or loop at selected monomers or linking moieties which are then converted to haloacetylamino groups as described above.
- Amino- derivatized bases of nucleoside monomers may be introduced as taught by Urdea et al, U.S. Pat. No. 5,093,232; Ruth U.S. Pat. No. 4,948,882; Haralambidis et al, Nucleic Acids Research, 15:4857-4876 (1987); or the like.
- Amino functionalities may also be introduced by a protected hydroxyamine phosphoramidite commercially available from Clontech Laboratories (Palo Alto, Calif.) as Aminomodifier II.TM..
- amino functionalities are introduced by generating a derivatized phosphoramidate linkage by oxidation of a phosphite linkage with I 2 and an alkyldiamine, e.g. as taught by Agrawal et al, Nucleic Acids Research, 18:5419-5423 (1990); and Jager et al, Biochemistry, 27:7237-7246 (1988).
- haloacyl- or haloalkylamino derivatized polymeric units be prepared separately from the phosphorothioate derivatized polymeric units, otherwise the phosphorothioate moieties require protective groups.
- supports are rigid solids that have a surface, preferably a substantially planar surface so that single molecules to be interrogated are in the same plane. The latter feature permits efficient signal collection by detection optics, for example.
- solid supports of the invention are nonporous, particularly when random arrays of single molecules are analyzed by hybridization reactions requiring small volumes. Suitable solid support materials include materials such as glass, polyacrylamide-coated glass, ceramics, silica, silicon, quartz, various plastics, and the like.
- the area of a planar surface may be in the range of from 0.5 to 4 cm 2 .
- the solid support is glass or quartz , such as a microscope slide, having a surface that is uniformly silanized.
- This may be accomplished using conventional protocols, e.g. acid treatment followed by immersion in a solution of 3- glycidoxypropyl trimethoxysilane, N,N-diisopropylethylamine, and anhydrous xylene (8:1 :24 v/v) at 80oC, which forms an epoxysilanized surface, e.g. Beattie et a (1995), Molecular Biotechnology, 4: 213.
- Such a surface is readily treated to permit end-attachment of capture oligonucleotides, e.g.
- capture oligonucleotides may comprise non- natural nucleosidic units and/or linkages that confer favorable properties, such as increased duplex stability; such compounds include, but not limited to, peptide nucleic acids (PNAs), locked nucleic acids (LNA), oligonucleotide N3'-»P5' phosphoramidates, oligo-2'-O-alkylribonucleotides, and the like.
- PNAs peptide nucleic acids
- LNA locked nucleic acids
- oligonucleotide N3'-»P5' phosphoramidates oligo-2'-O-alkylribonucleotides, and the like.
- photolithography, electron beam lithography, nano imprint lithography, and nano printing may be used to generate such patterns on a wide variety of surfaces, e.g. Pirrung et al, U.S. patent 5,143,854; Fodor et al, U.S. patent 5,774,305; Guo, (2004) Journal of Physics D: Applied Physics, 37: R123-141; which are incorporated herein by reference.
- surfaces containing a plurality of discrete spaced apart regions are fabricated by photolithography.
- a commercially available, optically flat, quartz substrate is spin coated with a 100- 500nm thick layer of photo-resist.
- the photo-resist is then baked on to the quartz substrate.
- An image of a reticle with a pattern of regions to be activated is projected onto the surface of the photoresist, using a stepper.
- the photo-resist is developed, removing the areas of the projected pattern which were exposed to the UV source. This is accomplished by plasma etching, a dry developing technique capable of producing very fine detail.
- the substrate is then baked to strengthen the remaining photo-resist. After baking, the quartz wafer is ready for functionalization.
- the wafer is then subjected to vapor-deposition of 3-aminopropyldimethylethoxysilane.
- the density of the amino functionalized monomer can be tightly controlled by varying the concentration of the monomer and the time of exposure of the substrate. Only areas of quartz exposed by the plasma etching process may react with and capture the monomer.
- the substrate is then baked again to cure the monolayer of amino-functionalized monomer to the exposed quartz. After baking, the remaining photo-resist may be removed using acetone. Because of the difference in attachment chemistry between the resist and silane, aminosilane-functionalized areas on the substrate may remain intact through the acetone rinse.
- oligonucleotides can be prepared with a 5'-carboxy-modifier-clO linker (Glen Research). This technique allows the oligonucleotide to be attached directly to the amine modified support, thereby avoiding additional functionalization steps.
- surfaces containing a plurality of discrete spaced apart regions are fabricated by nano-imprint lithography (NIL).
- NIL nano-imprint lithography
- a quartz substrate is spin coated with a layer of resist, commonly called the transfer layer.
- a second type of resist is then applied over the transfer layer, commonly called the imprint layer.
- the master imprint tool then makes an impression on the imprint layer.
- the overall thickness of the imprint layer is then reduced by plasma etching until the low areas of the imprint reach the transfer layer. Because the transfer layer is harder to remove than the imprint layer, it remains largely untouched.
- the imprint and transfer layers are then hardened by heating.
- the substrate is then put into a plasma etcher until the low areas of the imprint reach the quartz.
- the substrate is then derivatized by vapor deposition as described above.
- surfaces containing a plurality of discrete spaced apart regions are fabricated by nano printing.
- This process uses photo, imprint, or e-beam lithography to create a master mold, which is a negative image of the features required on the print head.
- Print heads are usually made of a soft, flexible polymer such as polydimethylsiloxane (PDMS). This material, or layers of materials having different properties, are spin coated onto a quartz substrate. The mold is then used to emboss the features onto the top layer of resist material under controlled temperature and pressure conditions. The print head is then subjected to a plasma based etching process to improve the aspect ratio of the print head, and eliminate distortion of the print head due to relaxation over time of the embossed material.
- PDMS polydimethylsiloxane
- Random array substrates are manufactured using nano-printing by depositing a pattern of amine modified oligonucleotides onto a homogenously derivatized surface. These oligo-nucleotides would serve as capture probes for the RCR products.
- One potential advantage to nano-printing is the ability to print interleaved patterns of different capture probes onto the random array support. This would be accomplished by successive printing with multiple print heads, each head having a differing pattern, and all patterns fitting together to form the final structured support pattern. Such methods allow for some positional encoding of DNA elements within the random array. For example, control concatemers containing a specific sequence can be bound at regular intervals throughout a random array.
- a high density array of capture oligonucleotide spots of sub micron size is prepared using a printing head or imprint-master prepared from a bundle, or bundle of bundles, of about 10,000 to 100 million optical fibers with a core and cladding material.
- a unique material is produced that has about 50-1000 nm cores separated by a similar or 2-5 fold smaller or larger size cladding material.
- differential etching (dissolving) of cladding material a nano-printing head is obtained having a very large number of nano-sized posts.
- This printing head may be used for depositing oligonucleotides or other biological (proteins, oligopeptides, DNA, aptamers) or chemical compounds such as silane with various active groups.
- the glass fiber tool is used as a patterned support to deposit oligonucleotides or other biological or chemical compounds. In this case only posts created by etching may be contacted with material to be deposited. Also, a flat cut of the fused fiber bundle may be used to guide light through cores and allow light-induced chemistry to occur only at the tip surface of the cores, thus eliminating the need for etching.
- the same support may then be used as a light guiding/collection device for imaging fluorescence labels used to tag oligonucleotides or other reactants.
- This device provides a large field of view with a large numerical aperture (potentially > 1 ).
- Stamping or printing tools that perform active material or oligonucleotide deposition may be used to print 2 to 100 different oligonucleotides in an interleaved pattern. This process requires precise positioning of the print head to about 50-500 nm.
- This type of oligonucleotide array may be used for attaching 2 to 100 different DNA populations such as different source DNA. They also may be used for parallel reading from sub- light resolution spots by using DNA specific anchors or tags.
- DNA specific tags e.g. 16 specific anchors for 16 DNAs and read 2 bases by a combination of 5-6 colors and using 16 ligation cycles or one ligation cycle and 16 decoding cycles. This way of making arrays is efficient if limited information (e.g. a small number of cycles) is required per fragment, thus providing more information per cycle or more cycles per surface.
- "inert" concatemers are used to prepare a surface for attachment of test concatemers. The surface is first covered by capture oligonucleotides complementary to the binding site present on two types of synthetic concatemers; one is a capture concatemer, the other is a spacer concatemer.
- the spacer concatemers do not have DNA segments complementary to the adapter used in preparation of test concatemers and they are used in about 5-50, preferably 10 x excess to capture concatemers.
- the surface with capture oligonucleotide is "saturated" with a mix of synthetic concatemers (prepared by chain ligation or by RCR) in which the spacer concatemers are used in about 10 -fold (or 5 to 50-fold) excess to capture concatemers. Because of the ⁇ 10:l ratio between spacer and capture concatemers, the capture concatemers are mostly individual islands in a sea of spacer concatemers. The 10:1 ratio provides that two capture concatemers are on average separated by two spacer concatemers.
- concatemers are about 200 nm in diameter, then two capture concatemers are at about 600 nm center-to-center spacing. This surface is then used to attach test concatemers or other molecular structures that have a binding site complementary to a region of the capture concatemers but not present on the spacer concatemers. Capture concatemers may be prepared to have less copies than the number of binding sites in test concatemers to assure single test concatemer attachment per capture concatemer spot. Because the test DNA can bind only to capture concatemers, an array of test concatemers may be prepared that have high site occupancy without congregation.
- test concatemers Due to random attachment, some areas on the surface may not have any concatemers attached, but these areas with free capture oligonucleotide may not be able to bind test concatemers since they are designed not to have binding sites for the capture oligonculeotide.
- An array of individual test concatemers as described would not be arranged in a grid pattern. An ordered grid pattern should simplify data collection because less pixels are needed and less sophisticated image analysis systems are needed also.
- multiple arrays of the invention may be place on a single surface.
- patterned array substrates may be produced to match the standard 96 or 384 well plate format.
- a production format can be an 8 x 12 pattern of 6mm x 6mm arrays at 9mm pitch or 16x24 of 3.33mm x 3.33mm array at 4.5mm pitch, on a single piece of glass or plastic and other optically compatible material.
- each 6mm x 6mm array consists of 36 million 250-500nm square regions at 1 micrometer pitch. Hydrophobic or other surface or physical barriers may be used to prevent mixing different reactions between unit arrays.
- binding sites i.e. discrete spaced apart regions
- binding sites for DNA samples are prepared by silanization of lithographically defined sites on silicon dioxide on silicon, quartz, or glass surfaces with 3-aminopropyldimethylethoxysilane or similar silanization agent followed by derivatization with p-phenylenediisothiocyanate or similar derivatization agent.
- the binding sites may be square, circular or regular/irregular polygons produced by photolithography, direct-write electron beam, or nano-imprint lithography.
- the wetability (hydrophobic v.hydrophilic) and reactivity of the field surrounding the binding sites can be controlled to prevent DNA samples from binding in the field; that is, in places other than the binding sites.
- the field may be prepared with hexamethyldisilazane (HMDS), or a similar agent covalently bonded to the surface, to be hydrophobic and hence unsuitable to hydrophilic bonding of the DNA samples.
- HMDS hexamethyldisilazane
- the field may be coated with a chemical agent such as a fluorine-based carbon compound that renders it unreactive to DNA samples.
- DMF Dimethylformaide
- a glass surface may also be used for constructing random arrays of the invention.
- a suitable glass surface may be constructed from microscope cover slips.
- Microscope cover slips 22mm sq ⁇ 170um thick
- Teflon racks are placed in Teflon racks. They are soaked in 3 molar KOH in 95% ethanol/water for 2 minutes. They are then rinsed in water, followed by an acetone rinse. This removes surface contamination and prepares the glass for silanization.
- Plasma cleaning is an alternative to KOH cleaning.
- Fused silica or quartz may also be substituted for glass.
- the clean, dry cover slips are immersed in .3% 3-aminopropyldimethylethoxysilane, .3% water, in acetone.
- 3-aminopropyldimethylethoxysilane may be used as a replacement for 3- aminopropyltriethoxysilane because it forms a mono-layer on the glass surface.
- the monolayer surface provides a lower background.
- the silanization agent may also be applied using vapor deposition.
- 3-aininopropyltriethoxysilane tends to form more of a polymeric surface when deposited in solution phase.
- the amino modified silane is then terminated with a thiocyanate group. This is done in a solution of 10% pyridine and 90% N,N-Dimethylformaide (DMF) using 2.25mg p- phenylenediisothiocyanate (PDC) per ml of solution.
- DMF N,N-Dimethylformaide
- PDC p- phenylenediisothiocyanate
- glutaraldehyde can be used to modify the amino group at the end of the silanization agent to a aldehyde group which can be coupled to an amino modified oligonucleotide.
- Capture oligonucleotides are bound to the surface of the cover slide by applying a solution of 10-50 micromolar capture oligonucleotide in 100 millimolar sodium bicarbonate in water to the surface. The solution is allowed to dry, and is then washed in water.
- the oligonucleotide is applied in a solution that contains EDC ( l-Ethyl-3-(3-dimethylaminopropyl)- carbodiimide ).
- EDC l-Ethyl-3-(3-dimethylaminopropyl)- carbodiimide
- the aldehyde group the oligo is kept wet for 5-10 minutes then the surface is treated with a 1% solution of sodium borohydride.
- random arrays are prepared using nanometer-sized beads.
- Sub-micron glass or other types of beads are used which are derivatized with a short oligonucleotide, e.g. 6-30 nucleotides, complementary to an adaptor oligonucleotide in the circles used to generate concatemers.
- a short oligonucleotide e.g. 6-30 nucleotides
- the number of oligonucleotides on the bead and the length of the sequence can be controlled to weakly bind the concatemers in solution. Reaction rate of the beads should be much faster than that of the solid support alone.
- the beads After binding concatemers, the beads are then allowed to settle on the surface of an array substrate.
- the array substrate has longer, more stable, more numerous oligonucleotides, such that conditions may be selected to permit preferential binding to the surface, thereby forming a spaced array of concatemers.
- the beads are magnetic, a magnetic field can be used to pull them to the surface, it may also be used to move them around the surface. Alternatively, a centrifuge may be used to concentrate the beads on the surface.
- An exemplary protocol is as follows: 1. A preparation of 20 ul of concatemer solution with one million concatemers per IuI is mixed with 20 million nano-beads with about 500 capture oligonucleotides about 8 bases in length (6-16 bases may be use under different conditions).
- One way to control the density of capture probes is to mix in this case about 8 times more of a 2-4 bases long oligonucleotieds with the same attachment chemistry with the capture probe. Also, much smaller nano-beads (20-50 nm) may be used. 2. Reaction conditions (temperature, pH, salt concentration) are adjusted so that concatemers with over 300 copies will attach to nanobeads in significant numbers. 3.
- the reaction is applied under the same stringent conditions to a support with 4x4 mm of patterned surface with 16 million active sites about 200 ran in size, and nanobeads are allowed or forced to settle on the substrate surface bringing large concatemers with them.
- the largest distance that a nano-bead-concatemer has to travel is about lmm.
- the vertical movement of beads minimizes number of potential concatemer-concatemer encounters.
- the reaction solution may be applied in aliquots, e.g. 4 applications 5 ul each. In this case the thickness of the applied solution (e.g. the nano-bead maximal travel distance) is only about 250 microns. 4.
- Concatemers attached to nano-beads will predominately settle initially between active sites on the support because there are 25 times more inactive than active surface.
- Slight horizontal movement force e.g. substrate tilting, and other forces
- signals from single molecules on random arrays made in accordance with the invention are generated and detected by a number of detection systems, including, but not limited to, scanning electron microscopy, near field scanning optical microscopy (NSOM), total internal reflection fluorescence microscopy (TIRFM), and the like.
- NOM near field scanning optical microscopy
- TRFM total internal reflection fluorescence microscopy
- instruments for use with arrays of the invention comprise three basic components: (i) a fluidics system for storing and transferring detection and processing reagents, e.g. probes, wash solutions, and the like, to an array; (ii) a reaction chamber, or flow cell, holding or comprising an array and having flow-through and temperature control capability; and (iii) an illumination and detection system.
- a flow cell has a temperature control subsystem with ability to maintain temperature in the range from about 5-95 0 C, or more specifically 10-85 0 C, and can change temperature with a rate of about 0.5-2 0 C per second .
- a flow cell for 1 "square 170 micrometer thick cover slips can be used that has been derivatized to bind macromolecular structures of the invention.
- the cell encloses the "array” by sandwiching the glass and a gasket between two planes.
- One plane has an opening of sufficient size to permit imaging, and an indexing pocket for the cover slip.
- the other plane has an indexing pocket for the gasket, fluid ports, and a temperature control system.
- One fluid port is connected to a syringe pump which "pulls” or “pushes” fluid from the flow cell the other port is connected to a funnel like mixing chamber.
- the chamber in turn is equipped with a liquid level sensor.
- the solutions are dispensed into the funnel, mixed if needed, then drawn into the flow cell.
- the level sensor reads air in the funnels connection to the flow cell the pump is reversed a known amount to back the fluid up to the funnel. This prevents air from entering the flow cell.
- the cover slip surface may be sectioned off and divided into strips to accommodate fluid flow/capillary effects caused by sandwiching.
- Such substrate may be housed in an "open air” / "open face” chamber to promote even flow of the buffers over the substrate by eliminating capillary flow effects.
- Imaging may be accomplished with a 10Ox objective using TIRF or epi illumination and a 1.3 mega pixel Hamamatsu orca-er-ag on a Zeiss axiovert 200, or like system. This configuration images RCR concatemers bound randomly to a substrate (non-ordered array). Imaging speed may be improved by decreasing the objective magnification power, using grid patterned arrays and increasing the number of pixels of data collected in each image.
- up to four or more cameras may be used, preferably in the 10-16 megapixel range.
- Multiple band pass filters and dichroic mirrors may also be used to collect pixel data across up to four or more emission spectra.
- the power of the excitation light source can be increased.
- Throughput can be increased by using one or more flow chambers with each camera, so that the imaging system is not idle while the samples are being hybridized/reacted. Because the probing of arrays can be non- sequential, more than one imaging system can be used to collect data from a set of arrays, further decreasing assay time.
- the substrate must remain in focus.
- Some key factors in maintaining focus are the flatness of the substrate, orthogonality of the substrate to the focus plane, and mechanical forces on the substrate that may deform it.
- Substrate flatness can be well controlled, glass plates which have better than Vi wave flatness are readily obtained. Uneven mechanical forces on the substrate can be minimized through proper design of the hybridization chamber.
- Orthogonality to the focus plane can be achieved by a well adjusted, high precision stage.
- Auto focus routines generally take additional time to run, so it is desirable to run them only if necessary. After each image is acquired, it will be analyzed using a fast algorithm to determine if the image is in focus. If the image is out of focus, the auto focus routine will run. It will then store the objectives Z position information to be used upon return to that section of that array during the next imaging cycle. By mapping the objectives Z position at various locations on the substrate, we will reduce the time required for substrate image acquisition.
- a suitable illumination and detection system for fluorescence-based signal is a Zeiss Axiovert 200 equipped with a TIRF slider coupled to a 80 milliwatt 532 nm solid state laser.
- the slider illuminates the substrate through the objective at the correct TIRF illumination angle.
- TIRF can also be accomplished without the use of the objective by illuminating the substrate though a prism optically coupled to the substrate.
- Planar wave guides can also be used to implement TIRF on the substrate
- Epi illumination can also be employed.
- the light source can be rastered, spread beam, coherent, incoherent, and originate from a single or multi-spectrum source.
- One embodiment for the imaging system contains a 2Ox lens with a 1.25mm field of view, with detection being accomplished with a 10 megapixel camera.
- Such a system images approx 1.5 million concatemers attached to the patterned array at 1 micron pitch. Under this configuration there are approximately 6.4 pixels per concatemer.
- the number of pixels per concatemer can be adjusted by increasing or decreasing the field of view of the objective. For example a lmm field of view would yield a value of 10 pixels per concatemer and a 2mm field of view would yield a value of 2.5 pixels per concatemer.
- the field of view may be adjusted relative to the magnification and NA of the objective to yield the lowest pixel count per concatemer that is still capable of being resolved by the optics, and image analysis software.
- Both TIRF and EPI illumination allow for almost any light source to be used.
- One illumination schema is to share a common set of monochromatic illumination sources (about 4 lasers for 6-8 colors) amongst imagers. Each imager collects data at a different wavelength at any given time and the light sources would be switched to the imagers via an optical switching system.
- the illumination source preferably produces at least 6, but more preferably 8 different wavelengths.
- Such sources include gas lasers, multiple diode pumped solid state lasers combined through a fiber coupler, filtered Xenon Arc lamps, tunable lasers, or the more novel Spectralum Light Engine, soon to be offered by Tidal Photonics.
- the Spectralum Light Engine uses prism to spectrally separate light.
- the spectrum is projected onto a Texas Instruments Digital Light Processor, which can selectively reflect any portion of the spectrum into a fiber or optical connector.
- This system is capable of monitoring and calibrating the power output across individual wavelengths to keep them constant so as to automatically compensate for intensity differences as bulbs age or between bulb changes.
- the following table represent examples of possible lasers, dyes and filters, excitation laser filter eemmiissssiiooni filter Dye
- a preferred instrument design is 4 imager modules each serving 4 flow cells (16 flow cells total).
- the above described imaging schema assumes that each imager has a CCD detector with 10 million pixels and be used with an exposure time of roughly 300 milliseconds. This should be an acceptable method for collecting data for 6 fluorophor labels.
- One possible drawback to this imaging technique is that certain fluorophors may be unintentionally photo bleached by the light source while other fluorophores are being imaged. Keeping the illumination power low and exposure times to a minimum would greatly reduce photo bleaching.
- intensified CCDs ICCDs
- data could be collected of roughly the same quality with illumination intensities and exposure times that are orders of magnitude lower than standard CCDs.
- ICCDs are generally available in the 1 - 1.4 megapixel range. Because they require much shorter exposure times, a one megapixel ICCD can acquire ten or more images in the time a standard CCD acquires a single image. Used in conjunction with fast filter wheels, and a high speed flow cell stage, a one mega pixel ICCD should be able to collect the same amount of data as a 10 megapixel standard CCD.
- Optics capable of imaging larger fields of view with high numerical apertures can be manufactured as custom lens assemblies. Indications are that 20x optics capable of imaging a 3mm field of view with a NA >0.9 can be fabricated. Two such imaging systems, in combination with high pixel count CCD 's or CCD mosaic arrays should be able to image the complete eight flow cell assay in roughly 14 hours. As described, further gains can be realized by using 16 flow cells. Doubling the number of flow cells would reduce imaging time to 9 hours by reducing the number of images per each field of view.
- the reaction efficiency on the concatemer and other random DNA arrays may depend on the efficient use of probes, anchors or primers and enzymes.
- reaction mixes in a thin layer such as droplets or layers of about one to a few microns, but preferably less than 10 microns, in size/thickness.
- lxlxl micron volume designated for a lxlmicron spot area in lpmol/lul (IuM concentration) there would be about 1000 molecules of probe in close proximity to 1-1000 copies of DNA.
- a single robotic liquid handling gantry may service, for example, 16 flow cells.
- all components of the system may share a common temperature control system, and set of reagents.
- the robot may prepare probe pools and ligation buffers to be dispensed into the flow cell funnels.
- Dedicated syringe pumps may dispense wash and hybridization buffers directly into the funnel ports for each flow cell.
- Each imager may service a group of 2-4 flow cells.
- Each group of flow cells may be positioned on an XY motion platform, similar to the automated plate stages commonly found on research microscopes.
- System control and coordination between all system components may be performed via software running on a master computer.
- the control software may run assay cycles asynchronously, allowing each imager to run continuously throughout the assay.
- Flow cells are connected to a temperature control system with one heater and one chiller allowing for heating or cooling on demand of each flow cell or 2-4 blocks of cells independently.
- Each flow cell temperature may be monitored, and if a flow cell temperature drops below a set threshold, a valve may open to a hot water recirculation.
- a valve may open to a cold water recirculation. If a flow cell is within a set temperature range neither valve may open. The hot and cold recirculation water runs through the aluminum flow cell body, but remains separate and isolated from the assay buffers and reagents.
- random arrays of biomolecules such as genomic DNA fragments or cDNA fragments
- SAGE serial analysis of gene expression
- massively parallel signature sequencing e.g. Velculescu, et al, (1995), Science 270, 484-487; and Brenner et al (2000), Nature Biotechnology, 18: 630-634.
- Such genome-wide measurements include, but are not limited to, determination of polymorphisms, including nucleotide substitutions, deletions, and insertions, inversions, and the like, determination of methylation patterns, copy number patterns, and the like, such as could be carried out by a wide range of assays known to those with ordinary skill in the art, e.g. Syvanen (2005), Nature Genetics Supplement, 37: S5-S10; Gunderson et al (2005), Nature Genetics, 37: 549-554; Fan et al (2003), Cold Spring Harbor Symposia on Quantitative Biology, LXVIII: 69-78; and U.S. patents 4,883,750; 6,858,412; 5,871,921; 6,355,431; and the like, which are incorporated herein by reference.
- a variety of sequencing methodologies can be used with random arrays of the invention, including, but not limited to, hybridization-based methods, such as disclosed in Drmanac , U.S. patents 6,864,052; 6,309,824; and 6,401,267; and Drmanac et al, U.S. patent publication 2005/0191656, which are incorporated by reference, sequencing by synthesis methods, e.g. Nyren et al, U.S. patent 6,210,891; Ronaghi, U.S. patent 6,828,100; Ronaghi et al (1998), Science, 281: 363- 365; Balasubramanian, U.S. patent 6,833,246; Quake, U.S.
- a method of determining a nucleotide sequence of a target polynucleotide in accordance with the invention comprises the following steps: (a) generating a plurality of target concatemers from the target polynucleotide, each target concatemer comprising multiple copies of a fragment of the target polynucleotide and the plurality of target concatemers including a number of fragments that substantially covers the target polynucleotide; (b) forming a random array of target concatemers fixed to a surface at a density such that at least a majority of the target concatemers are optically resolvable; (c) identifying a sequence of at least a portion of each fragment in each target concatemer; and (d) reconstructing the nucleotide sequence of the target polynucleotide from the identities of the sequences of the portions of fragments of the concatemers.
- substantially covers means that the amount of DNA analyzed contains an equivalent of at least two copies of the target polynucleotide, or in another aspect, at least ten copies, or in another aspect, at least twenty copies, or in another aspect, at least 100 copies.
- Target polynucleotides may include DNA fragments, including genomic DNA fragments and cDNA fragments, and RNA fragments.
- a sequencing method for use with the invention for dete ⁇ nining sequences in a plurality of DNA or RNA fragments comprises the following steps: (a) generating a plurality of polynucleotide molecules each comprising a concatemer of a DNA or RNA fragment; (b) forming a random array of polynucleotide molecules fixed to a surface at a density such that at least a majority of the target concatemers are optically resolvable; and (c) identifying a sequence of at least a portion of each DNA or RNA fragment in resolvable polynucleotides using at least one chemical reaction of an optically detectable reactant.
- such optically detectable reactant is an oligonucleotide.
- such optically detectable reactant is a nucleoside triphosphate, e.g. a fluorescently labeled nucleoside triphosphate that may be used to extend an oligonucleotide hybridized to a concatemer.
- such optically detectable reagent is an oligonucleotide formed by ligating a first and second oligonucleotides that form adjacent duplexes on a concatemer.
- such chemical reaction is synthesis of DNA or RNA, e.g. by extending a primer hybridized to a concatemer.
- the above optically detectable reactant is a nucleic acid binding oligopeptide or polypeptide or protein.
- parallel sequencing of polynucleotide analytes of concatemers on a random array is accomplished by combinatorial SBH (cSBH), as disclosed by Drmanac in the above-cited patents.
- cSBH combinatorial SBH
- first and second sets of oligonucleotide probes comprise probes having selected nucleotide sequences designed to detect selected sets of target polynucleotides.
- Sequences are determined by hybridizing one probe or pool of probe, hybridizing a second probe or a second pool of probes, ligating probes that form perfectly matched duplexes on their target sequences, identifying those probes that are ligated to obtain sequence information about the target sequence, repeating the steps until all the probes or pools of probes have been hybridized, and determining the nucleotide sequence of the target from the sequence information accumulated during the hybridization and identification steps.
- the sets may be divided into subsets that are used together in pools, as disclosed in U.S. patent 6,864,052.
- Probes from the first and second sets may be hybridized to target sequences either together or in sequence, either as entire sets or as subsets, or pools.
- lengths of the probes in the first or second sets are in the range of from 5 to 10 nucleotides, and in another aspect, in the range of from 5 to 7 nucleotides, so that when ligated they form ligation products with a length in the range of from 10 to 20, and from 10 to 14, respectively.
- the sequence identity of each attached DNA concatemer may be determined by a "signature" approach. About 50 to 100 or possibly 200 probes are used such that about 25-50% or in some applications 10-30% of attached concatemers will have a full match sequence for each probe.
- This type of data allows each amplified DNA fragment within a concatemer to be mapped to the reference sequence. For example, by such a process one can score 64 4-mers (i.e. 25% of all possible 256 4-mers) using 16 hybridization/stripoff cycles in a 4 colors labeling schema. On a 60-70 base fragment amplified in a concatemer about 16 of 64 probes will be positive since there are 64 possible 4mers present in a 64 base long sequence (i.e.
- Unrelated 60-70 base fragments will have a very different set of about 16 positive decoding probes.
- a combination of 16 probes out of 64 probes has a random chance of occurrence in 1 of every one billion fragments which practically provides a unique signature for that concatemer.
- Scoring 80 probes in 20 cycles and generating 20 positive probes create a signature even more likely to be unique: occurrence by chance is 1 in billion billions.
- a "signature" approach was used to select novel genes from cDNA libraries.
- An implementation of a signature approach is to sort obtained intensities of all tested probes and select up to a predefined (expected) number of probes that satisfy the positive probe threshold.
- probes will be mapped to sequences of all DNA fragments (sliding window of a longer reference sequence may be used) expected to be present in the array.
- the sequence that has all or a statistically sufficient number of the selected positive probes is assigned as the sequence of the DNA fragment in the given concatemer.
- an expected signal can be defined for all used probes using their pre measured full match and mismatch hybridization/ligation efficiency. In this case a measure similar to the correlation factor can be calculated.
- a preferred way to score 4-mers is to ligate pairs of probes, for example: N (5 . 7) BBB with BN (7-9) , where B is the defined base and N is a degenerate base.
- N is the defined base
- N is a degenerate base.
- more unique bases will be used. For example, a 25% positive rate in a fragment 1000 bases in length would be achieved by N (4 _ 6) BBBB and Note that longer fragments need the same number of about 60-80 probes (15-20 ligation cycles using 4 colors).
- all probes of a given length may be used to determine complete sequence of the DNA in a concatemer.
- 1024 combinations OfN (S-7) B 3 and BBN (6-8) may be scored (256 cycles if 4 colors are used) to determine sequence of DNA fragments of up to about 250 bases, preferably up to about 100 bases.
- the decoding of sequencing probes with large numbers of Ns may be prepared from multiple syntheses of subsets of sequences at degenerated bases to minimize difference in the efficiency. Each subset is added to the mix at a proper concentration. Also, some subsets may have more degenerated positions than others. For example, each of 64 probes from the set N (5-7) BBB may be prepared in 4 different synthesis. One is regular all 5-7 bases to be fully degenerated; second is N0-3(A,T)5BBB; third is N0-2(A,T)(G,C)(A,T)(G,C)(A,T)BBB, and the fourth is NO- 2(G,C)(A,T)(G,C)(A,T)(G,C)BBB.
- Oligonucleotide preparation from the three specific syntheses is added in to regular synthesis in experimentally determined amounts to increase hybrid generation with target sequences that have in front of the BBB sequence an AT rich (e.g. AATAT) or (A or T) and (G or C) alternating sequence (e.g. ACAGT or GAGAC). These sequences are expected to be less efficient in forming a hybrid. All 1024 target sequences can be tested for the efficiency to form hybrid with N 0 . 3 NNNNNBBB probes and those types that give the weakest binding may be prepared in about 1-10 additional synthesis and added to the basic probe preparation.
- AT rich e.g. AATAT
- a or T A or T
- G or C alternating sequence
- Decoding by Signatures a smaller number of probes for small number of distinct samples: 5- 7 positive out of 20 probes (5 cycles using 4 colors) has capacity to distinct about 10-100 thousand distinct fragments
- Decoding of 8-20mer RCR products arrays are formed as random distributions of unique 8 to 20 base recognition sequences in the form of DNA concatemers. The probes need to be decoded to determine the sequence of the 8-20 base probe region. At least two options are available to do this and the following example describes the process for a 12 mer. In the first, one half of the sequence is determined by utilizing the hybridization specificity of short probes and the ligation specificity of fully matched hybrids.
- Six or more bases can be sequences with additional probe pools.
- the 6mer oligonucleotide can be positioned further into the 12mer sequence. This will necessitate the incorporation of degenerate bases into the 3-prime end of the non-labeled oligonucleotide to accommodate the shift. This is an example of decoding probes for position 6 and 7 in the 12-mer.
- the 6 bases from the right side of the 12mer can be decoded by using a fixed oligonucleotide and 5-prime labeled probes.
- 6 cycles are required to define 6 bases of one side of the 12mer. With redundant cycle analysis of bases distant to the ligation site this may increase to 7 or 8 cycles.
- complete sequencing of the 12mer could be accomplished with 12-16 cycles of ligation. Partial or complete sequencing of arrayed DNA by combining two distinct types of libraries of detector probes. In this approach one set has probes of the general type N 3-8 B 4-6 (anchors) that are ligated with the first 2 or 3 or 4 probes/probe pools from the set BN 6 .
- the process is: 1) Hybridize 1-4 4-mers or more 5-mer anchors to obtain 70-80% 1 or 2 anchors per DNA.
- One way to discriminate which anchor is positive from the pool is to mix specific probes with distinct hybrid stability (maybe different number of Ns in addition).
- Anchors may be also tagged to determine which anchor from the pool is hybridized to a spot.
- Tags, as additional DNA segment may be used for adjustable displacement as a detection method. For example, EEEEEEEENNNAAAAA and
- FFFFFFFFNNNCCCCC probes can be after hybridization or hybridization and ligation differentially removed with two corresponding displacers:
- EEEEEEEENNNNN and FFFFFFNNNNNNNNNN where the second is more efficient. Separate cycles may be used just to determine which anchor is positive. For this purpose anchors labeled or tagged with multiple colors may be ligated to unlabeled N7-N10 supporter oligonucleotides.
- Tagging probes with DNA tags for larger multiplex of decoding or sequence determination probes can be tagged with different oligonucleotide sequences made of natural bases or new synthetic bases (such as isoG and isoC).
- Tags can be designed to have very precise binding efficiency with their anti-tags using different oligonucleotide lengths (about 6-24 bases) and/or sequence including GC content. For example 4 different tags may be designed that can be recognized with specific anti-tags in 4 consecutive cycles or in one hybridization cycle followed by a discriminative wash. In the discriminative wash initial signal is reduced to 95-99%, 30-40%, 10-20% and 0-5% for each tag, respectively.
- each 6mm x 6mm array may require roughly 30 images for full coverage by using a 10 mega pixel camera with .
- Each of 1 micrometer array areas is read by about 8 pixels.
- Each image is acquired in 250 milliseconds, 150ms for exposure and 100ms to move the stage. Using this fast acquisition it will take -7.5 seconds to image each array, or 12 minutes to image the complete set of 96 arrays on each substrate.
- this high image acquisition rate is achieved by using four ten-megapixel cameras, each imaging the emission spectra of a different fluorophore.
- the cameras are coupled to the microscope through a series of dichroic beam splitters.
- the autofocus routine which takes extra time,, runs only if an acquired image is out of focus. It will then store the Z axis position information to be used upon return to that section of that array during the next imaging cycle. By mapping the autofocus position for each location on the substrate we will drastically reduce the time required for image acquisition.
- Each array requires about 12-24 cycles to decode.
- Each cycle consists of a hybridization, wash, array imaging, and strip-off step. These steps, in their respective orders, may take for the above example 5,2,12,and 5 minutes each, for a total of 24 minutes each cycle, or roughly 5-10 hours for each array, if the operations were performed linearly.
- the time to decode each array can be reduced by a factor of two by allowing the system to image constantly. To accomplish this, the imaging of two separate substrates on each microscope is staggered. While one substrate is being reacted, the other substrate is imaged.
- An exemplary decoding cycle using cSBH includes the following steps: (i) set temperature of array to hybridization temperature (usually in the range 5-25 0 C); (ii) use robot pipetter to pre mix a small amount of decoding probe with the appropriate amount of hybridization buffer; (iii) pipette mixed reagents into hybridization chamber; (iv) hybridize for predetermined time; (v) drain reagents from chamber using pump (syringe or other); (vi) add a buffer to wash mismatches of non-hybrids; (vii) adjust chamber temperature to appropriate wash temp (about 10-40 0 C); (viii) drain chamber; (ix) add more wash buffer if needed to improve imaging; (x) image each array, preferably with a mid power (2Ox) microscope objective optically coupled to a high pixel count high sensitivity ccd camera, or cameras; plate stage moves chambers (or perhaps flow-cells with input funnels) over object, or objective-optics assembly moves under chamber; certain optical arrangements
- oligonucleotide probes of the invention can be labeled in a variety of ways, including the direct or indirect attachment of radioactive moieties, fluorescent moieties, colorimetric moieties, chemiluminescent moieties, and the like.
- Many comprehensive reviews of methodologies for labeling DNA and constructing DNA adaptors provide guidance applicable to constructing oligonucleotide probes of the present invention. Such reviews include Kricka, Ann. Clin. Biochem., 39: 114-129 (2002); Schaferling et al, Anal. Bioanal. Chem., (April 12, 2006); Matthews et al, Anal. Biochem., VoI 169, pgs.
- one or more fluorescent dyes are used as labels for the oligonucleotide probes, e.g. as disclosed by Menchen et al, U.S. patent 5,188,934 (4,7-dichlorofluorscein dyes); Begot et al, U.S. patent 5,366,860 (spectrally resolvable rhodamine dyes); Lee et al, U.S. patent 5, 847,162 (4,7- dichlororhodamine dyes); Khanna et al, U.S. patent 4,318,846 (ether-substituted fluorescein dyes); Lee et al, U.S.
- fluorescent signal generating moiety means a signaling means which conveys information through the fluorescent absorption and/or emission properties of one or more molecules.
- fluorescent properties include fluorescence intensity, fluorescence life time, emission spectrum characteristics, energy transfer, and the like.
- fluorescent nucleotide analogues readily incorporated into the labeling oligonucleotides include, for example, Cy3-dCTP, Cy3-dUTP, Cy5-dCTP, Cy5-dUTP (Amersham Biosciences, Piscataway, New Jersey, USA), fluorescein- 12-dUTP, tetramethylrhodamine-6-dUTP, Texas Red®-5-dUTP, Cascade Blue®-7-dUTP, BODIPY®
- fluorophores available for post-synthetic attachment include, inter alia, Alexa Fluor® 350, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 647, BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red (available from Molecular Probe
- FRET tandem fluorophores may also be used, such as PerCP-Cy5.5, PE-Cy5, PE-Cy5.5, PE-Cy7, PE-Texas Red, and APC-Cy7; also, PE-Alexa dyes (610, 647, 680) and APC-Alexa dyes.
- Biotin, or a derivative thereof may also be used as a label on a detection oligonucleotide, and subsequently bound by a detectably labeled avidin/streptavidin derivative ⁇ e.g. phycoerythrin-conjugated streptavidin), or a detectably labeled anti-biotin antibody.
- Digoxigenin may be incorporated as a label and subsequently bound by a detectably labeled anti-digoxigenin antibody ⁇ e.g. fluoresceinated anti-digoxigenin).
- An aminoallyl-dUTP residue may be incorporated into a detection oligonucleotide and subsequently coupled to an N-hydroxy succinimide (NHS) derivitized fluorescent dye, such as those listed supra.
- NHS N-hydroxy succinimide
- any member of a conjugate pair may be incorporated into a detection oligonucleotide provided that a detectably labeled conjugate partner can be bound to permit detection.
- the term antibody refers to an antibody molecule of any class, or any subfragment thereof, such as an Fab.
- suitable labels for detection oligonucleotides may include fluorescein (FAM), digoxigenin, dinitrophenol (DNP), dansyl, biotin, bromodeoxyuridine (BrdU), hexahistidine (6xHis), phosphor-amino acids (e.g. P-tyr, P-ser, P-thr) , or any other suitable label.
- FAM fluorescein
- DNP dinitrophenol
- RhdU bromodeoxyuridine
- 6xHis hexahistidine
- phosphor-amino acids e.g. P-tyr, P-ser, P-thr
- the following hapten/antibody pairs are used for detection, in which each of the antibodies is derivatized with a detectable label: biotin/ ⁇ -biotin, digoxigenin/ ⁇ -digoxigenin, dinitrophenol (DNP)/ ⁇ -DNP, 5- Carboxyfluorescein (FAM)/ ⁇
- probes may also be indirectly labeled, especially with a hapten that is then bound by a capture agent, e.g. as disclosed in Holtke et al, U.S. patent 5,344,757; 5,702,888; and 5,354,657; Huber et al, U.S. patent 5,198,537; Miyoshi, U.S. patent 4,849,336; Misiura and Gait, PCT publication WO 91/17160; and the like. Many different hapten-capture agent pairs are available for use with the invention.
- haptens include, biotin, des-biotin and other derivatives, dinitrophenol, dansyl, fluorescein, CY5, and other dyes, digoxigenin, and the like.
- a capture agent may be avidin, streptavidin, or antibodies.
- Antibodies may be used as capture agents for the other haptens (many dye-antibody pairs being commercially available, e.g. Molecular Probes).
- kits for construction of random arrays of the invention include, but are not limited to, kits for determining the nucleotide sequence of a target polynucleotide, kits for large-scale identification of differences between reference DNA sequences and test DNA sequences, kits for profiling exons, and the like.
- a kit typically comprises at least one support having a surface and one or more reagents necessary or useful for constructing a random array of the invention or for carrying out an application therewith.
- Such reagents include, without limitation, nucleic acid primers, probes, adaptors, enzymes, and the like, and are each packaged in a container, such as, without limitation, a vial, tube or bottle, in a package suitable for commercial distribution, such as, without limitation, a box, a sealed pouch, a blister pack and a carton.
- the package typically contains a label or packaging insert indicating the uses of the packaged materials.
- packaging materials includes any article used in the packaging for distribution of reagents in a kit, including without limitation containers, vials, tubes, bottles, pouches, blister packaging, labels, tags, instruction sheets and package inserts.
- the invention provides a kit for making a random array of concatemers of DNA fragments from a source nucleic acid comprising the following components: (i) a support having a surface; and (ii) at least one adaptor oligonucleotide for ligating to each DNA fragment and forming a DNA circle therewith, each DNA circle capable of being replicated by a rolling circle replication reaction to form a concatemer that is capable of being randomly disposed on the surface.
- the surface may be a planar surface having an array of discrete spaced apart regions, wherein each discrete spaced apart region has a size equivalent to that of said concatemers.
- the discrete spaced apart regions may form a regular array with a nearest neighbor distance in the range of from 0.1 to 20 ⁇ m.
- the concatemers on the discrete spaced apart regions may have a nearest neighbor distance such that they are optically resolvable.
- the discrete spaced apart regions may have capture oligonucleotides attached and the adaptor oligonucleotides may each have a region complementary to the capture oligonucleotides such that the concatemers are capable of being attached to the discrete spaced apart regions by formation of complexes between the capture oligonucleotides and the complementary regions of the adaptor oligonucleotides.
- kits may further comprise (a) a terminal transferase for attaching a homopolymer tail to said DNA fragments to provide a binding site for a first end of said adaptor oligonucleotide, (b) a ligase for ligating a strand of said adaptor oligonucleotide to ends of said DNA fragment to form said DNA circle, (c) a primer for annealing to a region of the strand of said adaptor oligonucleotide, and (d) a DNA polymerase for extending the primer annealed to the strand in a rolling circle replication reaction.
- the above adaptor oligonucleotide may have a second end having a number of degenerate bases in the range of from 4 to 12.
- kits for sequencing a target polynucleotide comprising the following components: (i) a support having a planar surface having an array of optically resolvable discrete spaced apart regions, wherein each discrete spaced apart region has an area of less than 1 ⁇ m 2 ; (ii) a first set of probes for hybridizing to a plurality of concatemers randomly disposed on the discrete spaced apart regions, the concatemers each containing multiple copies of a DNA fragment of the target polynucleotide; and (iii) a second set of probes for hybridizing to the plurality of concatemers such that whenever a probe from the first set hybridizes contiguously to a probe from the second set, the probes are ligated.
- kits may further include a ligase, a ligase buffer, and a hybridization buffer.
- the discrete spaced apart regions may have capture oligonucleotides attached and the concatemers may each have a region complementary to the capture oligonucleotides such that said concatemers are capable of being attached to the discrete spaced apart regions by formation of complexes between the capture oligonucleotides and the complementary regions of said concatemers.
- kits for constructing a single molecule array comprising the following components: (i) a support having a surface having reactive functionalities; and (ii) a plurality of macromolecular structures each having a unique functionality and multiple complementary functionalities, the macromolecular structures being capable of being attached randomly on the surface wherein the attachment is fo ⁇ ned by one or more linkages formed by reaction of one or more reactive functionalities with one or more complementary functionalities; and wherein the unique functionality is capable of selectively reacting with a functionality on an analyte molecule to form the single molecule array.
- the surface is a planar surface having an array of discrete spaced apart regions containing said reactive functionalities and wherein each discrete spaced apart region has an area less than 1 ⁇ m 2 .
- the discrete spaced apart regions form a regular array with a nearest neighbor distance in the range of from 0.1 to 20 ⁇ m.
- the concatemers on the discrete spaced apart regions have a nearest neighbor distance such that they are optically resolvable.
- the macromolecular structures may be concatemers of one or more DNA fragments and wherein the unique functionalities are at a 3' end or a 5' end of the concatemers.
- kits for circularizing DNA fragments comprising the components: (a) at least one adaptor oligonucleotide for ligating to one or more DNA fragments and forming DNA circles therewith (b) a terminal transferase for attaching a homopolymer tail to said DNA fragments to provide a binding site for a first end of said adaptor oligonucleotide, (c) a ligase for ligating a strand of said adaptor oligonucleotide to ends of said DNA fragment to form said DNA circle, (d) a primer for annealing to a region of the strand of said adaptor oligonucleotide, and (e) a DNA polymerase for extending the primer annealed to the strand in a rolling circle replication reaction.
- the above adaptor oligonucleotide may have a second end having a number of degenerate bases in the range of from 4 to 12.
- the above kit may further include reaction buffers for the terminal transferase, ligase, and DNA polymerase.
- the invention includes a kit for circularizing DNA fragments using a Circligase enzyme (Epicentre Biotechnologies, Madison, WI), which kit comprises a volume exclusion polymer.
- such kit further includes the following components: (a) reaction buffer for controlling pH and providing an optimized salt composition for Circligase, and (b) Circligase cofactors.
- a reaction buffer for such kit comprises 0.5 M MOPS (pH 7.5), 0.1 M KCl, 50 mM MgCl 2 , and 10 mM DTT.
- such kit includes Circligase, e.g. 10-100 ⁇ L Circligase solution (at 100 unit/ ⁇ L).
- Exemplary volume exclusion polymers are disclosed in U.S. patent 4,886,741, and include polyethylene glycol, polyvinylpyrrolidone, dextran sulfate, and like polymers.
- polyethylene glycol (PEG) is 50% PEG4000.
- a kit for circle formation includes the following:
- Mismatch Enzyme Cleavage Arrays and sequencing methods of the invention used may be used for large-scale identification of polymorphisms using mismatch cleavage techniques.
- Several approaches to mutation detection employ a heteroduplex in which the mismatch itself is utilized for cleavage recognition. Chemical cleavage with piperidine at mismatches modified with hydroxylamine or osmium tetroxide provides one approach to release a cleaved fragment.
- EMC enzyme mismatch cleavage
- Cleavase is used in the cleavage fragments length polymorphism (CFLP) technique which has been commercialized by Third Wave Technologies. When single stranded DNA is allowed to fold and adopt a secondary structure the DNA will form internal hairpin loops at locations dependent upon the base sequence of the strand.
- CFLP cleavage fragments length polymorphism
- Cleavase will cut single stranded DNA five-prime of the loop and the fragments can then be separated by PAGE or similar size resolving techniques.
- Mismatch binding proteins such as Mut S and Mut Y also rely upon the formation of heteroduplexes for their ability to identify mutation sites. Mismatches are usually repaired but the binding action of the enzymes can be used for the selection of fragments through a mobility shift in gel electrophoresis or by protection from exonucleases, e.g. Ellis et al (cited above).
- Templates for heteroduplex formation are prepared by primer extension from genomic DNA.
- an excess of the opposite strand is prepared in the same way as the test DNA but in a separate reaction.
- the test DNA strand produced is biotinylated and is attached to a streptavidin support. Homoduplex formation is prevented by heating and removal of the complementary strand.
- the reference preparation is now combined with the single stranded test preparation and annealed to produce heteroduplexes. This heteroduplex is likely to contain a number of mismatches. Residual DNA is washed away before the addition of the mismatch endonuclease, which, if there is a mismatch every 1 kb would be expected to produce about 10 fragments for a 10kb primer extension.
- each fragment can bind an adapter at each end and enter the mismatch-fragment circle selection process.
- Capture of mismatch cleaved DNA from Large genomic fragments The 5-10 kb genomic fragments prepared from large genomic fragments as described above are biotinylated by the addition of a biotinylated dideoxy nucleotide at the 3-prime end with terminal transferase and excess biotinylated nucleotide are removed by filtration.
- a reference BAC clone that covers the same region of sequence is digested with the same six-base cutter to match the fragments generated from the test DNA.
- the biotinylated genomic fragments are heat denatured in the presence of the BAC reference DNA and slowly annealed to generate biotinylated heteroduplexes.
- the reference BAC DNA is in large excess to the genomic DNA so the majority of biotinylated products will be heteroduplexes.
- the biotinylated DNA can then be attached to the surface for removal of the reference DNA. Residual DNA is washed away before the addition of the mismatch endonuclease. After cleavage, each fragment can bind an adapter at each end and enter the mismatch circle selection process as follows, (a) DNA is cleaved on both sides of the mismatch, (b) 5-prime overhangs are generated that can be ligated.
- 3' overhangs are also created by digesting with an appropriate restriction endonuclease having a four base recognition site.)
- An adapter is introduced that contains an active overhang at one side,
- An adapter is ligated to each of the two generated fragments (only ligation to the right from the 5' phosphate after addition of sequences to the 3' end of the top strand),
- the molecule is phosphorylated and a bridging oligonucleotide is used to ligate the two ends of the single stranded molecule,
- a concatemer is generated by extending a primer in a RCR reaction.
- heteroduplexes generated above can be used for selection of small DNA circles, as illustrated in Figs. 7 and 8.
- heteroduplex (700) of a sample is treated with the mismatch enzyme to create products cleaved on both strands (704 and 706) surrounding the mutation site (702) to produce fragments (707) and (705).
- T7 endonuclease I or similar enzyme cleaves 5-prime of the mutation site to reveal a 5-prime overhang of varying length on both strands surrounding the mutation.
- the next phase is to capture the cleaved products in a form suitable for amplification and sequencing.
- Adapter (710) is ligated to the overhang produced by the mismatch cutting (only fragment (705) shown), but because the nature of the overhang is unknown, at least three adapters are needed and each adapter is synthesized with degenerate bases to accommodate all possible ends.
- the adapter can be prepared with an internal biotin (708) on the non-circularizing strand to allow capture for buffer exchange and sample cleanup, and also for direct amplification on the surface if desired. Because the intervening sequence between mutations does not need to be sequenced and reduces the sequencing capacity of the system it is removed when studying genomic-derived samples. Reduction of sequence complexity is accomplished by a type Hs enzyme that cuts the DNA at a point away from the enzyme recognition sequence.
- the cut site and resultant overhangs will be a combination of all base variants.
- Enzymes that can be used include Mmel (20 bases with 2 base 3' overhang) and Eco P 151 (with 25 bases and 2 base 5' overhang).
- the adapter is about 50 bp in length to provide sequences for initiation of rolling circle amplification and also provide stuffer sequence for circle formation, as well as recognition site (715) for a type Hs restriction endonuclease. Once the adapter has been ligated to the fragment the DNA is digested (720) with the type Hs restriction enzyme to release all but 20-25 bases of sequence containing the mutation site that remains attached to the adapter.
- the adaptered DNA fragment is now attached to a streptavidin support for removal of excess fragment DNA. Excess adapter that did not ligate to mismatch cleaved ends will also bind to the streptavidin solid support.
- the new degenerate end created by the type Hs enzyme can now be ligated to a second adapter through the phosphorylation of one strand of the second adapter. The other strand is non-phosphorylated and blocked at the 3-prime end with a dideoxy nucleotide.
- the structure formed is essentially the genomic fragment of interest captured between two different adapters. To create a circle from this structure would simply require both ends of the molecule coming together and ligating, e.g.
- second adapter If second adapter has been attached then it will be protected from digestion because there is no 5-prime phosphate available. If only the first adapter is attached to the surface then the 5-prime phosphate is exposed for degradation of the lower strand of the adapter. This will lead to loss of excess first adapter from the surface.
- the 5 prime end of the top strand of the first adapter is prepared for ligation to the 3-prime end of the second adapter.
- This can be achieved by introducing a restriction enzyme site into the adapters so that re-circularizatioii of the molecule can occur with ligation.
- Amplification of DNA captured into the circular molecules proceeds by a rolling circle amplification to form long linear concatemer copies of the circle. If extension initiates 5-prime of the biotin, the circle and newly synthesized strand is released into solution.
- Complementary oligonucleotides on the surface are responsible for condensation and provide sufficient attachment for downstream applications.
- One strand is a closed circle and acts as the template. The other strand, with an exposed 3-prime end, acts as an initiating primer and is extended.
- the adapter can be prepared with a 3-prime biotin (808) on the non- circularized strand to allow capture for buffer exchange and sample cleanup.
- Reduction of sequence complexity of the 10 kb heteroduplex fragments described above occurs through the use of 4-base cutting restriction enzymes, e.g. with restriction sites (810), (812), and (814). Use of 2 or 3 enzymes in the one reaction could reduce the genomic fragment size down to about 100 bases.
- the adapter-DNA fragment can be attached to a streptavidin support for removal of excess fragment DNA. Excess adapter that did not ligate to mismatch cleaved ends will also bind to the streptavidin solid support.
- the biotinylated and phosphorylated strand can now be removed by lambda exonuclease which will degrade from the 5-prime end but leave the non-phosphorylated strand intact.
- To create a circle from this structure now requires both ends of the molecule coming together and ligating to form the circle.
- Several approaches are available to form the circle using a bridging oligonucleotide, as described above.
- a polynucleotide can be added to the 3-prime end with terminal transferase to create a sequence for one half of a bridge oligonucleotide (818) to hybridize to, shown as polyA tail (816). The other half will bind to sequences in the adapter.
- an adapter can be added to the end generated by the 4-base cutter which will provide sequence for the bridge to hybridize to after removal of one strand by exonuclease.
- a key aspect of this selection procedure is the ability to select the strand for circularization and amplification. This ensures that only the strand with the original mutation (from the 5-prime overhang) and not the strand from the adapter is amplified. If the 3-prime recessed strand was amplified then a mismatch from the adapter could create a false base call at the site of or near to the mutation. Amplification of DNA captured into the circular molecules proceeds by a rolling circle amplification to form linear concatemer copies of the circle.
- mis-match derived small circular DNA molecules may be amplified by other means such as PCR. Common primer binding sites can be incorporated into the adapter sequences
- the amplified material can be used for mutation detection by methods such as Sanger sequencing or array based sequencing.
- the first step of this procedure will involve ligating a gene specific oligonucleotide directed to the 5-prime end with a poly dA sequence for binding to the poly dT sequence of the 3-prime end of the cDNA.
- This oligonucleotide acts as a bridge to allow T4 DNA ligase to ligate the two ends and form a circle.
- the second step of the reaction is to use a primer, or the bridging oligonucleotide, for a strand displacing polymerase such as Phi 29 polymerase to create a concatemer of the circle.
- the long linear molecules will then be diluted and arrayed in 1536 well plates such that wells with single molecules can be selected. To ensure about 10 % of the wells contain 1 molecule approximately 90% would have to be sacrificed as having no molecules.
- a dendrimer that recognizes a universal sequence in the target is hybridized to generate 1 OK-10OK dye molecules per molecule of target. Excess dendrimer is removed through hybridization to biotinylated capture oligos. The wells are analyzed with a fluorescent plate reader and the presence of DNA scored. Positive wells are then re-arrayed to consolidate the clones into plates with complete wells for further amplification
- Splice Variant Detection and Exon Profiling The process described is based on random DNA arrays and "smart" probe pools for the identification and quantification of expression levels of thousands of genes and their splice variants.
- spliceosomes interact with splice sites on the primary transcript to excise out the introns, e.g. Maniatis et al, Nature, 418: 236-243 (2002).
- methods of the invention permit large-scale measurement of splice variants with the following steps: (a) Prepare full length first strand cDNA for targeted or all mRNAs. (b) Circularize the generated full length (or all) first strand cDNA molecules by incorporating an adapter sequence, (c) By using primer complementary to the adapter sequence perform rolling circle replication (RCR) of cDNA circles to form concatemers with over 100 copies of initial cDNA.
- RCR rolling circle replication
- This system provides a complete analysis of the exon pattern on a single transcript, instead of merely providing information on the ratios of exon usage or quantification of splicing events over the entire population of transcribed genes using the current expression arrays hybridized with labeled mRNA/cDNA. At the maximum limit of its sensitivity, it allows a detailed analysis down to a single molecule of a mRNA type present in only one in hundreds of other cells; this would provide unique potentials for early diagnosis of cancer cells.
- the proposed splice variant profiling process is equivalent to high throughput sequencing of individual full length cDNA clones; rSBH throughput can reach one billion cDNA molecules profiled in a 4-8 hour assay.
- This system will provide a powerful tool to monitor changes in expression levels of various splice variants during disease emergence and progression. It can enable discovery of novel splice variants or validate known splice variants to serve as biomarkers to monitor cancer progression. It can also provide means to further understanding the roles of alternative splice variants and their possible uses as therapeutic targets. Universal nature and flexibility of this low cost and high throughput assay provides great commercial opportunities for cancer research and diagnostics and in all other biomedical areas. This high capacity system is ideal for service providing labs or companies.
- PCR products are generated from cDNA using gene specific oligos for the full length sequence. For longer genes, PCR products are generated comprising about 500 bp that corresponding to contiguous block of exons and ordered the fragments by cloning into appropriate cloning sites in the MCS of pBluescript.
- the last site of the MCS is used to insert a string of 40 A's to simulate the polyA tails of cellular mRNA. This is to control for the possibility that the polyA tail might interfere with the sample preparation step described below, although it is not expected to be a problem since a poly-dA tail is incorporated in sample preparation of genomic fragments as described.
- T7 RNA polymerase will be used to generate the run-off transcripts and the RNA generated will be purified with the standard methods.
- cDNA is prepared for those specific genes only.
- gene-specific primers are used, therefore for 1000 genes, 1000 primers are used.
- the location of the priming site for the reverse transcription is selected with care, since it is not reasonable to expect the synthesis of cDNA >2kb to be of high efficiency. It is quite common that the last exon would consist of the end of the coding sequence and a long 3' untranslated region.
- the 3' UTR comprises of 3kb, while the coding region is only 2.2 kb.
- the logical location of the reverse transcription primer site is usually immediately downstream of the end of the coding sequence.
- the alternative exons are often clustered together as a block to create a region of variability.
- Tenascin C variants the most common isoform has a block of 8 extra exons, and there is evidence to suggest that there is variability in exon usage in that region. So for Tenascin C, the primer will be located just downstream of that region. Because of the concern of synthesizing cDNA with length >2kb, for long genes, it might be necessary to divide the exons into blocks of 2 kb with multiple primers.
- Reverse transcription reactions may be carried out with commercial systems, e.g. Superscript III system from Invitrogen (Carlsbad, CA) and the StrataScript system from Stratagene (La Jolla, CA).
- Superscript III system from Invitrogen (Carlsbad, CA)
- StrataScript system from Stratagene (La Jolla, CA).
- a single template oligonucleotide that is complementary to both the adaptor sequence and the universal tag can be used to ligate the adaptor to all the target molecules, without using the template oligonucleotide with degenerate bases.
- the 3' end of the cDNA (5' end of the mRNA) which is usually ill-defined, it may be treated like a random sequence end of a genomic fragment. Similar methods of adding a polyA tail will be applied, thus the same circle closing reaction may also be used.
- Reverse transcriptases are prone to terminate prematurely to create truncated cDNAs. Severely truncated cDNAs probably will not have enough probe binding sites to be identified with a gene assignment, thus would not be analyzed.
- cDNA molecules that are close, but not quite full- length may show up as splice variant with missing 5' exons. If there are no corroborating evidence from a sequence database to support such variants, they may be discounted. A way to avoid such problem is to select for only the full-length cDNA (or those with the desired 3' end) to be compatible with circle closing reaction, then any truncated molecules will not be circularized nor replicated.
- First a dideoxy-cytosine residue can be added to the 3' end of all the cDNA to block ligation, then by using a mismatch oligo targeting the desired sequence, a new 3' end can be generated by enzyme mismatch cleavage using T4 endonuclease VII. With the new 3' end, the cDNA can proceed with the adding a poly-dA tail and with the standard protocols of circularization and replication.
- Replicated and arrayed concatemers of the exon fragments may be carried out using combinatorial SBH, as described above.
- the algorithm of the following steps may be used to select 5-mer and 6-mer probes for use in the technique:
- Step 1 Select 1000-2000 shortest exons (total about 20 - 50 kb), and find out matching sequences for each of 1024 available labeled 5-mers. On average each 5-mer will occur 20 times over 20 kb, but some may occur over 50 or over 100 times. By selecting the most frequent 5-mer, the largest number of short exons will be detected with the single labeled probe. A goal would be to detect about 50-100 short exons (10%-20% of 500 exons) per cycle. Thus less than 10 labeled probes and 50-100 unlabeled 6-mers would be sufficient. Small number of labeled probes is favorable because it minimizes overall fluorescent background.
- Step 2 Find out all 6-mers that are contiguous with all sites in all 1000 genes that are complementary to 10 selected 5-mers. On average 20 such sites will exist in each 2kb gene. Total number of sites would be about 20,000, e.g., each 6-mer on average will occur 5 times. Sort 6-mers by the hit frequency. The most frequent may have over 20 hits, e.g. such 6-mer will detect 20 genes through combinations with 10 labeled probes. Thus, to get a single probe pair for each of the 500 genes a minimum of 25 6-mer probes would be required. Realistically, 100 to 200 6-mers may be required. Due to benefits of combinatorial SBH that uses pre-made libraries of 6-mer and 5-mer probes
- probe pools are readily prepared with about 200 probes per pool using established pipetting robotics.
- the information generated is equivalent to having over 3 probes per exon, therefore the use of 8000 5-mers and 6-mers effectively replaces the 30,000 longer exons specific probes required for a single set of 1000 genes.
- Exon profiling The profiling of exons can be performed in two phases : the gene identification phase and the exon identification phase.
- the gene identification phase each concatemer on the array can be uniquely identified with a particular gene.
- 10 probe pools or hybridization cycles will be enough to identify 1000 genes using the following scheme.
- Each gene is assigned a unique binary code. The number of binary digits thus depends on the total number of genes: 3 digits for 8 genes, 10 digits for 1024 genes.
- Each probe pool is designed to correspond to a digit of the binary code and would contain probes that would hit a unique combination of half of the genes and one hit per gene only. Thus for each hybridization cycle, an unique half of the genes will score a 1 for that digit and the other half will score zero.
- Ten hybridization cycles with 10 probe pools will generate 1024 unique binary codes, enough to assign 1000 unique genes to all the concatemers on the array. To provide redundancy in the identification data, 15-20 cycles would be used. If 20 cycles are used, it would provide 1 million unique binary codes and there should be enough information to account for loss of signals due to missing exons or gene deletions.
- exon identification phase After identifying each ampliot with a gene assignment, its exon pattern will be profiled in the exon identification phase. For the exon identification phase, one exon per gene in all or most of the genes is tested per hybridization cycle. In most cases 10-20 exon identification cycles should be sufficient. Thus, in the case of using 20 exon identification cycles we will obtain information of 2 probes per each of 10 exons in each gene. For genes with more than 20 exons, methods can be developed so that 2 exons per gene can be probed at the same cycle. One possibility is using multiple fluorophores of different colors, and another possibility is to exploit differential hybrid stabilities of different ligation probe pairs.
- a total of about 40 assay cycles will provide sufficient information to obtain gene identity at each spot and to provide three matching probe-pairs for each of 10,000 exons with enough informational redundancy to provide accurate identification of missing exons due to alternative splicing or chromosomal deletions.
- a glass cover slip is prepared for use as a support for disposing DNA concatemers.
- the following materials are used: Millipore DI water 2.5 ml of 3-Aminopropyldimethylethoxysilane (Gelest)
- KOH is dissolving, lay out 6 pre-washed glass containers, fill containers 2-5 with DI water until V 2 inch from top ( ⁇ 800ml). Fill container 6 with acetone V 2 " to top. Carefully pour dissolved KOH solution into container 1 until V 2 " to top. Add racked cover slips to container 1 wait 3 minutes, remove racks from container 1 and wash in containers 2-5 leaving racks in each container a minimum of 15 seconds. Submerse racks briefly in container 6. Set aside racks, dispose the solutions from containers 1 and 2 in the basic waste container using the large funnel and thick nitrile gloves, clean and dry labware. Lay out 7 clean and dry glass containers. Add 775 ml of acetone to container 1 add
- E.coli genomic DNA (32 ug) (Sigma Chemical Co) was fragmented with 0.16 U of Dnasel (Epicentre) at 37 0 C for 10 min and then heat inactivated at 95 0 C for 10 min. Reaction products were distributed with an average size of 200 bp as determined by agarose gel electrophoresis. If reaction products did not meet the required size distribution they were further digested with the addition of fresh enzyme. The final concentration was 200 ng/ul of genomic DNA.
- the Dnase digested DNA (26 ng/ul) was reacted with Terminal deoxynucleotide transferase (0.66 U/ul) from New England Biolabs (NEB) in reaction buffer supplied by NEB.
- the reaction contained dATP (2 mM) and was performed at 37C for 30 min and then heat inactivated at 70 C for 10 min.
- the DNA sample was then heated to 95C for 5 min before rapid cooling on ice.
- a synthetic DNA adapter was then ligated to the 5' end of the genomic DNA by first forming a hybrid of a 65-base oligonucleotide
- the shorter oligo will act as a splint for ligation of the 65mer to the 5' end of the genomic fragments.
- the splint molecule consists of 7 degenerate bases at its 5' end to hybridize to variable bases at the 5' end of the genomic DNA.
- the adapter hybrid was formed by slowly hybridizing 1200 pmol of adapter with 1200 pmol of splint in 52 ul from 95C to room temperature over lhr.
- T4 DNA Ligase (0.3 U/ul) was combined with genomic DNA (17 ng/ul) and adapter-splint (0.5 uM) in IX ligase reaction buffer supplied by NEB. The ligation proceeded at 15C for 30 min, 2OC for 30 min and then inactivated at 7OC for 10 min. A second splint molecule (AGATGATATTTTTTTT 3' 2'3'ddC) (SEQ ID NO: 10) (0.6 uM) was then added to the reaction and the mix was supplemented with more ligase buffer and T4 DNA ligase (0.3 U/ul). The reaction proceeded at 15C for 30 min and then at 2OC for 30 min before inactivation for 10 min at 7OC. The ligation mix was then treated with exonuclease I (NEB) (1 U/ul) at 37 C for 60 min, followed by inactivation at 8OC for 20 min
- Rolling circle replication was performed in reaction buffer supplied by NEB with BSA (0.1 ug/ul), 0.2 mM each dNTP, an initiating primer (TCAGCTTCCTTTTGTCTTCCTAAC) (SEQ ID NO: 11) at 2 fmol/ul, exonuclease treated ligation of genomic DNA at 24 pg/ul, and Phi 29 polymerase (0.2 U/ul).
- the reaction was performed for 1 hr at 30C and then heat inactivated at 7OC for 10 min.
- RCR reaction products were attached to the surface of cover slips by first attaching amine modified oligonucleotides to the surface of the cover slips.
- a capture probe [AMINOC6][SP- CIS][SP-CI S]GGATGTTAGGAAGACAAAAGGAAGCTGAGG) (SEQ ID NO: 12) (50 uM) was added to the DITC derivatized cover slips in 0.1 uM NaHCO3 and allowed to dry at 40 C for about 30 min.
- the cover slips were rinsed in DDI water for 15 min and dried.
- RCR reaction products (4.5 ul) were then combined with 0.5 ul of 20 X SSPE and added to the center of the slide.
- RCR reaction products were formed from a single stranded 80mer synthetic DNA target (NNNNNNNNGCATANCACGANGTCATNATCGTNCAAACGTCAGTCCANGAATCNAGATC CACTTAGANTAAAAAAAAAAAA) (SEQ ID NO: 13) as above but without poly A addition with TDT.
- the RCR reaction contained target molecules at an estimated 12.6 fmol/ul.
- Reaction products (5 ul) were combined with SSPE (2X) and SDS (0.3%) in a total reaction volume of 20 ul.
- the sample was applied to a cover-slip in which lines of capture probe ([AMINOCo][SP-C 18] [SP- C18]GGATGTTAGGAAGACAAAAGGAAGCTGAGG),deposited in a solution of 50 uM with 0.1 uM NaHCO3, were dried onto the surface and left in a humid chamber for 30 min. The solution was then washed off in 3x SSPE for 10 min and then briefly in water.
- lines of capture probe [AMINOCo][SP-C 18] [SP- C18]GGATGTTAGGAAGACAAAAGGAAGCTGAGG
- RCR reaction products may be attached by method 2. Attachment method 1. RCR reaction products (4.5 ul) were combined with 0.5 ul of 20 X SSPE and added to the center of the slide. The sample was allowed to air dry and non-attached material was washed off for 10 min in 3x SSPE and then briefly in DDI water. The slide was then dried before assembly on the microscope.
- Attached RCR products were visualized by hybridizing an 1 lmer TAMRA labeled probe that is complementary to a region of the adapter. Attachment method 2. RCR reaction products (1 ul) were combined with 50 ul of 3XSSPE and added to the center of the cover slip with capture probe attached. Addition of SDS (0.3%) was found to promote specific attachment to the capture probes and not to the derivatized surface. The sample was incubated at room temperature for 30 min and non-attached material was washed off for 10 min in 3x SSPE and then briefly in DDI water. The slide was then dried before assembly on the microscope. Attached RCR products were visualized by hybridizing an 1 lmer TAMRA labeled probe that is complementary to a region of the adapter. The above protocols provide RCR product densities of about 1 RCR product per 2-4 micron square. Exemplary image of a resulting cover slip is shown in Fig. 3.
- a 155 bp amplicon sequence from B. anthracis and a 275 bp amplicon sequence from Y. pestis were amplified using standard PCR techniques with PCR primers in which one primer of the pair was phosphorylated.
- a single stranded form of the PCR products was generated by degradation of the phosphorylated strand using lambda exonuclease. The 5' end of the remaining strand was then phosphorylated using T4 DNA polynucleotide kinase to allow ligation of the single stranded product to the universal adaptor.
- the universal adaptor was ligated using T4 DNA ligase to the 5' end of the target molecule, assisted by a template oligonucleotide complementary to the 5' end of the targets and 3' end of the universal adaptor.
- the adaptor ligated targets were then circularized using bridging oligonucleotides with bases complementary to the adaptor and to the 3' end of the targets.
- Linear DNA molecules were removed by treating with exonuclease I.
- RCR products DNA concatemers
- Phi29 polymerase were generated by mixing the single-stranded samples and using Phi29 polymerase to replicate around the circularized adaptor- target molecules with the bridging oligonucleotides as the initiating primers.
- cover slips for attaching amine-modified oligonucleotides were first cleaned in a potassium/ethanol solution followed by rinsing and drying. They were then treated with a solution of 3-aminopropyldimethylethoxysilane, acetone, and water for 45 minutes and cured in an oven at 100°C for 1 hour. As a final step, the cover slips were treated with a solution of p- phenylenediisothiocyanate (PDC), pyridine, and dimethylformamide for 2 hours.
- PDC p- phenylenediisothiocyanate
- the capture oligonucleotide (sequence 5'-GGATGTTAGGAAGACAAAAGGAAGCTGAGG-S') (SEQ ID NO: 14) is complementary to the universal adaptor sequence, and is modified at the 5' end with an amine group and 2 C-18 linkers.
- 10 ⁇ l of the capture oligo at 10 ⁇ M in 0.1M NaHCO 3 was spotted onto the center of the derivatized cover slip, dried for 10 minutes in a 70°C oven and rinsed with water.
- the RCR reaction containing the DNA concatemers was diluted 10-folds with 3X SSPE, 20 ⁇ l of which was then deposited over the immobilized capture oligonucleotides on the cover slip surface for 30 minutes in a moisture saturated chamber.
- the cover slip with the DNA concatemers was then assembled into a reaction chamber and was rinsed by 2 ml of 3X SSPE.
- pestis PCR amplicons were probed sequentially with TAMRA-labeled oligomer: probe BrPrb3 (sequence : 5'-CATTAACGGAC ⁇ ' (SEQ ID NO: 15), specifically complementary to the universal adaptor sequence), probe Ba3 (sequence : 5'-TGAGCGATTCG-S' (SEQ ID NO: 16), specifically complementary to the Ba3 amplicon sequence), probe Yp3 (sequence : 5'-GGTGTCATGGA-S', specifically complementary to the Yp3 amplicon sequence).
- the probes were hybridized to the array at a concentration of 0.1 ⁇ M for 20 min in 3X SSPE at room temperature.
- Individual molecules of a synthetic oligonucleotide containing a degenerate base can be divided into 4 sub-populations, each may have either an A, C, G or T base at that particular position.
- An array of concatemers created from this synthetic DNA may have about 25% of spots with each of the bases.
- Successful identification of these sub-populations of concatemers was demonstrated by four successive hybridization and ligation of pairs of probes, specific to each of the 4 bases, as shown in Fig. 5.
- a 5' phosphorylated, 3' TAMRA-labeled pentamer oligonucleotide was paired with one of the four hexamer oligonucleotides.
- Each of these 4 ligation probe pairs should hybridize to either an A, C, G or T containing version of the target.
- Discrimination scores of greater than 3 were obtained for most targets, demonstrating the ability to identify single base differences between the nanoball targets.
- the discrimination score is the highest spot score divided by the average of the other 3 base-specific signals of the same spot.
- the results further demonstrate the ability to determine partial or complete sequences of DNA present in concatemers by increasing the number of consecutive probe cycles or by using 4 or more probes labeled with different dyes per each cycle.
- Synthetic oligonucleotide (TlA : 5'- NNNNNNNNGCATANCACGANGTCATNATCGTNCAAACGTCAGTCCANGAATCNAGATCC ACTTAGANTAAAAAAAAAA-3') (SEQ ID NO: 13) contains at position 32 a degenerate base. Universal adaptor was ligated to this oligonucleotide and the adaptor-TIA DNA was circularized as described before. DNA concatemers made using the rolling circle replication (RCR) reaction on this target were arrayed onto the random array.
- RCR rolling circle replication
- DNA in a particular arrayed spot would contain either an A, or a C, or a G, or a T at positions corresponding to position 32 of TlA.
- a set of 4 ligation probes specific to each of the 4 bases was used.
- a 5' phosphorylated, 3' TAMRA-labeled pentamer oligonucleotide corresponding to position 33-37 of TlA with sequence CAAAC (probe TlA9b) was paired with one of the following hexamer oligonucleotides corresponding to position 27-32 : ACTGTA (probe TlA9a), ACTGTC (probe TlAlOa), ACTGTG (probe TlAl Ia), ACTGTT (probe Tl A12a).
- ACTGTA probe TlA9a
- ACTGTC probe TlAlOa
- ACTGTG probe TlAl Ia
- ACTGTT probe Tl A12a
- the probes were incubated with the array in a ligation/hybridization buffer containing T4 DNA ligase at 20°C for 5 minutes. Excess probes were washed off at 20°C and images were taken with a TIRF microscope. Bound probes were stripped to prepare for the next round of hybridization.
- An adaptor specific probe (BrPrb3) was hybridized to the array to establish the positions of all the spots.
- the 4 ligation probe pairs, at 0.4 ⁇ M, were then hybridized successively to the array with the base identifications as illustrated for four spots in Fig. 5. It is clear that most of the spots are associated with only one of the 4 ligation probe pairs, and thus the nature of the base at position 32 of TlA can be determined specifically.
- the same synthetic oligonucleotide described above contains 8 degenerate bases at the 5' end to simulate random genomic DNA ends.
- the concatemers created from this oligonucleotide may have these 8 degenerate bases placed directly next to the adaptor sequence.
- a 12-mer oligonucleotide (UKO- 12 sequence 5'-ACATTAACGGAC-S') (SEQ ID NO: 17) with a specific sequence to hybridize to the 3' end of the adaptor sequence was used as the anchor, and a set of 16 TAMRA-labeled oligonucleotides in the form of BBNNNNNN were used as the sequence-reading probes.
- BBNNNNNN probe were incubated with the array in a ligation/hybridization buffer containing T4 DNA ligase at 20°C for 10 minutes. Excess probes were washed off at 20°C and images were taken with a TIRF microscope. Bound probes were stripped to prepare for the next round of hybridization. Using a subset of the BBNNNNNN probe set (namely GA, GC, GG and GT in the place of BB), spots were able to be identified spots on the concatemer array created from targets that specifically bind to one of these 4 probes, with an average full match/mismatch ratio of over 20, as shown in Fig. 6.
- Amplicon means the product of a polynucleotide amplification reaction. That is, it is a population of polynucleotides, usually double stranded, that are replicated from one or more starting sequences. The one or more starting sequences may be one or more copies of the same sequence, or it may be a mixture of different sequences. Amplicons may be produced by a variety of amplification reactions whose products are multiple replicates of one or more target nucleic acids. Generally, amplification reactions producing amplicons are "template-driven” in that base pairing of reactants, either nucleotides or oligonucleotides, have complements in a template polynucleotide that are required for the creation of reaction products.
- template-driven reactions are primer extensions with a nucleic acid polymerase or oligonucleotide ligations with a nucleic acid ligase.
- Such reactions include, but are not limited to, polymerase chain reactions (PCRs), linear polymerase reactions, nucleic acid sequence-based amplification (NASBAs), rolling circle amplifications, and the like, disclosed in the following references that are incorporated herein by reference: MuMs et al, U.S. patents 4,683,195; 4,965,188; 4,683,202; 4,800,159 (PCR); Gelfand et al, U.S. patent 5,210,015 (real-time PCR with "taqman” probes); Wittwer et al, U.S.
- amplicons of the invention are produced by PCRs.
- An amplification reaction may be a "real-time" amplification if a detection chemistry is available that permits a reaction product to be measured as the amplification reaction progresses, e.g.
- reaction mixture means a solution containing all the necessary reactants for performing a reaction, which may include, but not be limited to, buffering agents to maintain pH at a selected level during a reaction, salts, co-factors, scavengers, and the like.
- Complementary or substantially complementary refers to the hybridization or base pairing or the formation of a duplex between nucleotides or nucleic acids, such as, for instance, between the two strands of a double stranded DNA molecule or between an oligonucleotide primer and a primer binding site on a single stranded nucleic acid.
- Complementary nucleotides are, generally, A and T (or A and U), or C and G.
- Two single stranded RNA or DNA molecules are said to be substantially complementary when the nucleotides of one strand, optimally aligned and compared and with appropriate nucleotide insertions or deletions, pair with at least about 80% of the nucleotides of the other strand, usually at least about 90% to 95%, and more preferably from about 98 to 100%.
- substantial complementarity exists when an RNA or DNA strand will hybridize under selective hybridization conditions to its complement.
- selective hybridization will occur when there is at least about 65% complementary over a stretch of at least 14 to 25 nucleotides, preferably at least about 75%, more preferably at least about 90% complementary. See, M. Kanehisa Nucleic Acids Res. 12:203 (1984), incorporated herein by reference.
- Duplex means at least two oligonucleotides and/or polynucleotides that are fully or partially complementary undergo Watson-Crick type base pairing among all or most of their nucleotides so that a stable complex is formed.
- annealing and “hybridization” are used interchangeably to mean the formation of a stable duplex.
- Perfectly matched in reference to a duplex means that the poly- or oligonucleotide strands making up the duplex form a double stranded structure with one another such that every nucleotide in each strand undergoes Watson-Crick basepairing with a nucleotide in the other strand.
- duplex comprehends the pairing of nucleoside analogs, such as deoxyinosine, nucleosides with 2-aminopurine bases, PNAs, and the like, that may be employed.
- a "mismatch" in a duplex between two oligonucleotides or polynucleotides means that a pair of nucleotides in the duplex fails to undergo Watson-Crick bonding.
- Genetic locus in reference to a genome or target polynucleotide, means a contiguous subregion or segment of the genome or target polynucleotide.
- genetic locus, or locus may refer to the position of a nucleotide, a gene, or a portion of a gene in a genome, including mitochondrial DNA, or it may refer to any contiguous portion of genomic sequence whether or not it is within, or associated with, a gene.
- a genetic locus refers to any portion of genomic sequence, including mitochondrial DNA, from a single nucleotide to a segment of few hundred nucleotides, e.g. 100-300, in length.
- Genetic variant means a substitution, inversion, insertion, or deletion of one or more nucleotides at genetic locus, or a translocation of DNA from one genetic locus to another genetic locus.
- genetic variant means an alternative nucleotide sequence at a genetic locus that may be present in a population of individuals and that includes nucleotide substitutions, insertions, and deletions with respect to other members of the population.
- insertions or deletions at a genetic locus comprises the addition or the absence of from 1 to 10 nucleotides at such locus, in comparison with the same locus in another individual of a population.
- Hybridization refers to the process in which two single-stranded polynucleotides bind non- covalently to fo ⁇ n a stable double-stranded polynucleotide.
- the term “hybridization” may also refer to triple-stranded hybridization.
- the resulting (usually) double-stranded polynucleotide is a “hybrid” or “duplex.”
- “Hybridization conditions” will typically include salt concentrations of less than about IM, more usually less than about 500 mM and less than about 200 mM.
- a “hybridization buffer” is a buffered salt solution such as 5X SSPE, or the like.
- Hybridization temperatures can be as low as 5° C, but are typically greater than 22° C, more typically greater than about 30° C, and preferably in excess of about 37° C.
- Hybridizations are usually performed under stringent conditions, i.e. conditions under which a probe will hybridize to its target subsequence. Stringent conditions are sequence-dependent and are different in different circumstances. Longer fragments may require higher hybridization temperatures for specific hybridization. As other factors may affect the stringency of hybridization, including base composition and length of the complementary strands, presence of organic solvents and extent of base mismatching, the combination of parameters is more important than the absolute measure of any one alone. Generally, stringent conditions are selected to be about 5° C. lower than the T m for the specific sequence at s defined ionic strength and pH.
- Exemplary stringent conditions include salt concentration of at least 0.01 M to no more than 1 M Na ion concentration (or other salts) at a pH 7.0 to 8.3 and a temperature of at least 25° C.
- conditions of 5xSSPE 750 mM NaCl, 50 mM NaPhosphate, 5 mM EDTA, pH 7.4
- a temperature of 25-30° C. are suitable for allele-specific probe hybridizations.
- Hybridizing specifically to or “specifically hybridizing to” or like expressions refer to the binding, duplexing, or hybridizing of a molecule substantially to or only to a particular nucleotide sequence or sequences under stringent conditions when that sequence is present in a complex mixture (e.g., total cellular) DNA or RNA.
- Ligation means to form a covalent bond or linkage between the termini of two or more nucleic acids, e.g. oligonucleotides and/or polynucleotides, in a template-driven reaction.
- the nature of the bond or linkage may vary widely and the ligation may be carried out enzymatically or chemically.
- ligations are usually carried out enzymatically to form a phosphodiester linkage between a 5' carbon of a terminal nucleotide of one oligonucleotide with 3' carbon of another oligonucleotide.
- Enzymatic ligation usually takes place in a ligase buffer, which is a buffered salt solution containing any required divalent cations, cofactors, and the like, for the particular ligase employed.
- “Microarray” or “array” refers to a solid phase support having a surface, usually planar or substantially planar, which carries an array of sites containing nucleic acids, such that each member site of the array comprises identical copies of immobilized oligonucleotides or polynucleotides and is spatially defined and not overlapping with other member sites of the array; that is, the sites are spatially discrete.
- sites of a microarray may also be spaced apart as well as discrete; that is, different sites do not share boundaries, but are separated by inter-site regions, usually free of bound nucleic acids.
- Spatially defined hybridization sites may additionally be "addressable" in that its location and the identity of its immobilized oligonucleotide are known or predetermined, for example, prior to its use.
- the oligonucleotides or polynucleotides are single stranded and are covalently attached to the solid phase support, usually by a 5 '-end or a 3 '-end.
- oligonucleotides or polynucleotides are attached to the solid phase support non- covalently, e.g. by a biotin-streptavidin linkage, hybridization to a capture oligonucleotide that is covalently bound, and the like.
- random array or “random microarray” refers to a microarray whose spatially discrete regions of oligonucleotides or polynucleotides are not spatially addressed. That is, the identity of the attached oligonucleoties or polynucleotides is not discernable, at least initially, from its location, but may be determined by a particular operation on the array, e.g.
- Random microarrays are frequently formed from a planar array of microbeads, e.g. Brenner et al, Nature Biotechnology, 18: 630-634 (2000); Tulley et al, U.S. patent 6,133,043; Stuelpnagel et al, U.S. patent 6,396,995; Chee et al, U.S. patent 6,544,732; and the like.
- mismatch means a base pair between any two of the bases A, T (or U for RNA), G, and C other than the Watson-Crick base pairs G-C and A-T.
- the eight possible mismatches are A-A, T-T, G-G, C-C, T-G, C-A, T-C, and A-G.
- “Mutation” and “polymorphism” are usually used somewhat interchangeably to mean a DNA molecule, such as a gene, that differs in nucleotide sequence from a reference DNA sequence, or wild type sequence, or normal tissue sequence, by one or more bases, insertions, and/or deletions.
- the usage of Cotton is followed in that a mutation is understood to be any base change whether pathological to an organism or not, whereas a polymorphism is usually understood to be a base change with no direct pathological consequences.
- Nucleoside as used herein includes the natural nucleosides, including 2'-deoxy and 2'- hydroxyl forms, e.g. as described in Kornberg and Baker, DNA Replication, 2nd Ed. (Freeman, San Francisco, 1992).
- "Analogs” in reference to nucleosides includes synthetic nucleosides having modified base moieties and/or modified sugar moieties, e.g. described by Scheit, Nucleotide Analogs (John Wiley, New York, 1980); Uhlman and Peyman, Chemical Reviews, 90: 543-584 (1990), or the like, with the proviso that they are capable of specific hybridization.
- Such analogs include synthetic nucleosides designed to enhance binding properties, reduce complexity, increase specificity, and the like.
- Polynucleotides comprising analogs with enhanced hybridization or nuclease resistance properties are described in Uhlman and Peyman (cited above); Crooke et al, Exp. Opin. Ther. Patents, 6: 855-870 (1996); Mesmaeker et al, Current Opinion in Structual Biology, 5: 343-355 (1995); and the like.
- Exemplary types of polynucleotides that are capable of enhancing duplex stability include oligonucleotide N3'-»P5' phosphoramidates (referred to herein as “amidates”), peptide nucleic acids (referred to herein as "PNAs”), oligo-2'-O-alkylribonucleotides, polynucleotides containing C-5 propynylpyrimidines, locked nucleic acids (LNAs), and like compounds.
- Such oligonucleotides are either available commercially or may be synthesized using methods described in the literature.
- PCR Polymerase chain reaction
- PCR is a reaction for making multiple copies or replicates of a target nucleic acid flanked by primer binding sites, such reaction comprising one or more repetitions of the following steps: (i) denaturing the target nucleic acid, (ii) annealing primers to the primer binding sites, and (iii) extending the primers by a nucleic acid polymerase in the presence of nucleoside triphosphates.
- the reaction is cycled through different temperatures optimized for each step in a thermal cycler instrument.
- a double stranded target nucleic acid may be denatured at a temperature >90°C, primers annealed at a temperature in the range 50-75 0 C, and primers extended at a temperature in the range 72-78 0 C.
- PCR encompasses derivative forms of the reaction, including but not limited to, RT-PCR, real-time PCR, nested PCR, quantitative PCR, multiplexed PCR, and the like. Reaction volumes range from a few hundred nanoliters, e.g. 200 nL, to a few hundred ⁇ L, e.g. 200 ⁇ L.
- Reverse transcription PCR or "RT-PCR,” means a PCR that is preceded by a reverse transcription reaction that converts a target RNA to a complementary single stranded DNA, which is then amplified, e.g. Tecott et al, U.S. patent 5,168,038, which patent is incorporated herein by reference.
- Real-time PCR means a PCR for which the amount of reaction product, i.e. amplicon, is monitored as the reaction proceeds.
- Nested PCR means a two-stage PCR wherein the amplicon of a first PCR becomes the sample for a second PCR using a new set of primers, at least one of which binds to an interior location of the first amplicon.
- initial primers in reference to a nested amplification reaction mean the primers used to generate a first amplicon
- secondary primers mean the one or more primers used to generate a second, or nested, amplicon.
- Multiplexed PCR means a PCR wherein multiple target sequences (or a single target sequence and one or more reference sequences) are simultaneously carried out in the same reaction mixture, e.g. Bernard et al, Anal.
- Quantitative PCR means a PCR designed to measure the abundance of one or more specific target sequences in a sample or specimen. Quantitative PCR includes both absolute quantitation and relative quantitation of such target sequences. Quantitative measurements are made using one or more reference sequences that may be assayed separately or together with a target sequence. The reference sequence may be endogenous or exogenous to a sample or specimen, and in the latter case, may comprise one or more competitor templates.
- Typical endogenous reference sequences include segments of transcripts of the following genes: ⁇ -actin, GAPDH, ⁇ 2 -microglobulin, ribosomal RNA, and the like.
- Techniques for quantitative PCR are well-known to those of ordinary skill in the art, as exemplified in the following references that are incorporated by reference: Freeman et al, Biotechniques, 26: 112-126 (1999); Becker-Andre et al, Nucleic Acids Research, 17: 9437-9447 (1989); Zimmerman et al, Biotechniques, 21 : 268-279 (1996); Diviacco et al, Gene, 122: 3013-3020 (1992); Becker-Andre et al, Nucleic Acids Research, 17: 9437-9446 (1989); and the like.
- Polynucleotide or “oligonucleotide” are used interchangeably and each mean a linear polymer of nucleotide monomers. As used herein, the terms may also refer to double stranded forms. Monomers making up polynucleotides and oligonucleotides are capable of specifically binding to a natural polynucleotide by way of a regular pattern of monomer-to-monomer interactions, such as Watson-Crick type of base pairing, base stacking, Hoogsteen or reverse Hoogsteen types of base pairing, or the like, to form duplex or triplex forms. Such monomers and their internucleosidic linkages may be naturally occurring or may be analogs thereof, e.g.
- Non-naturally occurring analogs may include PNAs, phosphorothioate internucleosidic linkages, bases containing linking groups permitting the attachment of labels, such as fluorophores, or haptens, and the like.
- oligonucleotide or polynucleotide requires enzymatic processing, such as extension by a polymerase, ligation by a ligase, or the like, one of ordinary skill would understand that oligonucleotides or polynucleotides in those instances would not contain certain analogs of internucleosidic linkages, sugar moities, or bases at any or some positions, when such analogs are incompatable with enzymatic reactions.
- Polynucleotides typically range in size from a few monomeric units, e.g. 5-40, when they are usually referred to as "oligonucleotides," to several thousand monomeric units.
- a polynucleotide or oligonucleotide is represented by a sequence of letters (upper or lower case), such as "ATGCCTG,” it will be understood that the nucleotides are in 5'— >3' order from left to right and that "A” denotes deoxyadenosine, “C” denotes deoxycytidine, “G” denotes deoxyguanosine, and “T” denotes thymidine, “I” denotes deoxyinosine, "U” denotes uridine, unless otherwise indicated or obvious from context.
- polynucleotides comprise the four natural nucleosides (e.g. deoxyadenosine, deoxycytidine, deoxyguanosine, deoxythymidine for DNA or their ribose counterparts for RNA) linked by phosphodiester linkages; however, they may also comprise non-natural nucleotide analogs, e.g. including modified bases, sugars, or internucleosidic linkages.
- nucleosides e.g. deoxyadenosine, deoxycytidine, deoxyguanosine, deoxythymidine for DNA or their ribose counterparts for RNA
- non-natural nucleotide analogs e.g. including modified bases, sugars, or internucleosidic linkages.
- Primer means an oligonucleotide, either natural or synthetic, that is capable, upon forming a duplex with a polynucleotide template, of acting as a point of initiation of nucleic acid synthesis and being extended from its 3' end along the template so that an extended duplex is formed.
- the sequence of nucleotides added during the extension process are determined by the sequence of the template polynucleotide.
- primers are extended by a DNA polymerase. Primers usually have a length in the range of from 9 to 40 nucleotides, or in some embodiments, from 14 to 36 nucleotides.
- Readout means a parameter, or parameters, which are measured and/or detected that can be converted to a number or value.
- readout may refer to an actual numerical representation of such collected or recorded data.
- a readout of fluorescent intensity signals from a microarray is the position and fluorescence intensity of a signal being generated at each hybridization site of the microarray; thus, such a readout may be registered or stored in various ways, for example, as an image of the microarray, as a table of numbers, or the like.
- Solid support “support”, and “solid phase support” are used interchangeably and refer to a material or group of materials having a rigid or semi-rigid surface or surfaces.
- at least one surface of the solid support will be substantially flat, although in some embodiments it may be desirable to physically separate synthesis regions for different compounds with, for example, wells, raised regions, pins, etched trenches, or the like.
- the solid support(s) will take the form of beads, resins, gels, microspheres, or other geometric configurations.
- Microarrays usually comprise at least one planar solid phase support, such as a glass microscope slide.
- Reference sequence or “reference population” of DNA refers to individual DNA sequences or a collection of DNAs (or RNAs derived from it) which is compared to a test population of DNA or RNA, (or “test DNA sequence,” or “test DNA population”) by the formation of heteroduplexes between the complementary strands of the reference DNA population and test DNA population. If perfectly matched heteroduplexes form, then the respective members of the reference and test populations are identical; otherwise, they are variants of one another. Typically, the nucleotide sequences of members of the reference population are known and the sequences typically are listed in sequence databases, such as Genbank, Embl, or the like.
- a reference population of DNA may comprise a cDNA library or genomic library from a known cell type or tissue source.
- a reference population of DNA may comprise a cDNA library or a genomic library derived from the tissue of a healthy individual and a test population of DNA may comprise a cDNA library or genomic library derived from the same tissue of a diseased individual.
- Reference populations of DNA may also comprise an assembled collection of individual polynucleotides, cDNAs, genes, or exons thereof, e.g. genes or exons encoding all or a subset of known p53 variants, genes of a signal transduction pathway, or the like.
- Specific or “specificity” in reference to the binding of one molecule to another molecule means the recognition, contact, and formation of a stable complex between the two molecules, together with substantially less recognition, contact, or complex formation of that molecule with other molecules.
- “specific” in reference to the binding of a first molecule to a second molecule means that to the extent the first molecule recognizes and forms a complex with another molecules in a reaction or sample, it forms the largest number of the complexes with the second molecule. Preferably, this largest number is at least fifty percent.
- molecules involved in a specific binding event have areas on their surfaces or in cavities giving rise to specific recognition between the molecules binding to each other.
- specific binding examples include antibody-antigen interactions, en2yme-substrate interactions, formation of duplexes or triplexes among polynucleotides and/or oligonucleotides, receptor-ligand interactions, and the like.
- contact in reference to specificity or specific binding means two molecules are close enough that weak noncovalent chemical interactions, such as Van der Waal forces, hydrogen bonding, base-stacking interactions, ionic and hydrophobic interactions, and the like, dominate the interaction of the molecules.
- T 1n is used in reference to the "melting temperature.”
- the melting temperature is the temperature at which a population of double-stranded nucleic acid molecules becomes half dissociated into single strands.
- Tm 81.5 + 0.41 (% G + C), when a nucleic acid is in aqueous solution at 1 M NaCl (see e.g., Anderson and Young, Quantitative Filter Hybridization, in Nucleic Acid Hybridization (1985).
- Other references e.g., Allawi, H.T.
- sample usually means a quantity of material from a biological, environmental, medical, or patient source in which detection, measurement, or labeling of target nucleic acids is sought.
- sample usually means a specimen or culture (e.g., microbiological cultures).
- sample may include both biological and environmental samples.
- a sample may include a specimen of synthetic origin.
- Biological samples may be animal, including human, fluid, solid (e.g., stool) or tissue, as well as liquid and solid food and feed products and ingredients such as dairy items, vegetables, meat and meat by-products, and waste.
- Biological samples may include materials taken from a patient including, but not limited to cultures, blood, saliva, cerebral spinal fluid, pleural fluid, milk, lymph, sputum, semen, needle aspirates, and the like.
- Biological samples may be obtained from all of the various families of domestic animals, as well as feral or wild animals, including, but not limited to, such animals as ungulates, bear, fish, rodents, etc.
- Environmental samples include environmental material such as surface matter, soil, water and industrial samples, as well as samples obtained from food and dairy processing instruments, apparatus, equipment, utensils, disposable and non-disposable items. These examples are not to be construed as limiting the sample types applicable to the present invention.
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK06784802.8T DK1907583T4 (en) | 2005-06-15 | 2006-06-13 | SINGLE MOLECULE ARRAYS FOR GENETIC AND CHEMICAL ANALYSIS |
AU2006259565A AU2006259565B2 (en) | 2005-06-15 | 2006-06-13 | Single molecule arrays for genetic and chemical analysis |
CN200680029826.4A CN101466847B (en) | 2005-06-15 | 2006-06-13 | Single molecule arrays for genetic and chemical analysis |
EP12180882.8A EP2620510B2 (en) | 2005-06-15 | 2006-06-13 | Single molecule arrays for genetic and chemical analysis |
CA2611671A CA2611671C (en) | 2005-06-15 | 2006-06-13 | Single molecule arrays for genetic and chemical analysis |
JP2008516994A JP5331476B2 (en) | 2005-06-15 | 2006-06-13 | Single molecule array for genetic and chemical analysis |
EP06784802.8A EP1907583B2 (en) | 2005-06-15 | 2006-06-13 | Single molecule arrays for genetic and chemical analysis |
EP18202997.5A EP3492602A1 (en) | 2005-06-15 | 2006-06-13 | Single molecule arrays for genetic and chemical analysis |
IL188142A IL188142A (en) | 2005-06-15 | 2007-12-13 | Single molecule arrays for genetic and chemical analysis |
IL241986A IL241986A0 (en) | 2005-06-15 | 2015-10-08 | Single molecule arrays for genetic and chemical analysis |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69077105P | 2005-06-15 | 2005-06-15 | |
US60/690,771 | 2005-06-15 | ||
US72511605P | 2005-10-07 | 2005-10-07 | |
US60/725,116 | 2005-10-07 | ||
US77641506P | 2006-02-24 | 2006-02-24 | |
US60/776,415 | 2006-02-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006138257A2 true WO2006138257A2 (en) | 2006-12-28 |
WO2006138257A3 WO2006138257A3 (en) | 2008-12-11 |
Family
ID=37571035
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/022950 WO2006138284A2 (en) | 2005-06-15 | 2006-06-13 | Nucleic acid analysis by random mixtures of non-overlapping fragments |
PCT/US2006/022895 WO2006138257A2 (en) | 2005-06-15 | 2006-06-13 | Single molecule arrays for genetic and chemical analysis |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/022950 WO2006138284A2 (en) | 2005-06-15 | 2006-06-13 | Nucleic acid analysis by random mixtures of non-overlapping fragments |
Country Status (11)
Country | Link |
---|---|
US (27) | US7709197B2 (en) |
EP (7) | EP2463386B1 (en) |
JP (4) | JP5331476B2 (en) |
CN (1) | CN101466847B (en) |
AU (1) | AU2006259565B2 (en) |
CA (2) | CA2611743C (en) |
DK (4) | DK2463386T3 (en) |
HK (1) | HK1209795A1 (en) |
IL (2) | IL188142A (en) |
SG (1) | SG162795A1 (en) |
WO (2) | WO2006138284A2 (en) |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007124651A1 (en) * | 2006-04-26 | 2007-11-08 | Zuhong Lu | An array chip of multiple copies of unimolecular nucleic acids |
EP1994180A2 (en) * | 2006-02-24 | 2008-11-26 | Callida Genomics, Inc. | High throughput genome sequencing on dna arrays |
WO2009034181A2 (en) * | 2007-09-14 | 2009-03-19 | Twof, Inc. | Methods for the preparation of dna microarrays with linear high density probes |
WO2009045344A2 (en) | 2007-09-28 | 2009-04-09 | Pacific Biosciences Of California, Inc. | Error-free amplification of dna for clonal sequencing |
US20090270273A1 (en) * | 2008-04-21 | 2009-10-29 | Complete Genomics, Inc. | Array structures for nucleic acid detection |
US7771934B2 (en) | 2000-12-13 | 2010-08-10 | Nugen Technologies, Inc. | Methods and compositions for generation of multiple copies of nucleic acid sequences and methods of detection thereof |
US7771946B2 (en) | 2001-03-09 | 2010-08-10 | Nugen Technologies, Inc. | Methods, kits and compositions for single primer linear isothermal amplification of nucleic acid sequences |
US7846666B2 (en) | 2008-03-21 | 2010-12-07 | Nugen Technologies, Inc. | Methods of RNA amplification in the presence of DNA |
US7846733B2 (en) | 2000-06-26 | 2010-12-07 | Nugen Technologies, Inc. | Methods and compositions for transcription-based nucleic acid amplification |
US7939258B2 (en) | 2005-09-07 | 2011-05-10 | Nugen Technologies, Inc. | Nucleic acid amplification procedure using RNA and DNA composite primers |
JP2011520420A (en) * | 2007-12-05 | 2011-07-21 | コンプリート・ジェノミックス・インコーポレイテッド | Efficient base determination in sequencing reactions |
US8034568B2 (en) | 2008-02-12 | 2011-10-11 | Nugen Technologies, Inc. | Isothermal nucleic acid amplification methods and compositions |
EP2546360A1 (en) * | 2005-10-07 | 2013-01-16 | Callida Genomics, Inc. | Self-assembled single molecule arrays and uses thereof |
WO2011123246A3 (en) * | 2010-04-01 | 2013-05-30 | Illumina, Inc. | Solid-phase clonal amplification and related methods |
US8465950B2 (en) | 2003-04-14 | 2013-06-18 | Nugen Technologies, Inc. | Global amplification using a randomly primed composite primer |
EP2620510A1 (en) | 2005-06-15 | 2013-07-31 | Callida Genomics, Inc. | Single molecule arrays for genetic and chemical analysis |
WO2013166517A1 (en) | 2012-05-04 | 2013-11-07 | Complete Genomics, Inc. | Methods for determining absolute genome-wide copy number variations of complex tumors |
US8725422B2 (en) | 2010-10-13 | 2014-05-13 | Complete Genomics, Inc. | Methods for estimating genome-wide copy number variations |
WO2014133905A1 (en) * | 2013-02-26 | 2014-09-04 | Illumina, Inc. | Gel patterned surfaces |
WO2014122548A3 (en) * | 2013-02-07 | 2014-11-20 | Koninklijke Philips N.V. | Processing of nucleotide sequences |
US8951731B2 (en) | 2007-10-15 | 2015-02-10 | Complete Genomics, Inc. | Sequence analysis using decorated nucleic acids |
EP2774978A4 (en) * | 2011-10-31 | 2015-07-15 | Hitachi High Tech Corp | Nucleic acid amplification method, nucleic acid substrate, nucleic acid analysis method, and nucleic acid analysis device |
CN103290106B (en) * | 2007-12-05 | 2015-07-29 | 考利达基因组股份有限公司 | In sequencing reaction, base effectively determines |
US9222132B2 (en) | 2008-01-28 | 2015-12-29 | Complete Genomics, Inc. | Methods and compositions for efficient base calling in sequencing reactions |
US9228228B2 (en) | 2006-10-27 | 2016-01-05 | Complete Genomics, Inc. | Efficient arrays of amplified polynucleotides |
US9238834B2 (en) | 2007-11-29 | 2016-01-19 | Complete Genomics, Inc. | Efficient shotgun sequencing methods |
US9249460B2 (en) | 2011-09-09 | 2016-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for obtaining a sequence |
US9267172B2 (en) | 2007-11-05 | 2016-02-23 | Complete Genomics, Inc. | Efficient base determination in sequencing reactions |
US9334490B2 (en) | 2006-11-09 | 2016-05-10 | Complete Genomics, Inc. | Methods and compositions for large-scale analysis of nucleic acids using DNA deletions |
US9359641B2 (en) | 2010-04-30 | 2016-06-07 | Complete Genomics, Inc. | Method and system for accurate alignment and registration of array for DNA sequencing |
WO2016100196A1 (en) * | 2014-12-15 | 2016-06-23 | Illumina, Inc. | Compositions and methods for single molecular placement on a substrate |
US9499863B2 (en) | 2007-12-05 | 2016-11-22 | Complete Genomics, Inc. | Reducing GC bias in DNA sequencing using nucleotide analogs |
US9524369B2 (en) | 2009-06-15 | 2016-12-20 | Complete Genomics, Inc. | Processing and analysis of complex nucleic acid sequence data |
US9680163B2 (en) | 2007-07-26 | 2017-06-13 | Plansee Se | Fuel cell and method for production thereof |
GB2559526B (en) * | 2015-11-03 | 2021-02-17 | Harvard College | Method and apparatus for volumetric imaging of a three-dimensional nucleic acid containing matrix |
US11021737B2 (en) | 2011-12-22 | 2021-06-01 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11078520B2 (en) | 2013-03-12 | 2021-08-03 | President And Fellows Of Harvard College | Method for generating a three-dimensional nucleic acid containing matrix |
US11085072B2 (en) | 2016-08-31 | 2021-08-10 | President And Fellows Of Harvard College | Methods of generating libraries of nucleic acid sequences for detection via fluorescent in situ sequencing |
US11193163B2 (en) | 2018-07-30 | 2021-12-07 | Readcoor, Llc | Methods and systems for sample processing or analysis |
WO2022008931A1 (en) * | 2020-07-10 | 2022-01-13 | Vidya Holdings Ltd | Improvements in or relating to an apparatus for imaging |
EP3818166A4 (en) * | 2018-07-05 | 2022-03-30 | AccuraGen Holdings Limited | Compositions and methods for digital polymerase chain reaction |
US11293054B2 (en) | 2011-12-22 | 2022-04-05 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11312992B2 (en) | 2011-10-14 | 2022-04-26 | President And Fellows Of Harvard College | Sequencing by structure assembly |
US11447807B2 (en) | 2016-08-31 | 2022-09-20 | President And Fellows Of Harvard College | Methods of combining the detection of biomolecules into a single assay using fluorescent in situ sequencing |
US11473139B2 (en) | 2012-06-05 | 2022-10-18 | President And Fellows Of Harvard College | Spatial sequencing of nucleic acids using DNA origami probes |
GB2613480A (en) * | 2018-11-15 | 2023-06-07 | Element Biosciences Inc | Methods for generating circular nucleic acid molecules |
US11713485B2 (en) | 2016-04-25 | 2023-08-01 | President And Fellows Of Harvard College | Hybridization chain reaction methods for in situ molecular detection |
Families Citing this family (509)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1791682B (en) * | 2003-02-26 | 2013-05-22 | 凯利达基因组股份有限公司 | Random array DNA analysis by hybridization |
US7692219B1 (en) | 2004-06-25 | 2010-04-06 | University Of Hawaii | Ultrasensitive biosensors |
EP1910562B1 (en) | 2005-06-23 | 2010-12-08 | Keygene N.V. | Strategies for high throughput identification and detection of polymorphisms |
US11111544B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
US11111543B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
CA2910861C (en) | 2005-09-29 | 2018-08-07 | Michael Josephus Theresia Van Eijk | High throughput screening of mutagenized populations |
US10316364B2 (en) * | 2005-09-29 | 2019-06-11 | Keygene N.V. | Method for identifying the source of an amplicon |
US7960104B2 (en) | 2005-10-07 | 2011-06-14 | Callida Genomics, Inc. | Self-assembled single molecule arrays and uses thereof |
WO2007120208A2 (en) * | 2005-11-14 | 2007-10-25 | President And Fellows Of Harvard College | Nanogrid rolling circle dna sequencing |
ES2882401T3 (en) | 2005-12-22 | 2021-12-01 | Keygene Nv | High-throughput AFLP-based polymorphism detection method |
SG10201405158QA (en) * | 2006-02-24 | 2014-10-30 | Callida Genomics Inc | High throughput genome sequencing on dna arrays |
US20080221832A1 (en) * | 2006-11-09 | 2008-09-11 | Complete Genomics, Inc. | Methods for computing positional base probabilities using experminentals base value distributions |
US7629125B2 (en) * | 2006-11-16 | 2009-12-08 | General Electric Company | Sequential analysis of biological samples |
US20080242560A1 (en) * | 2006-11-21 | 2008-10-02 | Gunderson Kevin L | Methods for generating amplified nucleic acid arrays |
WO2008063135A1 (en) | 2006-11-24 | 2008-05-29 | Agency For Science, Technology And Research | Apparatus for processing a sample in a liquid droplet and method of using the same |
US9874501B2 (en) | 2006-11-24 | 2018-01-23 | Curiox Biosystems Pte Ltd. | Use of chemically patterned substrate for liquid handling, chemical and biological reactions |
US8262900B2 (en) * | 2006-12-14 | 2012-09-11 | Life Technologies Corporation | Methods and apparatus for measuring analytes using large scale FET arrays |
US11339430B2 (en) | 2007-07-10 | 2022-05-24 | Life Technologies Corporation | Methods and apparatus for measuring analytes using large scale FET arrays |
US8349167B2 (en) | 2006-12-14 | 2013-01-08 | Life Technologies Corporation | Methods and apparatus for detecting molecular interactions using FET arrays |
EP2653861B1 (en) | 2006-12-14 | 2014-08-13 | Life Technologies Corporation | Method for sequencing a nucleic acid using large-scale FET arrays |
US20090053690A1 (en) * | 2007-02-02 | 2009-02-26 | California Institute Of Technology | Surface chemistry and deposition techniques |
US20080194416A1 (en) * | 2007-02-08 | 2008-08-14 | Sigma Aldrich | Detection of mature small rna molecules |
US20080318233A1 (en) * | 2007-03-30 | 2008-12-25 | Glenn Travis C | Source tagging and normalization of DNA for parallel DNA sequencing, and direct measurement of mutation rates using the same |
EP2164985A4 (en) * | 2007-06-01 | 2014-05-14 | 454 Life Sciences Corp | System and meth0d for identification of individual samples from a multiplex mixture |
US20110105366A1 (en) * | 2007-06-18 | 2011-05-05 | Illumina, Inc. | Microfabrication methods for the optimal patterning of substrates |
US8222040B2 (en) * | 2007-08-28 | 2012-07-17 | Lightspeed Genomics, Inc. | Nucleic acid sequencing by selective excitation of microparticles |
US8759077B2 (en) * | 2007-08-28 | 2014-06-24 | Lightspeed Genomics, Inc. | Apparatus for selective excitation of microparticles |
US20090061424A1 (en) * | 2007-08-30 | 2009-03-05 | Sigma-Aldrich Company | Universal ligation array for analyzing gene expression or genomic variations |
US8278047B2 (en) | 2007-10-01 | 2012-10-02 | Nabsys, Inc. | Biopolymer sequencing by hybridization of probes to form ternary complexes and variable range alignment |
US7897344B2 (en) * | 2007-11-06 | 2011-03-01 | Complete Genomics, Inc. | Methods and oligonucleotide designs for insertion of multiple adaptors into library constructs |
US20090263872A1 (en) * | 2008-01-23 | 2009-10-22 | Complete Genomics Inc. | Methods and compositions for preventing bias in amplification and sequencing reactions |
US8518640B2 (en) * | 2007-10-29 | 2013-08-27 | Complete Genomics, Inc. | Nucleic acid sequencing and process |
EP2215209B1 (en) | 2007-10-30 | 2018-05-23 | Complete Genomics, Inc. | Apparatus for high throughput sequencing of nucleic acids |
US7988918B2 (en) * | 2007-11-01 | 2011-08-02 | Complete Genomics, Inc. | Structures for enhanced detection of fluorescence |
WO2009061840A1 (en) * | 2007-11-05 | 2009-05-14 | Complete Genomics, Inc. | Methods and oligonucleotide designs for insertion of multiple adaptors employing selective methylation |
US10725020B2 (en) | 2007-11-14 | 2020-07-28 | Curiox Biosystems Pte Ltd. | High throughput miniaturized assay system and methods |
WO2013114217A1 (en) * | 2012-02-05 | 2013-08-08 | Curiox Biosystems Pte Ltd. | Array plates and methods for making and using same |
US9551026B2 (en) | 2007-12-03 | 2017-01-24 | Complete Genomincs, Inc. | Method for nucleic acid detection using voltage enhancement |
US20090171640A1 (en) * | 2007-12-28 | 2009-07-02 | Microsoft Corporation | Population sequencing using short read technologies |
EP2283132B1 (en) | 2008-05-02 | 2016-10-26 | Epicentre Technologies Corporation | Selective 5' ligation tagging of rna |
US8039817B2 (en) | 2008-05-05 | 2011-10-18 | Illumina, Inc. | Compensator for multiple surface imaging |
TWI460602B (en) * | 2008-05-16 | 2014-11-11 | Counsyl Inc | Device for universal preconception screening |
JP5667049B2 (en) | 2008-06-25 | 2015-02-12 | ライフ テクノロジーズ コーポレーション | Method and apparatus for measuring analytes using large-scale FET arrays |
US9650668B2 (en) | 2008-09-03 | 2017-05-16 | Nabsys 2.0 Llc | Use of longitudinally displaced nanoscale electrodes for voltage sensing of biomolecules and other analytes in fluidic channels |
WO2010028140A2 (en) | 2008-09-03 | 2010-03-11 | Nabsys, Inc. | Use of longitudinally displaced nanoscale electrodes for voltage sensing of biomolecules and other analytes in fluidic channels |
US8262879B2 (en) | 2008-09-03 | 2012-09-11 | Nabsys, Inc. | Devices and methods for determining the length of biopolymers and distances between probes bound thereto |
US8383345B2 (en) | 2008-09-12 | 2013-02-26 | University Of Washington | Sequence tag directed subassembly of short sequencing reads into long sequencing reads |
US20100137143A1 (en) | 2008-10-22 | 2010-06-03 | Ion Torrent Systems Incorporated | Methods and apparatus for measuring analytes |
US20100301398A1 (en) | 2009-05-29 | 2010-12-02 | Ion Torrent Systems Incorporated | Methods and apparatus for measuring analytes |
US9080211B2 (en) | 2008-10-24 | 2015-07-14 | Epicentre Technologies Corporation | Transposon end compositions and methods for modifying nucleic acids |
EP2508529B1 (en) | 2008-10-24 | 2013-08-28 | Epicentre Technologies Corporation | Transposon end compositions and methods for modifying nucleic acids |
US9506119B2 (en) | 2008-11-07 | 2016-11-29 | Adaptive Biotechnologies Corp. | Method of sequence determination using sequence tags |
US8748103B2 (en) | 2008-11-07 | 2014-06-10 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
US9365901B2 (en) | 2008-11-07 | 2016-06-14 | Adaptive Biotechnologies Corp. | Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia |
CN102272327B (en) | 2008-11-07 | 2015-11-25 | 赛昆塔公司 | By the method for sequential analysis monitoring situation |
US9528160B2 (en) | 2008-11-07 | 2016-12-27 | Adaptive Biotechnolgies Corp. | Rare clonotypes and uses thereof |
US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
WO2010083456A1 (en) | 2009-01-15 | 2010-07-22 | Imdaptive Inc. | Adaptive immunity profiling and methods for generation of monoclonal antibodies |
WO2010091021A2 (en) * | 2009-02-03 | 2010-08-12 | Complete Genomics, Inc. | Oligomer sequences mapping |
EP2394165A4 (en) * | 2009-02-03 | 2013-12-11 | Complete Genomics Inc | Oligomer sequences mapping |
WO2010091023A2 (en) * | 2009-02-03 | 2010-08-12 | Complete Genomics, Inc. | Indexing a reference sequence for oligomer sequence mapping |
US8455260B2 (en) | 2009-03-27 | 2013-06-04 | Massachusetts Institute Of Technology | Tagged-fragment map assembly |
EP2511843B1 (en) | 2009-04-29 | 2016-12-21 | Complete Genomics, Inc. | Method and system for calling variations in a sample polynucleotide sequence with respect to a reference polynucleotide sequence |
US20130296189A1 (en) * | 2009-05-08 | 2013-11-07 | Suzhou Institute of Nano-tech and Nano-bionics, Chinese Academy of Sciences | Probes utilizing universal tags, a kit comprising the same and detection methods |
US8246799B2 (en) | 2009-05-28 | 2012-08-21 | Nabsys, Inc. | Devices and methods for analyzing biomolecules and probes bound thereto |
US20120261274A1 (en) | 2009-05-29 | 2012-10-18 | Life Technologies Corporation | Methods and apparatus for measuring analytes |
US8673627B2 (en) | 2009-05-29 | 2014-03-18 | Life Technologies Corporation | Apparatus and methods for performing electrochemical reactions |
US8776573B2 (en) | 2009-05-29 | 2014-07-15 | Life Technologies Corporation | Methods and apparatus for measuring analytes |
CN102459592B (en) | 2009-06-15 | 2017-04-05 | 考利达基因组股份有限公司 | For the method and composition of long fragment read sequencing |
EP2446052B1 (en) | 2009-06-25 | 2018-08-08 | Fred Hutchinson Cancer Research Center | Method of measuring adaptive immunity |
KR20110018763A (en) * | 2009-08-18 | 2011-02-24 | 삼성전자주식회사 | Method and apparatus for fixing a target molecule on a substrate |
EP2467479B1 (en) | 2009-08-20 | 2016-01-06 | Population Genetics Technologies Ltd | Compositions and methods for intramolecular nucleic acid rearrangement |
WO2011037990A1 (en) * | 2009-09-22 | 2011-03-31 | President And Fellows Of Harvard College | Entangled mate sequencing |
ES2640776T3 (en) | 2009-09-30 | 2017-11-06 | Natera, Inc. | Methods for non-invasively calling prenatal ploidy |
JP5901530B2 (en) * | 2009-11-10 | 2016-04-13 | ネステク ソシエテ アノニム | Cardiac aging biomarker and method of use |
US9023769B2 (en) | 2009-11-30 | 2015-05-05 | Complete Genomics, Inc. | cDNA library for nucleic acid sequencing |
US9217144B2 (en) * | 2010-01-07 | 2015-12-22 | Gen9, Inc. | Assembly of high fidelity polynucleotides |
DE202011003570U1 (en) | 2010-03-06 | 2012-01-30 | Illumina, Inc. | Systems and apparatus for detecting optical signals from a sample |
US8502867B2 (en) | 2010-03-19 | 2013-08-06 | Lightspeed Genomics, Inc. | Synthetic aperture optics imaging method using minimum selective excitation patterns |
US9465228B2 (en) * | 2010-03-19 | 2016-10-11 | Optical Biosystems, Inc. | Illumination apparatus optimized for synthetic aperture optics imaging using minimum selective excitation patterns |
US20190300945A1 (en) | 2010-04-05 | 2019-10-03 | Prognosys Biosciences, Inc. | Spatially Encoded Biological Assays |
US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
ES2555106T3 (en) | 2010-04-05 | 2015-12-29 | Prognosys Biosciences, Inc. | Spatially coded biological assays |
US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11332793B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
CA2798758C (en) | 2010-05-18 | 2019-05-07 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11339429B2 (en) | 2010-05-18 | 2022-05-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
US11326208B2 (en) | 2010-05-18 | 2022-05-10 | Natera, Inc. | Methods for nested PCR amplification of cell-free DNA |
US11408031B2 (en) | 2010-05-18 | 2022-08-09 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
US11332785B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
EP2580353B1 (en) | 2010-06-11 | 2015-07-29 | Life Technologies Corporation | Alternative nucleotide flows in sequencing-by-synthesis methods |
US9353412B2 (en) | 2010-06-18 | 2016-05-31 | Illumina, Inc. | Conformational probes and methods for sequencing nucleic acids |
TWI569025B (en) | 2010-06-30 | 2017-02-01 | 生命技術公司 | Methods and apparatus for testing isfet arrays |
EP2598804B1 (en) | 2010-06-30 | 2021-10-20 | Life Technologies Corporation | Method to generate an output signal in an isfet-array |
WO2012003363A1 (en) | 2010-06-30 | 2012-01-05 | Life Technologies Corporation | Ion-sensing charge-accumulation circuits and methods |
US11307166B2 (en) | 2010-07-01 | 2022-04-19 | Life Technologies Corporation | Column ADC |
US8653567B2 (en) | 2010-07-03 | 2014-02-18 | Life Technologies Corporation | Chemically sensitive sensor with lightly doped drains |
WO2012011877A2 (en) | 2010-07-23 | 2012-01-26 | Curiox Biosystems Pte Ltd | Apparatus and method for multiple reactions in small volumes |
AU2011291538A1 (en) * | 2010-08-20 | 2013-03-14 | The Regents Of The University Of California | Small molecule arrays and methods for making and using them |
US9671344B2 (en) | 2010-08-31 | 2017-06-06 | Complete Genomics, Inc. | High-density biochemical array chips with asynchronous tracks for alignment correction by moiré averaging |
US9880089B2 (en) | 2010-08-31 | 2018-01-30 | Complete Genomics, Inc. | High-density devices with synchronous tracks for quad-cell based alignment correction |
FR2964391B1 (en) * | 2010-09-03 | 2014-04-11 | Centre Nat Rech Scient | BIOPUCES FOR ANALYSIS OF THE DYNAMICS OF NUCLEIC ACID MOLECULES |
US9618475B2 (en) | 2010-09-15 | 2017-04-11 | Life Technologies Corporation | Methods and apparatus for measuring analytes |
EP2619564B1 (en) | 2010-09-24 | 2016-03-16 | Life Technologies Corporation | Matched pair transistor circuits |
US8715933B2 (en) | 2010-09-27 | 2014-05-06 | Nabsys, Inc. | Assay methods using nicking endonucleases |
EP2632593B1 (en) | 2010-10-27 | 2021-09-29 | Illumina, Inc. | Flow cells for biological or chemical analysis |
US9074251B2 (en) | 2011-02-10 | 2015-07-07 | Illumina, Inc. | Linking sequence reads using paired code tags |
WO2012067911A1 (en) | 2010-11-16 | 2012-05-24 | Nabsys, Inc. | Methods for sequencing a biomolecule by detecting relative positions of hybridized probes |
CN103608466B (en) | 2010-12-22 | 2020-09-18 | 纳特拉公司 | Non-invasive prenatal paternity testing method |
WO2012118555A1 (en) | 2010-12-29 | 2012-09-07 | Life Technologies Corporation | Time-warped background signal for sequencing-by-synthesis operations |
WO2012092455A2 (en) | 2010-12-30 | 2012-07-05 | Life Technologies Corporation | Models for analyzing data from sequencing-by-synthesis operations |
US20130060482A1 (en) | 2010-12-30 | 2013-03-07 | Life Technologies Corporation | Methods, systems, and computer readable media for making base calls in nucleic acid sequencing |
US10241075B2 (en) | 2010-12-30 | 2019-03-26 | Life Technologies Corporation | Methods, systems, and computer readable media for nucleic acid sequencing |
US8951781B2 (en) | 2011-01-10 | 2015-02-10 | Illumina, Inc. | Systems, methods, and apparatuses to image a sample for biological or chemical analysis |
EP2670863B1 (en) | 2011-01-31 | 2018-06-27 | H. Hoffnabb-La Roche Ag | Methods of identifying multiple epitopes in cells |
EP2670894B1 (en) | 2011-02-02 | 2017-11-29 | University Of Washington Through Its Center For Commercialization | Massively parallel continguity mapping |
WO2012109574A2 (en) | 2011-02-11 | 2012-08-16 | Nabsys, Inc. | Assay methods using dna binding proteins |
CN105861645B (en) | 2011-04-08 | 2020-02-21 | 生命科技股份有限公司 | Phase-protected reagent flow ordering for use in sequencing-by-synthesis |
GB201106254D0 (en) | 2011-04-13 | 2011-05-25 | Frisen Jonas | Method and product |
CN103843001B (en) * | 2011-04-14 | 2017-06-09 | 考利达基因组股份有限公司 | The treatment and analysis of complex nucleic acid sequence data |
US8778848B2 (en) | 2011-06-09 | 2014-07-15 | Illumina, Inc. | Patterned flow-cells useful for nucleic acid analysis |
EP3624124B1 (en) | 2011-08-18 | 2023-11-22 | Life Technologies Corporation | Systems for making base calls in nucleic acid sequencing |
US9679103B2 (en) | 2011-08-25 | 2017-06-13 | Complete Genomics, Inc. | Phasing of heterozygous loci to determine genomic haplotypes |
US10704164B2 (en) | 2011-08-31 | 2020-07-07 | Life Technologies Corporation | Methods, systems, computer readable media, and kits for sample identification |
US10385475B2 (en) | 2011-09-12 | 2019-08-20 | Adaptive Biotechnologies Corp. | Random array sequencing of low-complexity libraries |
US9453258B2 (en) | 2011-09-23 | 2016-09-27 | Illumina, Inc. | Methods and compositions for nucleic acid sequencing |
US10378051B2 (en) | 2011-09-29 | 2019-08-13 | Illumina Cambridge Limited | Continuous extension and deblocking in reactions for nucleic acids synthesis and sequencing |
CA2853088C (en) | 2011-10-21 | 2018-03-13 | Adaptive Biotechnologies Corporation | Quantification of adaptive immune cell genomes in a complex mixture of cells |
WO2013063382A2 (en) | 2011-10-28 | 2013-05-02 | Illumina, Inc. | Microarray fabrication system and method |
US10837879B2 (en) * | 2011-11-02 | 2020-11-17 | Complete Genomics, Inc. | Treatment for stabilizing nucleic acid arrays |
US9970984B2 (en) | 2011-12-01 | 2018-05-15 | Life Technologies Corporation | Method and apparatus for identifying defects in a chemical sensor array |
US9824179B2 (en) | 2011-12-09 | 2017-11-21 | Adaptive Biotechnologies Corp. | Diagnosis of lymphoid malignancies and minimal residual disease detection |
US9499865B2 (en) | 2011-12-13 | 2016-11-22 | Adaptive Biotechnologies Corp. | Detection and measurement of tissue-infiltrating lymphocytes |
EP2605001A1 (en) * | 2011-12-15 | 2013-06-19 | Hain Lifescience GmbH | A device and method for optically measuring fluorescence of nucleic acids in test samples and use of the device and method |
US8821798B2 (en) | 2012-01-19 | 2014-09-02 | Life Technologies Corporation | Titanium nitride as sensing layer for microwell structure |
US8747748B2 (en) | 2012-01-19 | 2014-06-10 | Life Technologies Corporation | Chemical sensor with conductive cup-shaped sensor surface |
US9864846B2 (en) | 2012-01-31 | 2018-01-09 | Life Technologies Corporation | Methods and computer program products for compression of sequencing data |
US9515676B2 (en) | 2012-01-31 | 2016-12-06 | Life Technologies Corporation | Methods and computer program products for compression of sequencing data |
JP6012767B2 (en) | 2012-02-07 | 2016-10-25 | ヴィブラント ホールディングス リミテッド ライアビリティ カンパニー | Substrates, peptide arrays, and methods |
US20130217023A1 (en) * | 2012-02-22 | 2013-08-22 | 454 Life Sciences Corporation | System And Method For Generation And Use Of Compact Clonally Amplified Products |
JP6302847B2 (en) | 2012-03-05 | 2018-03-28 | アダプティヴ バイオテクノロジーズ コーポレーション | Determination of paired immunoreceptor chains from frequency matched subunits |
CN108300765B (en) * | 2012-03-13 | 2022-01-11 | 斯威夫特生物科学公司 | Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by nucleic acid polymerases |
IN2014DN08135A (en) * | 2012-03-16 | 2015-05-01 | Life Technologies Corp | |
US9803239B2 (en) * | 2012-03-29 | 2017-10-31 | Complete Genomics, Inc. | Flow cells for high density array chips |
US20130261984A1 (en) | 2012-03-30 | 2013-10-03 | Illumina, Inc. | Methods and systems for determining fetal chromosomal abnormalities |
EP4219012A1 (en) | 2012-04-03 | 2023-08-02 | Illumina, Inc. | Method of imaging a substrate comprising fluorescent features and use of the method in nucleic acid sequencing |
US20130274148A1 (en) | 2012-04-11 | 2013-10-17 | Illumina, Inc. | Portable genetic detection and analysis system and method |
PL2831276T3 (en) | 2012-05-08 | 2016-10-31 | Compositions and method for measuring and calibrating amplification bias in multiplexed pcr reactions | |
US9646132B2 (en) | 2012-05-11 | 2017-05-09 | Life Technologies Corporation | Models for analyzing data from sequencing-by-synthesis operations |
US9052963B2 (en) | 2012-05-21 | 2015-06-09 | International Business Machines Corporation | Cloud computing data center machine monitor and control |
US8786331B2 (en) | 2012-05-29 | 2014-07-22 | Life Technologies Corporation | System for reducing noise in a chemical sensor array |
US9628676B2 (en) | 2012-06-07 | 2017-04-18 | Complete Genomics, Inc. | Imaging systems with movable scan mirrors |
US9488823B2 (en) | 2012-06-07 | 2016-11-08 | Complete Genomics, Inc. | Techniques for scanned illumination |
US9012022B2 (en) | 2012-06-08 | 2015-04-21 | Illumina, Inc. | Polymer coatings |
US8895249B2 (en) | 2012-06-15 | 2014-11-25 | Illumina, Inc. | Kinetic exclusion amplification of nucleic acid libraries |
WO2014008635A1 (en) * | 2012-07-11 | 2014-01-16 | 北京贝瑞和康生物技术有限公司 | Detection method and detection kit for dna fragments, and use thereof |
US9977861B2 (en) | 2012-07-18 | 2018-05-22 | Illumina Cambridge Limited | Methods and systems for determining haplotypes and phasing of haplotypes |
US10221442B2 (en) | 2012-08-14 | 2019-03-05 | 10X Genomics, Inc. | Compositions and methods for sample processing |
US10400280B2 (en) | 2012-08-14 | 2019-09-03 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US9567631B2 (en) | 2012-12-14 | 2017-02-14 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US9951386B2 (en) | 2014-06-26 | 2018-04-24 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10752949B2 (en) | 2012-08-14 | 2020-08-25 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US9701998B2 (en) | 2012-12-14 | 2017-07-11 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10323279B2 (en) | 2012-08-14 | 2019-06-18 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US9388465B2 (en) | 2013-02-08 | 2016-07-12 | 10X Genomics, Inc. | Polynucleotide barcode generation |
CN113528634A (en) | 2012-08-14 | 2021-10-22 | 10X基因组学有限公司 | Microcapsule compositions and methods |
US11591637B2 (en) | 2012-08-14 | 2023-02-28 | 10X Genomics, Inc. | Compositions and methods for sample processing |
US10273541B2 (en) | 2012-08-14 | 2019-04-30 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
NL2017959B1 (en) | 2016-12-08 | 2018-06-19 | Illumina Inc | Cartridge assembly |
CA3178340A1 (en) | 2012-08-20 | 2014-02-27 | Illumina, Inc. | Method and system for fluorescence lifetime based sequencing |
US10006909B2 (en) | 2012-09-28 | 2018-06-26 | Vibrant Holdings, Llc | Methods, systems, and arrays for biomolecular analysis |
WO2014052989A2 (en) * | 2012-09-28 | 2014-04-03 | Vibrant Holdings, Llc | Methods, systems, and arrays for biomolecular analysis |
WO2014055561A1 (en) | 2012-10-01 | 2014-04-10 | Adaptive Biotechnologies Corporation | Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization |
US10329608B2 (en) | 2012-10-10 | 2019-06-25 | Life Technologies Corporation | Methods, systems, and computer readable media for repeat sequencing |
DK2914741T3 (en) | 2012-11-02 | 2017-11-20 | Life Technologies Corp | New Compositions and Methods for Improving PCR Specificity |
US10286376B2 (en) | 2012-11-14 | 2019-05-14 | Vibrant Holdings, Llc | Substrates, systems, and methods for array synthesis and biomolecular analysis |
US10829816B2 (en) | 2012-11-19 | 2020-11-10 | Apton Biosystems, Inc. | Methods of analyte detection |
US20150330974A1 (en) | 2012-11-19 | 2015-11-19 | Apton Biosystems, Inc. | Digital Analysis of Molecular Analytes Using Single Molecule Detection |
US10533221B2 (en) | 2012-12-14 | 2020-01-14 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US9914966B1 (en) | 2012-12-20 | 2018-03-13 | Nabsys 2.0 Llc | Apparatus and methods for analysis of biomolecules using high frequency alternating current excitation |
US9080968B2 (en) | 2013-01-04 | 2015-07-14 | Life Technologies Corporation | Methods and systems for point of use removal of sacrificial material |
US9841398B2 (en) | 2013-01-08 | 2017-12-12 | Life Technologies Corporation | Methods for manufacturing well structures for low-noise chemical sensors |
US9683230B2 (en) | 2013-01-09 | 2017-06-20 | Illumina Cambridge Limited | Sample preparation on a solid support |
US10294516B2 (en) | 2013-01-18 | 2019-05-21 | Nabsys 2.0 Llc | Enhanced probe binding |
US8962366B2 (en) | 2013-01-28 | 2015-02-24 | Life Technologies Corporation | Self-aligned well structures for low-noise chemical sensors |
GB2547875B (en) | 2013-02-01 | 2017-12-13 | Univ California | Methods for meta-genomics analysis of microbes |
US9411930B2 (en) | 2013-02-01 | 2016-08-09 | The Regents Of The University Of California | Methods for genome assembly and haplotype phasing |
CA2923379C (en) | 2013-02-15 | 2023-01-03 | Vibrant Holdings, Llc | Methods and compositions for amplified electrochemiluminescence detection |
US8963216B2 (en) | 2013-03-13 | 2015-02-24 | Life Technologies Corporation | Chemical sensor with sidewall spacer sensor surface |
US8841217B1 (en) | 2013-03-13 | 2014-09-23 | Life Technologies Corporation | Chemical sensor with protruded sensor surface |
EP2969479B1 (en) | 2013-03-13 | 2021-05-05 | Illumina, Inc. | Multilayer fluidic devices and methods for their fabrication |
EP2970951B1 (en) | 2013-03-13 | 2019-02-20 | Illumina, Inc. | Methods for nucleic acid sequencing |
US20140296080A1 (en) | 2013-03-14 | 2014-10-02 | Life Technologies Corporation | Methods, Systems, and Computer Readable Media for Evaluating Variant Likelihood |
WO2014149779A1 (en) | 2013-03-15 | 2014-09-25 | Life Technologies Corporation | Chemical device with thin conductive element |
US9328382B2 (en) | 2013-03-15 | 2016-05-03 | Complete Genomics, Inc. | Multiple tagging of individual long DNA fragments |
JP6581074B2 (en) | 2013-03-15 | 2019-09-25 | ライフ テクノロジーズ コーポレーション | Chemical sensor with consistent sensor surface area |
JP6431895B2 (en) * | 2013-03-15 | 2018-12-05 | アダプティブ バイオテクノロジーズ コーポレイション | Reconstituted adaptive immune receptor genes uniquely tagged in a complex gene set |
WO2014142981A1 (en) | 2013-03-15 | 2014-09-18 | Illumina, Inc. | Enzyme-linked nucleotides |
WO2014149780A1 (en) | 2013-03-15 | 2014-09-25 | Life Technologies Corporation | Chemical sensor with consistent sensor surface areas |
US9116117B2 (en) | 2013-03-15 | 2015-08-25 | Life Technologies Corporation | Chemical sensor with sidewall sensor surface |
US9835585B2 (en) | 2013-03-15 | 2017-12-05 | Life Technologies Corporation | Chemical sensor with protruded sensor surface |
CA2905410A1 (en) * | 2013-03-15 | 2014-09-25 | Abbott Molecular Inc. | Systems and methods for detection of genomic copy number changes |
SG10201708498VA (en) | 2013-04-17 | 2017-11-29 | Agency Science Tech & Res | Method for generating extended sequence reads |
US20140336063A1 (en) | 2013-05-09 | 2014-11-13 | Life Technologies Corporation | Windowed Sequencing |
US10458942B2 (en) | 2013-06-10 | 2019-10-29 | Life Technologies Corporation | Chemical sensor array having multiple sensors per well |
WO2014210225A1 (en) | 2013-06-25 | 2014-12-31 | Prognosys Biosciences, Inc. | Methods and systems for determining spatial patterns of biological targets in a sample |
US9708657B2 (en) | 2013-07-01 | 2017-07-18 | Adaptive Biotechnologies Corp. | Method for generating clonotype profiles using sequence tags |
KR102070483B1 (en) | 2013-07-01 | 2020-01-29 | 일루미나, 인코포레이티드 | Catalyst-free surface functionalization and polymer grafting |
ES2628485T3 (en) | 2013-07-03 | 2017-08-03 | Illumina, Inc. | Sequencing by orthogonal synthesis |
US9557318B2 (en) | 2013-07-09 | 2017-01-31 | Curiox Biosystems Pte Ltd. | Array plates for washing samples |
US9926597B2 (en) | 2013-07-26 | 2018-03-27 | Life Technologies Corporation | Control nucleic acid sequences for use in sequencing-by-synthesis and methods for designing the same |
KR102291045B1 (en) | 2013-08-05 | 2021-08-19 | 트위스트 바이오사이언스 코포레이션 | De novo synthesized gene libraries |
DK3030645T3 (en) | 2013-08-08 | 2023-01-30 | Illumina Inc | FLUID SYSTEM FOR DELIVERY OF REAGENTS TO A FLOW CELL |
WO2015027112A1 (en) | 2013-08-22 | 2015-02-26 | Apton Biosystems, Inc. | Digital analysis of molecular analytes using electrical methods |
CN105637099B (en) | 2013-08-23 | 2020-05-19 | 深圳华大智造科技有限公司 | Long fragment de novo assembly using short reads |
US10395758B2 (en) | 2013-08-30 | 2019-08-27 | 10X Genomics, Inc. | Sequencing methods |
KR20160081896A (en) | 2013-08-30 | 2016-07-08 | 일루미나, 인코포레이티드 | Manipulation of droplets on hydrophilic or variegated-hydrophilic surfaces |
US9352315B2 (en) | 2013-09-27 | 2016-05-31 | Taiwan Semiconductor Manufacturing Company, Ltd. | Method to produce chemical pattern in micro-fluidic structure |
US10577655B2 (en) | 2013-09-27 | 2020-03-03 | Natera, Inc. | Cell free DNA diagnostic testing standards |
US10410739B2 (en) | 2013-10-04 | 2019-09-10 | Life Technologies Corporation | Methods and systems for modeling phasing effects in sequencing using termination chemistry |
EP3875601A1 (en) | 2013-10-17 | 2021-09-08 | Illumina, Inc. | Methods and compositions for preparing nucleic acid libraries |
CA2931533C (en) | 2013-12-09 | 2023-08-08 | Illumina, Inc. | Methods and compositions for targeted nucleic acid sequencing |
JP6672149B2 (en) | 2013-12-10 | 2020-03-25 | イラミーナ インコーポレーテッド | Biosensor for biological or chemical analysis and method of manufacturing the same |
KR102379877B1 (en) | 2013-12-11 | 2022-03-30 | 아큐라젠 홀딩스 리미티드 | Compositions and methods for detecting rare sequence variants |
US11286519B2 (en) | 2013-12-11 | 2022-03-29 | Accuragen Holdings Limited | Methods and compositions for enrichment of amplification products |
US11859246B2 (en) | 2013-12-11 | 2024-01-02 | Accuragen Holdings Limited | Methods and compositions for enrichment of amplification products |
US9824068B2 (en) | 2013-12-16 | 2017-11-21 | 10X Genomics, Inc. | Methods and apparatus for sorting data |
JP6366719B2 (en) | 2013-12-20 | 2018-08-01 | イルミナ インコーポレイテッド | Preservation of genomic connectivity information in fragmented genomic DNA samples |
JP2015139373A (en) * | 2014-01-27 | 2015-08-03 | 株式会社日立ハイテクノロジーズ | Biomolecule analytical device, and biomolecule analyzer |
WO2015134787A2 (en) | 2014-03-05 | 2015-09-11 | Adaptive Biotechnologies Corporation | Methods using randomer-containing synthetic molecules |
EP3122894A4 (en) * | 2014-03-28 | 2017-11-08 | GE Healthcare Bio-Sciences Corp. | Accurate detection of rare genetic variants in next generation sequencing |
US10066265B2 (en) | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
MX2016013156A (en) | 2014-04-10 | 2017-02-14 | 10X Genomics Inc | Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same. |
ES2777529T3 (en) | 2014-04-17 | 2020-08-05 | Adaptive Biotechnologies Corp | Quantification of adaptive immune cell genomes in a complex mixture of cells |
RU2717641C2 (en) | 2014-04-21 | 2020-03-24 | Натера, Инк. | Detection of mutations and ploidy in chromosomal segments |
EP3138088A4 (en) | 2014-05-02 | 2017-12-06 | Synthetic Genomics, Inc. | Tamper-resistant assembly for securing valuable material |
SG11201610168YA (en) | 2014-05-16 | 2017-01-27 | Illumina Inc | Nucleic acid synthesis techniques |
CN113249435A (en) | 2014-06-26 | 2021-08-13 | 10X基因组学有限公司 | Methods of analyzing nucleic acids from individual cells or cell populations |
SG11201610691QA (en) | 2014-06-26 | 2017-01-27 | 10X Genomics Inc | Processes and systems for nucleic acid sequence assembly |
CA2955356C (en) | 2014-07-15 | 2024-01-02 | Illumina, Inc. | Biochemically activated electronic device |
US20160032281A1 (en) * | 2014-07-31 | 2016-02-04 | Fei Company | Functionalized grids for locating and imaging biological specimens and methods of using the same |
EP3174980A4 (en) | 2014-08-01 | 2018-01-17 | Dovetail Genomics, LLC | Tagging nucleic acids for sequence assembly |
CN107076739B (en) | 2014-08-21 | 2018-12-25 | 伊卢米纳剑桥有限公司 | Reversible surface functionalization |
US10570385B2 (en) | 2014-08-26 | 2020-02-25 | Japan Science And Technology Agency | Method for non-enzymatic combination of nucleic acid chains |
KR102538753B1 (en) | 2014-09-18 | 2023-05-31 | 일루미나, 인코포레이티드 | Methods and systems for analyzing nucleic acid sequencing data |
WO2016060974A1 (en) | 2014-10-13 | 2016-04-21 | Life Technologies Corporation | Methods, systems, and computer-readable media for accelerated base calling |
SG10201903408VA (en) | 2014-10-17 | 2019-05-30 | Illumina Cambridge Ltd | Contiguity preserving transposition |
AU2015339148B2 (en) | 2014-10-29 | 2022-03-10 | 10X Genomics, Inc. | Methods and compositions for targeted nucleic acid sequencing |
CA2966201A1 (en) | 2014-10-29 | 2016-05-06 | Adaptive Biotechnologies Corp. | Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples |
ES2772127T3 (en) | 2014-10-31 | 2020-07-07 | Illumina Cambridge Ltd | DNA copolymer polymers and coatings |
US9975122B2 (en) | 2014-11-05 | 2018-05-22 | 10X Genomics, Inc. | Instrument systems for integrated sample processing |
WO2016073237A1 (en) | 2014-11-05 | 2016-05-12 | Illumina Cambridge Limited | Reducing dna damage during sample preparation and sequencing using siderophore chelators |
US10246701B2 (en) | 2014-11-14 | 2019-04-02 | Adaptive Biotechnologies Corp. | Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture |
US10900065B2 (en) | 2014-11-14 | 2021-01-26 | University Of Washington | Methods and kits for labeling cellular molecules |
US10954559B2 (en) | 2014-11-21 | 2021-03-23 | Mgi Tech Co., Ltd. | Bubble-shaped adaptor element and method of constructing sequencing library with bubble-shaped adaptor element |
CA2965988A1 (en) * | 2014-11-21 | 2016-05-26 | Research Institute At Nationwide Children's Hospital | Parallel-processing systems and methods for highly scalable analysis of biological sequence data |
US10233490B2 (en) | 2014-11-21 | 2019-03-19 | Metabiotech Corporation | Methods for assembling and reading nucleic acid sequences from mixed populations |
EP3224384A4 (en) | 2014-11-25 | 2018-04-18 | Adaptive Biotechnologies Corp. | Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing |
EP3234575B1 (en) | 2014-12-18 | 2023-01-25 | Life Technologies Corporation | Apparatus for measuring analytes using large scale fet arrays |
US10077472B2 (en) | 2014-12-18 | 2018-09-18 | Life Technologies Corporation | High data rate integrated circuit with power management |
KR102593647B1 (en) | 2014-12-18 | 2023-10-26 | 라이프 테크놀로지스 코포레이션 | High data rate integrated circuit with transmitter configuration |
KR102321863B1 (en) | 2015-01-12 | 2021-11-08 | 10엑스 제노믹스, 인크. | Method and system for preparing nucleic acid sequencing library and library prepared using same |
KR20170106979A (en) | 2015-01-13 | 2017-09-22 | 10엑스 제노믹스, 인크. | System and method for visualizing structure variation and phase adjustment information |
GB2548763B (en) * | 2015-02-02 | 2021-07-21 | Hitachi High Tech Corp | Multicolor fluorescence analysis device |
CA2975855A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Compositions and methods for synthetic gene assembly |
CA2975852A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
SG11201705996PA (en) | 2015-02-09 | 2017-09-28 | 10X Genomics Inc | Systems and methods for determining structural variation and phasing using variant call data |
CA2976786A1 (en) * | 2015-02-17 | 2016-08-25 | Complete Genomics, Inc. | Dna sequencing using controlled strand displacement |
US9715573B2 (en) | 2015-02-17 | 2017-07-25 | Dovetail Genomics, Llc | Nucleic acid sequence assembly |
AU2016222788B2 (en) | 2015-02-24 | 2022-03-31 | Adaptive Biotechnologies Corp. | Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing |
EP4286516A3 (en) | 2015-02-24 | 2024-03-06 | 10X Genomics, Inc. | Partition processing methods and systems |
EP3936619A1 (en) | 2015-02-24 | 2022-01-12 | 10X Genomics, Inc. | Methods for targeted nucleic acid sequence coverage |
CN114250278A (en) | 2015-03-13 | 2022-03-29 | 生命技术公司 | Methods, compositions and kits for capturing, detecting and quantifying small RNAs |
AU2016235288B2 (en) | 2015-03-24 | 2019-02-28 | Illumina Cambridge Limited | Methods, carrier assemblies, and systems for imaging samples for biological or chemical analysis |
US11807896B2 (en) | 2015-03-26 | 2023-11-07 | Dovetail Genomics, Llc | Physical linkage preservation in DNA storage |
WO2016161273A1 (en) | 2015-04-01 | 2016-10-06 | Adaptive Biotechnologies Corp. | Method of identifying human compatible t cell receptors specific for an antigenic target |
EP3901281B1 (en) | 2015-04-10 | 2022-11-23 | Spatial Transcriptomics AB | Spatially distinguished, multiplex nucleic acid analysis of biological specimens |
WO2016172377A1 (en) | 2015-04-21 | 2016-10-27 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
US11479812B2 (en) | 2015-05-11 | 2022-10-25 | Natera, Inc. | Methods and compositions for determining ploidy |
EP4190912A1 (en) | 2015-05-11 | 2023-06-07 | Illumina, Inc. | Platform for discovery and analysis of therapeutic agents |
EP4220645A3 (en) | 2015-05-14 | 2023-11-08 | Life Technologies Corporation | Barcode sequences, and related systems and methods |
EP3302804B1 (en) | 2015-05-29 | 2022-07-13 | Illumina, Inc. | Sample carrier and assay system for conducting designated reactions |
US10545139B2 (en) | 2015-06-16 | 2020-01-28 | Curiox Biosystems Pte Ltd. | Methods and devices for performing biological assays using magnetic components |
CN107924121B (en) | 2015-07-07 | 2021-06-08 | 亿明达股份有限公司 | Selective surface patterning via nanoimprinting |
US20180207920A1 (en) | 2015-07-17 | 2018-07-26 | Illumina, Inc. | Polymer sheets for sequencing applications |
BR112017023418A2 (en) | 2015-07-30 | 2018-07-24 | Illumina, Inc. | orthogonal nucleotide unlocking |
CN108474805A (en) | 2015-08-24 | 2018-08-31 | 亿明达股份有限公司 | For accumulator and flow control system in biological and chemical setting-out line road |
US10906044B2 (en) | 2015-09-02 | 2021-02-02 | Illumina Cambridge Limited | Methods of improving droplet operations in fluidic systems with a filler fluid including a surface regenerative silane |
KR20180050411A (en) | 2015-09-18 | 2018-05-14 | 트위스트 바이오사이언스 코포레이션 | Oligonucleotide mutant library and its synthesis |
CN113604546A (en) | 2015-09-22 | 2021-11-05 | 特韦斯特生物科学公司 | Flexible substrates for nucleic acid synthesis |
EP3359693A4 (en) | 2015-10-09 | 2019-03-06 | Accuragen Holdings Limited | Methods and compositions for enrichment of amplification products |
SG11201803289VA (en) | 2015-10-19 | 2018-05-30 | Dovetail Genomics Llc | Methods for genome assembly, haplotype phasing, and target independent nucleic acid detection |
US10253352B2 (en) | 2015-11-17 | 2019-04-09 | Omniome, Inc. | Methods for determining sequence profiles |
US11371094B2 (en) | 2015-11-19 | 2022-06-28 | 10X Genomics, Inc. | Systems and methods for nucleic acid processing using degenerate nucleotides |
WO2017095958A1 (en) | 2015-12-01 | 2017-06-08 | Twist Bioscience Corporation | Functionalized surfaces and preparation thereof |
CN115927547A (en) * | 2015-12-03 | 2023-04-07 | 安可济控股有限公司 | Methods and compositions for forming ligation products |
EP3882357B1 (en) | 2015-12-04 | 2022-08-10 | 10X Genomics, Inc. | Methods and compositions for nucleic acid analysis |
CA3008031A1 (en) | 2016-01-11 | 2017-07-20 | Illumina Singapore Pte Ltd | Detection apparatus having a microfluorometer, a fluidic system, and a flow cell latch clamp module |
CN108779491B (en) | 2016-02-11 | 2021-03-09 | 10X基因组学有限公司 | Systems, methods, and media for de novo assembly of whole genome sequence data |
CA3014911A1 (en) | 2016-02-23 | 2017-08-31 | Dovetail Genomics, Llc | Generation of phased read-sets for genome assembly and haplotype phasing |
JP6584986B2 (en) | 2016-03-18 | 2019-10-02 | 株式会社東芝 | Nucleic acid detection method |
US10619205B2 (en) | 2016-05-06 | 2020-04-14 | Life Technologies Corporation | Combinatorial barcode sequences, and related systems and methods |
IL262946B2 (en) | 2016-05-13 | 2023-03-01 | Dovetail Genomics Llc | Recovering long-range linkage information from preserved samples |
WO2017197338A1 (en) | 2016-05-13 | 2017-11-16 | 10X Genomics, Inc. | Microfluidic systems and methods of use |
CN109511265B (en) * | 2016-05-16 | 2023-07-14 | 安可济控股有限公司 | Method for improving sequencing by strand identification |
KR102171865B1 (en) | 2016-05-18 | 2020-10-29 | 일루미나, 인코포레이티드 | Self-assembled patterning using patterned hydrophobic surfaces |
EP3465506B1 (en) | 2016-06-01 | 2024-04-03 | Life Technologies Corporation | Methods and systems for designing gene panels |
JP6889769B2 (en) * | 2016-07-18 | 2021-06-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Asymmetric templates and asymmetric methods of nucleic acid sequencing |
SG11201901296TA (en) * | 2016-08-15 | 2019-03-28 | Accuragen Holdings Ltd | Compositions and methods for detecting rare sequence variants |
WO2018038772A1 (en) | 2016-08-22 | 2018-03-01 | Twist Bioscience Corporation | De novo synthesized nucleic acid libraries |
US10428325B1 (en) | 2016-09-21 | 2019-10-01 | Adaptive Biotechnologies Corporation | Identification of antigen-specific B cell receptors |
KR102217487B1 (en) | 2016-09-21 | 2021-02-23 | 트위스트 바이오사이언스 코포레이션 | Nucleic acid-based data storage |
WO2018064116A1 (en) | 2016-09-28 | 2018-04-05 | Illumina, Inc. | Methods and systems for data compression |
US11485996B2 (en) | 2016-10-04 | 2022-11-01 | Natera, Inc. | Methods for characterizing copy number variation using proximity-litigation sequencing |
CN111781139B (en) | 2016-10-14 | 2023-09-12 | 亿明达股份有限公司 | Clamping box assembly |
US11667951B2 (en) | 2016-10-24 | 2023-06-06 | Geneinfosec, Inc. | Concealing information present within nucleic acids |
KR102639137B1 (en) | 2016-11-03 | 2024-02-21 | 엠쥐아이 테크 컴퍼니 엘티디. | Biosensors for biological or chemical analysis and methods of manufacturing the same |
WO2018093780A1 (en) | 2016-11-16 | 2018-05-24 | Illumina, Inc. | Validation methods and systems for sequence variant calls |
WO2018102759A1 (en) | 2016-12-01 | 2018-06-07 | Ignite Biosciences, Inc. | Methods of assaying proteins |
US10011870B2 (en) | 2016-12-07 | 2018-07-03 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
EA201991262A1 (en) | 2016-12-16 | 2020-04-07 | Твист Байосайенс Корпорейшн | LIBRARIES OF OPTIONS OF IMMUNOLOGICAL SYNAPSIS AND THEIR SYNTHESIS |
US10815525B2 (en) | 2016-12-22 | 2020-10-27 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10550429B2 (en) | 2016-12-22 | 2020-02-04 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10011872B1 (en) | 2016-12-22 | 2018-07-03 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
IL267836B2 (en) | 2017-01-04 | 2023-09-01 | Complete Genomics Inc | Stepwise sequencing by non-labeled reversible terminators or natural nucleotides |
GB201704754D0 (en) | 2017-01-05 | 2017-05-10 | Illumina Inc | Kinetic exclusion amplification of nucleic acid libraries |
EP4310183A3 (en) | 2017-01-30 | 2024-02-21 | 10X Genomics, Inc. | Methods and systems for droplet-based single cell barcoding |
US10995333B2 (en) | 2017-02-06 | 2021-05-04 | 10X Genomics, Inc. | Systems and methods for nucleic acid preparation |
WO2018152162A1 (en) | 2017-02-15 | 2018-08-23 | Omniome, Inc. | Distinguishing sequences by detecting polymerase dissociation |
CA3054303A1 (en) | 2017-02-22 | 2018-08-30 | Twist Bioscience Corporation | Nucleic acid based data storage |
CA3056388A1 (en) | 2017-03-15 | 2018-09-20 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
JP7305611B2 (en) * | 2017-03-17 | 2023-07-10 | アプトン バイオシステムズ インコーポレイテッド | Methods of sequencing and high-resolution imaging |
AU2018237066B2 (en) | 2017-03-20 | 2022-09-15 | Mgi Tech Co., Ltd. | Biosensors for biological or chemical analysis and methods of manufacturing the same |
WO2018187013A1 (en) | 2017-04-04 | 2018-10-11 | Omniome, Inc. | Fluidic apparatus and methods useful for chemical and biological reactions |
KR102446247B1 (en) | 2017-04-05 | 2022-09-21 | 큐리옥스 바이오시스템즈 피티이 엘티디. | Methods, devices and apparatus for cleaning samples on array plates |
US10161003B2 (en) | 2017-04-25 | 2018-12-25 | Omniome, Inc. | Methods and apparatus that increase sequencing-by-binding efficiency |
EP3625715A4 (en) | 2017-05-19 | 2021-03-17 | 10X Genomics, Inc. | Systems and methods for analyzing datasets |
US20180340169A1 (en) | 2017-05-26 | 2018-11-29 | 10X Genomics, Inc. | Single cell analysis of transposase accessible chromatin |
EP4230746A3 (en) | 2017-05-26 | 2023-11-01 | 10X Genomics, Inc. | Single cell analysis of transposase accessible chromatin |
US10538808B2 (en) | 2017-05-26 | 2020-01-21 | Vibrant Holdings, Llc | Photoactive compounds and methods for biomolecule detection and sequencing |
WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
KR20240013290A (en) | 2017-06-12 | 2024-01-30 | 트위스트 바이오사이언스 코포레이션 | Methods for seamless nucleic acid assembly |
JP6991504B2 (en) * | 2017-07-13 | 2022-01-12 | 国立研究開発法人産業技術総合研究所 | Target substance detection device and target substance detection method |
WO2019023948A1 (en) | 2017-08-01 | 2019-02-07 | 深圳华大智造科技有限公司 | Gene sequencing reaction device, gene sequencing system, and gene sequencing reaction method |
US10858701B2 (en) | 2017-08-15 | 2020-12-08 | Omniome, Inc. | Scanning apparatus and method useful for detection of chemical and biological analytes |
US11125748B2 (en) * | 2017-09-01 | 2021-09-21 | University Of British Columbia | Method for organizing individual molecules on a patterned substrate and structures assembled thereby |
GB2581620A (en) | 2017-09-11 | 2020-08-26 | Twist Bioscience Corp | GPCR binding proteins and synthesis thereof |
EP3685426A4 (en) | 2017-09-19 | 2021-06-09 | MGI Tech Co., Ltd. | Wafer level sequencing flow cell fabrication |
WO2019060771A2 (en) | 2017-09-22 | 2019-03-28 | University Of Washington | In situ combinatorial labeling of cellular molecules |
GB2566986A (en) | 2017-09-29 | 2019-04-03 | Evonetix Ltd | Error detection during hybridisation of target double-stranded nucleic acid |
US10837047B2 (en) | 2017-10-04 | 2020-11-17 | 10X Genomics, Inc. | Compositions, methods, and systems for bead formation using improved polymers |
US11485966B2 (en) | 2017-10-11 | 2022-11-01 | Mgi Tech Co., Ltd. | Method for improving loading and stability of nucleic acid |
KR102362711B1 (en) | 2017-10-16 | 2022-02-14 | 일루미나, 인코포레이티드 | Deep Convolutional Neural Networks for Variant Classification |
EP3622519B1 (en) | 2017-10-16 | 2023-09-13 | Illumina, Inc. | Deep learning-based aberrant splicing detection |
US11193166B2 (en) | 2017-10-19 | 2021-12-07 | Omniome, Inc. | Simultaneous background reduction and complex stabilization in binding assay workflows |
CN111565834B (en) | 2017-10-20 | 2022-08-26 | 特韦斯特生物科学公司 | Heated nanopores for polynucleotide synthesis |
WO2019084043A1 (en) | 2017-10-26 | 2019-05-02 | 10X Genomics, Inc. | Methods and systems for nuclecic acid preparation and chromatin analysis |
EP4241882A3 (en) | 2017-10-27 | 2023-12-06 | 10X Genomics, Inc. | Methods for sample preparation and analysis |
SG11201913654QA (en) | 2017-11-15 | 2020-01-30 | 10X Genomics Inc | Functionalized gel beads |
US10829815B2 (en) | 2017-11-17 | 2020-11-10 | 10X Genomics, Inc. | Methods and systems for associating physical and genetic properties of biological particles |
US11254980B1 (en) | 2017-11-29 | 2022-02-22 | Adaptive Biotechnologies Corporation | Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements |
WO2019108851A1 (en) | 2017-11-30 | 2019-06-06 | 10X Genomics, Inc. | Systems and methods for nucleic acid preparation and analysis |
CA3044782A1 (en) | 2017-12-29 | 2019-06-29 | Clear Labs, Inc. | Automated priming and library loading device |
EP3735459A4 (en) | 2018-01-04 | 2021-10-06 | Twist Bioscience Corporation | Dna-based digital information storage |
US11561196B2 (en) | 2018-01-08 | 2023-01-24 | Illumina, Inc. | Systems and devices for high-throughput sequencing with semiconductor-based detection |
NZ759650A (en) | 2018-01-08 | 2022-07-01 | Illumina Inc | High-throughput sequencing with semiconductor-based detection |
CA3065939A1 (en) | 2018-01-15 | 2019-07-18 | Illumina, Inc. | Deep learning-based variant classifier |
US11366303B2 (en) | 2018-01-30 | 2022-06-21 | Rebus Biosystems, Inc. | Method for detecting particles using structured illumination |
WO2019157529A1 (en) | 2018-02-12 | 2019-08-15 | 10X Genomics, Inc. | Methods characterizing multiple analytes from individual cells or cell populations |
US11639928B2 (en) | 2018-02-22 | 2023-05-02 | 10X Genomics, Inc. | Methods and systems for characterizing analytes from individual cells or cell populations |
US11203782B2 (en) | 2018-03-29 | 2021-12-21 | Accuragen Holdings Limited | Compositions and methods comprising asymmetric barcoding |
AU2019247652A1 (en) * | 2018-04-02 | 2020-10-15 | Enumera Molecular, Inc. | Methods, systems, and compositions for counting nucleic acid molecules |
WO2019195197A1 (en) | 2018-04-02 | 2019-10-10 | Dropworks, Inc. | Systems and methods for serial flow emulsion processes |
EP3775196A4 (en) | 2018-04-04 | 2021-12-22 | Nautilus Biotechnology, Inc. | Methods of generating nanoarrays and microarrays |
SG11202009889VA (en) | 2018-04-06 | 2020-11-27 | 10X Genomics Inc | Systems and methods for quality control in single cell processing |
WO2019200338A1 (en) | 2018-04-12 | 2019-10-17 | Illumina, Inc. | Variant classifier based on deep neural networks |
CN108444966A (en) * | 2018-04-16 | 2018-08-24 | 成都博奥晶芯生物科技有限公司 | A kind of concentration gradient fluorescent calibration piece of laser micro array chip scanner |
AU2019255987A1 (en) | 2018-04-19 | 2020-12-10 | Pacific Biosciences Of California, Inc. | Improving accuracy of base calls in nucleic acid sequencing methods |
WO2019209426A1 (en) | 2018-04-26 | 2019-10-31 | Omniome, Inc. | Methods and compositions for stabilizing nucleic acid-nucleotide-polymerase complexes |
CN112639094A (en) | 2018-05-08 | 2021-04-09 | 深圳华大智造科技股份有限公司 | Single-tube bead-based DNA co-barcoding for accurate and cost-effective sequencing, haplotyping and assembly |
CA3100739A1 (en) | 2018-05-18 | 2019-11-21 | Twist Bioscience Corporation | Polynucleotides, reagents, and methods for nucleic acid hybridization |
US11339428B2 (en) | 2018-05-31 | 2022-05-24 | Pacific Biosciences Of California, Inc. | Increased signal to noise in nucleic acid sequencing |
FI3810774T3 (en) | 2018-06-04 | 2023-12-11 | Illumina Inc | Methods of making high-throughput single-cell transcriptome libraries |
US11932899B2 (en) | 2018-06-07 | 2024-03-19 | 10X Genomics, Inc. | Methods and systems for characterizing nucleic acid molecules |
US11703427B2 (en) | 2018-06-25 | 2023-07-18 | 10X Genomics, Inc. | Methods and systems for cell and bead processing |
JP2020000197A (en) * | 2018-06-29 | 2020-01-09 | キヤノン株式会社 | Counting method, concentration measuring apparatus, and concentration measuring system |
US11525159B2 (en) | 2018-07-03 | 2022-12-13 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
US20200251183A1 (en) | 2018-07-11 | 2020-08-06 | Illumina, Inc. | Deep Learning-Based Framework for Identifying Sequence Patterns that Cause Sequence-Specific Errors (SSEs) |
WO2020023362A1 (en) | 2018-07-24 | 2020-01-30 | Omniome, Inc. | Serial formation of ternary complex species |
US20200032335A1 (en) | 2018-07-27 | 2020-01-30 | 10X Genomics, Inc. | Systems and methods for metabolome analysis |
US11519033B2 (en) | 2018-08-28 | 2022-12-06 | 10X Genomics, Inc. | Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample |
KR20210047364A (en) * | 2018-09-19 | 2021-04-29 | 앱톤 바이오시스템즈, 인코포레이티드 | Densely packed analyte layer and detection method |
CN113705585A (en) | 2018-10-15 | 2021-11-26 | 因美纳有限公司 | Method and system based on neural network implementation |
US20200149095A1 (en) * | 2018-11-14 | 2020-05-14 | Element Biosciences, Inc. | Low binding supports for improved solid-phase dna hybridization and amplification |
US10876148B2 (en) | 2018-11-14 | 2020-12-29 | Element Biosciences, Inc. | De novo surface preparation and uses thereof |
US10704094B1 (en) | 2018-11-14 | 2020-07-07 | Element Biosciences, Inc. | Multipart reagents having increased avidity for polymerase binding |
TW202043450A (en) | 2018-11-15 | 2020-12-01 | 中國商深圳華大智造科技有限公司 | System and method for integrated sensor cartridge |
WO2020101795A1 (en) | 2018-11-15 | 2020-05-22 | Omniome, Inc. | Electronic detection of nucleic acid structure |
WO2020108588A1 (en) | 2018-12-01 | 2020-06-04 | Mgi Tech Co., Ltd. | Methods and structures to improve light collection efficiency in biosensors |
US10710076B2 (en) | 2018-12-04 | 2020-07-14 | Omniome, Inc. | Mixed-phase fluids for nucleic acid sequencing and other analytical assays |
WO2020123319A2 (en) | 2018-12-10 | 2020-06-18 | 10X Genomics, Inc. | Methods of using master / copy arrays for spatial detection |
US11459607B1 (en) | 2018-12-10 | 2022-10-04 | 10X Genomics, Inc. | Systems and methods for processing-nucleic acid molecules from a single cell using sequential co-partitioning and composite barcodes |
US20200208214A1 (en) | 2018-12-19 | 2020-07-02 | Illumina, Inc. | Methods for improving polynucleotide cluster clonality |
CN113227348A (en) | 2018-12-20 | 2021-08-06 | 欧姆尼欧美公司 | Temperature control for analysis of nucleic acids and other analytes |
US11649485B2 (en) | 2019-01-06 | 2023-05-16 | 10X Genomics, Inc. | Generating capture probes for spatial analysis |
US11926867B2 (en) | 2019-01-06 | 2024-03-12 | 10X Genomics, Inc. | Generating capture probes for spatial analysis |
US11845983B1 (en) | 2019-01-09 | 2023-12-19 | 10X Genomics, Inc. | Methods and systems for multiplexing of droplet based assays |
WO2020157684A1 (en) | 2019-01-29 | 2020-08-06 | Mgi Tech Co., Ltd. | High coverage stlfr |
EP3924505A1 (en) | 2019-02-12 | 2021-12-22 | 10X Genomics, Inc. | Methods for processing nucleic acid molecules |
US11851683B1 (en) | 2019-02-12 | 2023-12-26 | 10X Genomics, Inc. | Methods and systems for selective analysis of cellular samples |
US11467153B2 (en) | 2019-02-12 | 2022-10-11 | 10X Genomics, Inc. | Methods for processing nucleic acid molecules |
US11499189B2 (en) | 2019-02-14 | 2022-11-15 | Pacific Biosciences Of California, Inc. | Mitigating adverse impacts of detection systems on nucleic acids and other biological analytes |
US11680950B2 (en) | 2019-02-20 | 2023-06-20 | Pacific Biosciences Of California, Inc. | Scanning apparatus and methods for detecting chemical and biological analytes |
US11655499B1 (en) | 2019-02-25 | 2023-05-23 | 10X Genomics, Inc. | Detection of sequence elements in nucleic acid molecules |
KR20210144698A (en) | 2019-02-26 | 2021-11-30 | 트위스트 바이오사이언스 코포레이션 | Variant Nucleic Acid Libraries for Antibody Optimization |
EP3930753A4 (en) | 2019-02-26 | 2023-03-29 | Twist Bioscience Corporation | Variant nucleic acid libraries for glp1 receptor |
SG11202102530QA (en) | 2019-03-01 | 2021-04-29 | Illumina Inc | High-throughput single-nuclei and single-cell libraries and methods of making and of using |
WO2020180813A1 (en) | 2019-03-06 | 2020-09-10 | Qiagen Sciences, Llc | Compositions and methods for adaptor design and nucleic acid library construction for rolony-based sequencing |
EP3938537A1 (en) | 2019-03-11 | 2022-01-19 | 10X Genomics, Inc. | Systems and methods for processing optically tagged beads |
WO2020205296A1 (en) | 2019-03-21 | 2020-10-08 | Illumina, Inc. | Artificial intelligence-based generation of sequencing metadata |
US11210554B2 (en) | 2019-03-21 | 2021-12-28 | Illumina, Inc. | Artificial intelligence-based generation of sequencing metadata |
US11783917B2 (en) | 2019-03-21 | 2023-10-10 | Illumina, Inc. | Artificial intelligence-based base calling |
NL2023316B1 (en) | 2019-03-21 | 2020-09-28 | Illumina Inc | Artificial intelligence-based sequencing |
EP3947718A4 (en) | 2019-04-02 | 2022-12-21 | Enumera Molecular, Inc. | Methods, systems, and compositions for counting nucleic acid molecules |
KR20220004947A (en) | 2019-04-29 | 2022-01-12 | 일루미나, 인코포레이티드 | Identification and Analysis of Microbial Samples by Rapid Incubation and Nucleic Acid Enrichment |
US11423306B2 (en) | 2019-05-16 | 2022-08-23 | Illumina, Inc. | Systems and devices for characterization and performance analysis of pixel-based sequencing |
US11593649B2 (en) | 2019-05-16 | 2023-02-28 | Illumina, Inc. | Base calling using convolutions |
WO2020252186A1 (en) | 2019-06-11 | 2020-12-17 | Omniome, Inc. | Calibrated focus sensing |
CN114729342A (en) | 2019-06-21 | 2022-07-08 | 特韦斯特生物科学公司 | Barcode-based nucleic acid sequence assembly |
WO2020264260A1 (en) * | 2019-06-27 | 2020-12-30 | Zymergen Inc. | Laboratory automation system implementing efficient path for material and labware transfers |
US11377655B2 (en) | 2019-07-16 | 2022-07-05 | Pacific Biosciences Of California, Inc. | Synthetic nucleic acids having non-natural structures |
US10656368B1 (en) | 2019-07-24 | 2020-05-19 | Omniome, Inc. | Method and system for biological imaging using a wide field objective lens |
US20230220466A1 (en) * | 2019-09-10 | 2023-07-13 | The Regents Of The University Of California | Immune cell sequencing methods |
TW202124406A (en) | 2019-09-10 | 2021-07-01 | 美商歐姆尼歐美公司 | Reversible modification of nucleotides |
EP4045683A1 (en) | 2019-10-18 | 2022-08-24 | Omniome, Inc. | Methods and compositions for capping nucleic acids |
EP4025711A2 (en) | 2019-11-08 | 2022-07-13 | 10X Genomics, Inc. | Enhancing specificity of analyte binding |
WO2021091611A1 (en) | 2019-11-08 | 2021-05-14 | 10X Genomics, Inc. | Spatially-tagged analyte capture agents for analyte multiplexing |
BR112021019640A2 (en) | 2019-12-19 | 2022-06-21 | Illumina Inc | High-throughput single cell libraries and methods of preparation and use |
SG11202106899SA (en) | 2019-12-23 | 2021-09-29 | 10X Genomics Inc | Methods for spatial analysis using rna-templated ligation |
US20210189483A1 (en) | 2019-12-23 | 2021-06-24 | Mgi Tech Co. Ltd. | Controlled strand-displacement for paired end sequencing |
US11732299B2 (en) | 2020-01-21 | 2023-08-22 | 10X Genomics, Inc. | Spatial assays with perturbed cells |
US11821035B1 (en) | 2020-01-29 | 2023-11-21 | 10X Genomics, Inc. | Compositions and methods of making gene expression libraries |
US11898205B2 (en) | 2020-02-03 | 2024-02-13 | 10X Genomics, Inc. | Increasing capture efficiency of spatial assays |
US20230054204A1 (en) | 2020-02-04 | 2023-02-23 | Pacific Biosciences Of California, Inc. | Flow cells and methods for their manufacture and use |
US11732300B2 (en) | 2020-02-05 | 2023-08-22 | 10X Genomics, Inc. | Increasing efficiency of spatial analysis in a biological sample |
US11835462B2 (en) | 2020-02-11 | 2023-12-05 | 10X Genomics, Inc. | Methods and compositions for partitioning a biological sample |
IL295560A (en) | 2020-02-20 | 2022-10-01 | Illumina Inc | Artificial intelligence-based many-to-many base calling |
US11891654B2 (en) | 2020-02-24 | 2024-02-06 | 10X Genomics, Inc. | Methods of making gene expression libraries |
US11926863B1 (en) | 2020-02-27 | 2024-03-12 | 10X Genomics, Inc. | Solid state single cell method for analyzing fixed biological cells |
EP4114966A1 (en) | 2020-03-03 | 2023-01-11 | Pacific Biosciences Of California, Inc. | Methods and compositions for sequencing double stranded nucleic acids |
US11768175B1 (en) | 2020-03-04 | 2023-09-26 | 10X Genomics, Inc. | Electrophoretic methods for spatial analysis |
WO2021188717A1 (en) * | 2020-03-18 | 2021-09-23 | Apton Biosystems, Inc. | Systems and methods of detecting densely-packed analytes |
WO2021216708A1 (en) | 2020-04-22 | 2021-10-28 | 10X Genomics, Inc. | Methods for spatial analysis using targeted rna depletion |
US20230183798A1 (en) | 2020-05-05 | 2023-06-15 | Pacific Biosciences Of California, Inc. | Compositions and methods for modifying polymerase-nucleic acid complexes |
US11188778B1 (en) | 2020-05-05 | 2021-11-30 | Illumina, Inc. | Equalization-based image processing and spatial crosstalk attenuator |
US11851700B1 (en) | 2020-05-13 | 2023-12-26 | 10X Genomics, Inc. | Methods, kits, and compositions for processing extracellular molecules |
US20230235392A1 (en) * | 2020-05-20 | 2023-07-27 | Element Biosciences, Inc. | Methods for paired-end sequencing library preparation |
WO2021237087A1 (en) | 2020-05-22 | 2021-11-25 | 10X Genomics, Inc. | Spatial analysis to detect sequence variants |
EP4153775A1 (en) | 2020-05-22 | 2023-03-29 | 10X Genomics, Inc. | Simultaneous spatio-temporal measurement of gene expression and cellular activity |
WO2021242834A1 (en) | 2020-05-26 | 2021-12-02 | 10X Genomics, Inc. | Method for resetting an array |
EP4025692A2 (en) | 2020-06-02 | 2022-07-13 | 10X Genomics, Inc. | Nucleic acid library methods |
WO2021247568A1 (en) | 2020-06-02 | 2021-12-09 | 10X Genomics, Inc. | Spatial trancriptomics for antigen-receptors |
EP4162074B1 (en) | 2020-06-08 | 2024-04-24 | 10X Genomics, Inc. | Methods of determining a surgical margin and methods of use thereof |
WO2021252617A1 (en) | 2020-06-09 | 2021-12-16 | Illumina, Inc. | Methods for increasing yield of sequencing libraries |
EP4165207A1 (en) | 2020-06-10 | 2023-04-19 | 10X Genomics, Inc. | Methods for determining a location of an analyte in a biological sample |
CN116034166A (en) | 2020-06-25 | 2023-04-28 | 10X基因组学有限公司 | Spatial analysis of DNA methylation |
US11761038B1 (en) | 2020-07-06 | 2023-09-19 | 10X Genomics, Inc. | Methods for identifying a location of an RNA in a biological sample |
US20240043913A1 (en) | 2020-07-17 | 2024-02-08 | The Regents Of The University Of Michigan | Materials and methods for localized detection of nucleic acids in a tissue sample |
US11200446B1 (en) | 2020-08-31 | 2021-12-14 | Element Biosciences, Inc. | Single-pass primary analysis |
US11926822B1 (en) | 2020-09-23 | 2024-03-12 | 10X Genomics, Inc. | Three-dimensional spatial analysis |
KR20230118570A (en) | 2020-11-11 | 2023-08-11 | 노틸러스 서브시디어리, 인크. | Affinity reagents with enhanced binding and detection properties |
US11827935B1 (en) | 2020-11-19 | 2023-11-28 | 10X Genomics, Inc. | Methods for spatial analysis using rolling circle amplification and detection probes |
AU2021409136A1 (en) | 2020-12-21 | 2023-06-29 | 10X Genomics, Inc. | Methods, compositions, and systems for capturing probes and/or barcodes |
AU2022227563A1 (en) | 2021-02-23 | 2023-08-24 | 10X Genomics, Inc. | Probe-based analysis of nucleic acids and proteins |
JP2024514405A (en) | 2021-03-11 | 2024-04-02 | ノーティラス・サブシディアリー・インコーポレイテッド | Systems and methods for biomolecule retention |
WO2022197754A1 (en) | 2021-03-16 | 2022-09-22 | Illumina Software, Inc. | Neural network parameter quantization for base calling |
WO2022198068A1 (en) | 2021-03-18 | 2022-09-22 | 10X Genomics, Inc. | Multiplex capture of gene and protein expression from a biological sample |
CA3210451A1 (en) | 2021-03-22 | 2022-09-29 | Illumina Cambridge Limited | Methods for improving nucleic acid cluster clonality |
US20220336054A1 (en) | 2021-04-15 | 2022-10-20 | Illumina, Inc. | Deep Convolutional Neural Networks to Predict Variant Pathogenicity using Three-Dimensional (3D) Protein Structures |
US20220336052A1 (en) * | 2021-04-19 | 2022-10-20 | University Of Utah Research Foundation | Systems and methods for facilitating rapid genome sequence analysis |
EP4352286A1 (en) * | 2021-06-11 | 2024-04-17 | Cellanome, Inc. | Systems and methods for analyzing biological samples |
EP4355476A1 (en) | 2021-06-15 | 2024-04-24 | Illumina, Inc. | Hydrogel-free surface functionalization for sequencing |
US11859241B2 (en) | 2021-06-17 | 2024-01-02 | Element Biosciences, Inc. | Compositions and methods for pairwise sequencing |
US11427855B1 (en) | 2021-06-17 | 2022-08-30 | Element Biosciences, Inc. | Compositions and methods for pairwise sequencing |
WO2023278184A1 (en) | 2021-06-29 | 2023-01-05 | Illumina, Inc. | Methods and systems to correct crosstalk in illumination emitted from reaction sites |
US20230027409A1 (en) | 2021-07-13 | 2023-01-26 | Illumina, Inc. | Methods and systems for real time extraction of crosstalk in illumination emitted from reaction sites |
US11455487B1 (en) | 2021-10-26 | 2022-09-27 | Illumina Software, Inc. | Intensity extraction and crosstalk attenuation using interpolation and adaptation for base calling |
US20230116852A1 (en) | 2021-07-23 | 2023-04-13 | Illumina, Inc. | Methods for preparing substrate surface for dna sequencing |
US20230057571A1 (en) * | 2021-08-03 | 2023-02-23 | 10X Genomics, Inc. | Nucleic acid concatemers and methods for stabilizing and/or compacting the same |
WO2023034489A1 (en) | 2021-09-01 | 2023-03-09 | 10X Genomics, Inc. | Methods, compositions, and kits for blocking a capture probe on a spatial array |
WO2023069927A1 (en) | 2021-10-20 | 2023-04-27 | Illumina, Inc. | Methods for capturing library dna for sequencing |
WO2023091592A1 (en) * | 2021-11-19 | 2023-05-25 | Dovetail Genomics, Llc | Dendrimers for genomic analysis methods and compositions |
US20230167488A1 (en) | 2021-11-30 | 2023-06-01 | Nautilus Biotechnology, Inc. | Particle-based isolation of proteins and other analytes |
WO2023107719A2 (en) * | 2021-12-10 | 2023-06-15 | Element Biosciences, Inc. | Primary analysis in next generation sequencing |
WO2023141154A1 (en) | 2022-01-20 | 2023-07-27 | Illumina Cambridge Limited | Methods of detecting methylcytosine and hydroxymethylcytosine by sequencing |
WO2023196572A1 (en) | 2022-04-07 | 2023-10-12 | Illumina Singapore Pte. Ltd. | Altered cytidine deaminases and methods of use |
WO2024015962A1 (en) | 2022-07-15 | 2024-01-18 | Pacific Biosciences Of California, Inc. | Blocked asymmetric hairpin adaptors |
WO2024030954A1 (en) | 2022-08-03 | 2024-02-08 | Nautilus Subsidiary, Inc. | Chemical modification of antibodies and functional fragments thereof |
WO2024040058A1 (en) | 2022-08-15 | 2024-02-22 | Element Biosciences, Inc. | Methods for preparing nucleic acid nanostructures using compaction oligonucleotides |
WO2024072614A1 (en) | 2022-09-27 | 2024-04-04 | Nautilus Subsidiary, Inc. | Polypeptide capture, in situ fragmentation and identification |
WO2024073047A1 (en) | 2022-09-30 | 2024-04-04 | Illumina, Inc. | Cytidine deaminases and methods of use in mapping modified cytosine nucleotides |
WO2024073043A1 (en) | 2022-09-30 | 2024-04-04 | Illumina, Inc. | Methods of using cpg binding proteins in mapping modified cytosine nucleotides |
WO2024069581A1 (en) | 2022-09-30 | 2024-04-04 | Illumina Singapore Pte. Ltd. | Helicase-cytidine deaminase complexes and methods of use |
CN115409174B (en) * | 2022-11-01 | 2023-03-31 | 之江实验室 | Base sequence filtering method and device based on DRAM memory calculation |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020012930A1 (en) | 1999-09-16 | 2002-01-31 | Rothberg Jonathan M. | Method of sequencing a nucleic acid |
US6355419B1 (en) | 1998-04-27 | 2002-03-12 | Hyseq, Inc. | Preparation of pools of nucleic acids based on representation in a sample |
US20020076716A1 (en) | 1998-04-09 | 2002-06-20 | Trustees Of Boston University | Nucleic acid arrays and methods of synthesis |
WO2003102231A1 (en) | 2002-05-29 | 2003-12-11 | Axaron Bioscience Ag | Method for parallelly sequencing a nucleic acid mixture by using a continuous flow system |
WO2004076683A2 (en) | 2003-02-26 | 2004-09-10 | Callida Genomics, Inc. | Random array dna analysis by hybridization |
Family Cites Families (408)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3356882A (en) | 1965-10-21 | 1967-12-05 | Ford Motor Co | Spark plug having the center electrode sheath with a nickel alloy |
US3958144A (en) | 1973-10-01 | 1976-05-18 | Franks Harry E | Spark plug |
JPS5180845A (en) | 1975-01-14 | 1976-07-15 | Teijin Ltd | 2*22 bisu * 3*55 jiburomu 44 * 22 hidorokishetokishi * fueniru * puropannoyojuhojiho |
US4318846A (en) | 1979-09-07 | 1982-03-09 | Syva Company | Novel ether substituted fluorescein polyamino acid compounds as fluorescers and quenchers |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
JPS5965108A (en) | 1982-10-06 | 1984-04-13 | Sumikin Kozai Kogyo Kk | Principal rafter-shaped steel dam and its construction |
US4994373A (en) * | 1983-01-27 | 1991-02-19 | Enzo Biochem, Inc. | Method and structures employing chemically-labelled polynucleotide probes |
US4605735A (en) | 1983-02-14 | 1986-08-12 | Wakunaga Seiyaku Kabushiki Kaisha | Oligonucleotide derivatives |
US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
US4719179A (en) | 1984-11-30 | 1988-01-12 | Pharmacia P-L Biochemicals, Inc. | Six base oligonucleotide linkers and methods for their use |
US4883750A (en) | 1984-12-13 | 1989-11-28 | Applied Biosystems, Inc. | Detection of specific sequences in nucleic acids |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4757141A (en) | 1985-08-26 | 1988-07-12 | Applied Biosystems, Incorporated | Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof |
US5093232A (en) | 1985-12-11 | 1992-03-03 | Chiron Corporation | Nucleic acid probes |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US4925785A (en) | 1986-03-07 | 1990-05-15 | Biotechnica Diagnostics, Inc. | Nucleic acid hybridization assays |
US5091519A (en) | 1986-05-01 | 1992-02-25 | Amoco Corporation | Nucleotide compositions with linking groups |
US5151507A (en) | 1986-07-02 | 1992-09-29 | E. I. Du Pont De Nemours And Company | Alkynylamino-nucleotides |
US4725254A (en) | 1986-11-24 | 1988-02-16 | Allied Corporation | Method for manufacturing a center electrode for a spark plug |
US6270961B1 (en) * | 1987-04-01 | 2001-08-07 | Hyseq, Inc. | Methods and apparatus for DNA sequencing and DNA identification |
US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
US4942124A (en) | 1987-08-11 | 1990-07-17 | President And Fellows Of Harvard College | Multiplex sequencing |
US5124246A (en) * | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
US4886741A (en) | 1987-12-09 | 1989-12-12 | Microprobe Corporation | Use of volume exclusion agents for the enhancement of in situ hybridization |
US5354657A (en) | 1988-01-12 | 1994-10-11 | Boehringer Mannheim Gmbh | Process for the highly specific detection of nucleic acids in solid |
DE3813278A1 (en) | 1988-01-12 | 1989-07-20 | Boehringer Mannheim Gmbh | METHOD FOR DETECTING NUCLEIC ACIDS |
US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
US5168038A (en) | 1988-06-17 | 1992-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | In situ transcription in cells and tissues |
US5066580A (en) | 1988-08-31 | 1991-11-19 | Becton Dickinson And Company | Xanthene dyes that emit to the red of fluorescein |
GB8822228D0 (en) | 1988-09-21 | 1988-10-26 | Southern E M | Support-bound oligonucleotides |
US5194599A (en) | 1988-09-23 | 1993-03-16 | Gilead Sciences, Inc. | Hydrogen phosphonodithioate compositions |
DE3836656A1 (en) | 1988-10-27 | 1990-05-03 | Boehringer Mannheim Gmbh | NEW DIGOXIGENINE DERIVATIVES AND THEIR USE |
US5091302A (en) * | 1989-04-27 | 1992-02-25 | The Blood Center Of Southeastern Wisconsin, Inc. | Polymorphism of human platelet membrane glycoprotein iiia and diagnostic and therapeutic applications thereof |
US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
US6346413B1 (en) * | 1989-06-07 | 2002-02-12 | Affymetrix, Inc. | Polymer arrays |
US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US5242974A (en) | 1991-11-22 | 1993-09-07 | Affymax Technologies N.V. | Polymer reversal on solid surfaces |
US6379895B1 (en) * | 1989-06-07 | 2002-04-30 | Affymetrix, Inc. | Photolithographic and other means for manufacturing arrays |
US5744101A (en) * | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
DE3924454A1 (en) | 1989-07-24 | 1991-02-07 | Cornelis P Prof Dr Hollenberg | THE APPLICATION OF DNA AND DNA TECHNOLOGY FOR THE CONSTRUCTION OF NETWORKS FOR USE IN CHIP CONSTRUCTION AND CHIP PRODUCTION (DNA CHIPS) |
JPH03101086A (en) | 1989-09-14 | 1991-04-25 | Ngk Spark Plug Co Ltd | Spark plug for internal combustion engine |
US5366860A (en) | 1989-09-29 | 1994-11-22 | Applied Biosystems, Inc. | Spectrally resolvable rhodamine dyes for nucleic acid sequence determination |
US5003097A (en) | 1989-10-02 | 1991-03-26 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the sulfurization of phosphorous groups in compounds |
US5252743A (en) | 1989-11-13 | 1993-10-12 | Affymax Technologies N.V. | Spatially-addressable immobilization of anti-ligands on surfaces |
US5188934A (en) | 1989-11-14 | 1993-02-23 | Applied Biosystems, Inc. | 4,7-dichlorofluorescein dyes as molecular probes |
US5166387A (en) | 1990-01-12 | 1992-11-24 | Applied Biosystems, Inc. | Method of synthesizing sulfurized oligonucleotide analogs with thiuram disulfides |
US5427930A (en) * | 1990-01-26 | 1995-06-27 | Abbott Laboratories | Amplification of target nucleic acids using gap filling ligase chain reaction |
CA2036946C (en) | 1990-04-06 | 2001-10-16 | Kenneth V. Deugau | Indexing linkers |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
US5073562A (en) | 1990-05-10 | 1991-12-17 | G. D. Searle & Co. | Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof |
US5091320A (en) * | 1990-06-15 | 1992-02-25 | Bell Communications Research, Inc. | Ellipsometric control of material growth |
WO1992001813A1 (en) | 1990-07-25 | 1992-02-06 | Syngene, Inc. | Circular extension for generating multiple nucleic acid complements |
US5386023A (en) | 1990-07-27 | 1995-01-31 | Isis Pharmaceuticals | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling |
US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
JP3080178B2 (en) | 1991-02-18 | 2000-08-21 | 東洋紡績株式会社 | Method for amplifying nucleic acid sequence and reagent kit therefor |
US5426180A (en) | 1991-03-27 | 1995-06-20 | Research Corporation Technologies, Inc. | Methods of making single-stranded circular oligonucleotides |
JP3085409B2 (en) | 1991-03-29 | 2000-09-11 | 東洋紡績株式会社 | Method for detecting target nucleic acid sequence and reagent kit therefor |
US5474796A (en) * | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
US6589726B1 (en) * | 1991-09-04 | 2003-07-08 | Metrigen, Inc. | Method and apparatus for in situ synthesis on a solid support |
JP2001524926A (en) | 1991-09-18 | 2001-12-04 | アフィマックス テクノロジーズ ナームロゼ フェンノートシャップ | Method for synthesizing a heterogeneous library of oligomers |
IL103267A (en) | 1991-09-24 | 2004-07-25 | Keygene Nv | Process and kit for amplification of restriction fragment obtained from starting dna |
US5632957A (en) * | 1993-11-01 | 1997-05-27 | Nanogen | Molecular biological diagnostic systems including electrodes |
US5981179A (en) | 1991-11-14 | 1999-11-09 | Digene Diagnostics, Inc. | Continuous amplification reaction |
US5550215A (en) | 1991-11-22 | 1996-08-27 | Holmes; Christopher P. | Polymer reversal on solid surfaces |
US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
DE69233331T3 (en) | 1991-11-22 | 2007-08-30 | Affymetrix, Inc., Santa Clara | Combinatorial Polymersynthesis Strategies |
US5644048A (en) | 1992-01-10 | 1997-07-01 | Isis Pharmaceuticals, Inc. | Process for preparing phosphorothioate oligonucleotides |
EP1382386A3 (en) | 1992-02-19 | 2004-12-01 | The Public Health Research Institute Of The City Of New York, Inc. | Novel oligonucleotide arrays and their use for sorting, isolating, sequencing, and manipulating nucleic acids |
US5403708A (en) * | 1992-07-06 | 1995-04-04 | Brennan; Thomas M. | Methods and compositions for determining the sequence of nucleic acids |
GB9214873D0 (en) | 1992-07-13 | 1992-08-26 | Medical Res Council | Process for categorising nucleotide sequence populations |
US6261808B1 (en) * | 1992-08-04 | 2001-07-17 | Replicon, Inc. | Amplification of nucleic acid molecules via circular replicons |
US5834202A (en) * | 1992-08-04 | 1998-11-10 | Replicon, Inc. | Methods for the isothermal amplification of nucleic acid molecules |
WO1994003624A1 (en) * | 1992-08-04 | 1994-02-17 | Auerbach Jeffrey I | Methods for the isothermal amplification of nucleic acid molecules |
US5583211A (en) | 1992-10-29 | 1996-12-10 | Beckman Instruments, Inc. | Surface activated organic polymers useful for location - specific attachment of nucleic acids, peptides, proteins and oligosaccharides |
US5593826A (en) | 1993-03-22 | 1997-01-14 | Perkin-Elmer Corporation, Applied Biosystems, Inc. | Enzymatic ligation of 3'amino-substituted oligonucleotides |
US5491074A (en) | 1993-04-01 | 1996-02-13 | Affymax Technologies Nv | Association peptides |
ATE246702T1 (en) | 1993-04-12 | 2003-08-15 | Univ Northwestern | METHOD FOR PREPARING OLIGONUCLEOTIDES |
US5714320A (en) * | 1993-04-15 | 1998-02-03 | University Of Rochester | Rolling circle synthesis of oligonucleotides and amplification of select randomized circular oligonucleotides |
US6096880A (en) * | 1993-04-15 | 2000-08-01 | University Of Rochester | Circular DNA vectors for synthesis of RNA and DNA |
US6077668A (en) * | 1993-04-15 | 2000-06-20 | University Of Rochester | Highly sensitive multimeric nucleic acid probes |
US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
US5837832A (en) * | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
US5473060A (en) | 1993-07-02 | 1995-12-05 | Lynx Therapeutics, Inc. | Oligonucleotide clamps having diagnostic applications |
WO1995001365A1 (en) * | 1993-07-02 | 1995-01-12 | Lynx Therapeutics, Inc. | Synthesis of branched nucleic acids |
US6401267B1 (en) | 1993-09-27 | 2002-06-11 | Radoje Drmanac | Methods and compositions for efficient nucleic acid sequencing |
EP0723598B1 (en) | 1993-09-27 | 2004-01-14 | Arch Development Corporation | Methods and compositions for efficient nucleic acid sequencing |
US5472672A (en) | 1993-10-22 | 1995-12-05 | The Board Of Trustees Of The Leland Stanford Junior University | Apparatus and method for polymer synthesis using arrays |
JPH09507121A (en) | 1993-10-26 | 1997-07-22 | アフィマックス テクノロジーズ ナームロゼ ベノートスハップ | Nucleic acid probe array on biological chip |
US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
US5429807A (en) | 1993-10-28 | 1995-07-04 | Beckman Instruments, Inc. | Method and apparatus for creating biopolymer arrays on a solid support surface |
US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
GB2285942A (en) | 1994-01-25 | 1995-08-02 | Ford Motor Co | Forming an erosion resistant coating on an electrode |
US5654419A (en) | 1994-02-01 | 1997-08-05 | The Regents Of The University Of California | Fluorescent labels and their use in separations |
US6090555A (en) | 1997-12-11 | 2000-07-18 | Affymetrix, Inc. | Scanned image alignment systems and methods |
US5631734A (en) | 1994-02-10 | 1997-05-20 | Affymetrix, Inc. | Method and apparatus for detection of fluorescently labeled materials |
US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
SE9400522D0 (en) | 1994-02-16 | 1994-02-16 | Ulf Landegren | Method and reagent for detecting specific nucleotide sequences |
US5637684A (en) | 1994-02-23 | 1997-06-10 | Isis Pharmaceuticals, Inc. | Phosphoramidate and phosphorothioamidate oligomeric compounds |
AU2360195A (en) | 1994-05-05 | 1995-11-29 | Beckman Instruments, Inc. | Oligonucleotide repeat arrays |
US5571639A (en) | 1994-05-24 | 1996-11-05 | Affymax Technologies N.V. | Computer-aided engineering system for design of sequence arrays and lithographic masks |
US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
US7625697B2 (en) | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
US5641658A (en) * | 1994-08-03 | 1997-06-24 | Mosaic Technologies, Inc. | Method for performing amplification of nucleic acid with two primers bound to a single solid support |
US5710000A (en) | 1994-09-16 | 1998-01-20 | Affymetrix, Inc. | Capturing sequences adjacent to Type-IIs restriction sites for genomic library mapping |
US6013445A (en) | 1996-06-06 | 2000-01-11 | Lynx Therapeutics, Inc. | Massively parallel signature sequencing by ligation of encoded adaptors |
US6654505B2 (en) * | 1994-10-13 | 2003-11-25 | Lynx Therapeutics, Inc. | System and apparatus for sequential processing of analytes |
US5604097A (en) | 1994-10-13 | 1997-02-18 | Spectragen, Inc. | Methods for sorting polynucleotides using oligonucleotide tags |
US5795716A (en) | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
FR2726286B1 (en) * | 1994-10-28 | 1997-01-17 | Genset Sa | SOLID PHASE NUCLEIC ACID AMPLIFICATION PROCESS AND REAGENT KIT USEFUL FOR CARRYING OUT SAID PROCESS |
US5744367A (en) | 1994-11-10 | 1998-04-28 | Igen International, Inc. | Magnetic particle based electrochemiluminescent detection apparatus and method |
US5599695A (en) | 1995-02-27 | 1997-02-04 | Affymetrix, Inc. | Printing molecular library arrays using deprotection agents solely in the vapor phase |
US5866337A (en) * | 1995-03-24 | 1999-02-02 | The Trustees Of Columbia University In The City Of New York | Method to detect mutations in a nucleic acid using a hybridization-ligation procedure |
US5750341A (en) | 1995-04-17 | 1998-05-12 | Lynx Therapeutics, Inc. | DNA sequencing by parallel oligonucleotide extensions |
US5624711A (en) | 1995-04-27 | 1997-04-29 | Affymax Technologies, N.V. | Derivatization of solid supports and methods for oligomer synthesis |
US5648245A (en) * | 1995-05-09 | 1997-07-15 | Carnegie Institution Of Washington | Method for constructing an oligonucleotide concatamer library by rolling circle replication |
DE69637315T2 (en) | 1995-05-12 | 2008-08-28 | Novartis Ag | PROCESS FOR THE PARALLEL DETERMINATION OF SEVERAL ANALYTS BY EVENT-RELATED LUMINESCENCE |
US5774305A (en) | 1995-06-07 | 1998-06-30 | Seagate Technology, Inc. | Head gimbal assembly to reduce slider distortion due to thermal stress |
US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
US5675209A (en) | 1995-06-19 | 1997-10-07 | Hoskins Manufacturing Company | Electrode material for a spark plug |
US5968740A (en) | 1995-07-24 | 1999-10-19 | Affymetrix, Inc. | Method of Identifying a Base in a Nucleic Acid |
US6132580A (en) | 1995-09-28 | 2000-10-17 | The Regents Of The University Of California | Miniature reaction chamber and devices incorporating same |
US20020068357A1 (en) | 1995-09-28 | 2002-06-06 | Mathies Richard A. | Miniaturized integrated nucleic acid processing and analysis device and method |
ATE496288T1 (en) | 1995-10-11 | 2011-02-15 | Luminex Corp | SIMULTANEOUS MULTIPLE ANALYSIS OF CLINICAL SAMPLES |
US5658734A (en) | 1995-10-17 | 1997-08-19 | International Business Machines Corporation | Process for synthesizing chemical compounds |
US6143495A (en) | 1995-11-21 | 2000-11-07 | Yale University | Unimolecular segment amplification and sequencing |
US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
AU704750B2 (en) * | 1995-12-05 | 1999-05-06 | Jorn Erland Koch | A cascade nucleic acid amplification reaction |
US6022963A (en) | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
US6660233B1 (en) | 1996-01-16 | 2003-12-09 | Beckman Coulter, Inc. | Analytical biochemistry system with robotically carried bioarray |
ATE305052T1 (en) * | 1996-03-01 | 2005-10-15 | Univ Dundee | DRUG INVESTIGATION SYSTEM |
US6013440A (en) * | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
US6458530B1 (en) | 1996-04-04 | 2002-10-01 | Affymetrix Inc. | Selecting tag nucleic acids |
US5800996A (en) | 1996-05-03 | 1998-09-01 | The Perkin Elmer Corporation | Energy transfer dyes with enchanced fluorescence |
US5847162A (en) | 1996-06-27 | 1998-12-08 | The Perkin Elmer Corporation | 4, 7-Dichlororhodamine dyes |
US5851804A (en) * | 1996-05-06 | 1998-12-22 | Apollon, Inc. | Chimeric kanamycin resistance gene |
US5981956A (en) | 1996-05-16 | 1999-11-09 | Affymetrix, Inc. | Systems and methods for detection of labeled materials |
ATE318327T1 (en) | 1996-06-04 | 2006-03-15 | Univ Utah Res Found | FLUORESCENCE-DONOR-ACCEPTOR PAIR |
US5869245A (en) * | 1996-06-05 | 1999-02-09 | Fox Chase Cancer Center | Mismatch endonuclease and its use in identifying mutations in targeted polynucleotide strands |
US6582921B2 (en) | 1996-07-29 | 2003-06-24 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses thereof |
EP0925494B1 (en) | 1996-09-04 | 2001-12-19 | Scandinavian Micro Biodevices A/S | A micro flow system for particle separation and analysis |
GB9620209D0 (en) | 1996-09-27 | 1996-11-13 | Cemu Bioteknik Ab | Method of sequencing DNA |
US5935793A (en) * | 1996-09-27 | 1999-08-10 | The Chinese University Of Hong Kong | Parallel polynucleotide sequencing method using tagged primers |
US6083697A (en) | 1996-11-14 | 2000-07-04 | Affymetrix, Inc. | Chemical amplification for the synthesis of patterned arrays |
US6054100A (en) * | 1996-11-18 | 2000-04-25 | Robbins Scientific Corporation | Apparatus for multi-well microscale synthesis |
US5916750A (en) | 1997-01-08 | 1999-06-29 | Biogenex Laboratories | Multifunctional linking reagents for synthesis of branched oligomers |
US6297006B1 (en) | 1997-01-16 | 2001-10-02 | Hyseq, Inc. | Methods for sequencing repetitive sequences and for determining the order of sequence subfragments |
US20020042048A1 (en) | 1997-01-16 | 2002-04-11 | Radoje Drmanac | Methods and compositions for detection or quantification of nucleic acid species |
US6309824B1 (en) | 1997-01-16 | 2001-10-30 | Hyseq, Inc. | Methods for analyzing a target nucleic acid using immobilized heterogeneous mixtures of oligonucleotide probes |
US5994068A (en) | 1997-03-11 | 1999-11-30 | Wisconsin Alumni Research Foundation | Nucleic acid indexing |
US6327410B1 (en) * | 1997-03-14 | 2001-12-04 | The Trustees Of Tufts College | Target analyte sensors utilizing Microspheres |
AU6846798A (en) | 1997-04-01 | 1998-10-22 | Glaxo Group Limited | Method of nucleic acid sequencing |
ES2563643T3 (en) | 1997-04-01 | 2016-03-15 | Illumina Cambridge Limited | Nucleic acid sequencing method |
US5888737A (en) * | 1997-04-15 | 1999-03-30 | Lynx Therapeutics, Inc. | Adaptor-based sequence analysis |
US20040229221A1 (en) | 1997-05-08 | 2004-11-18 | Trustees Of Columbia University In The City Of New York | Method to detect mutations in a nucleic acid using a hybridization-ligation procedure |
US5919626A (en) † | 1997-06-06 | 1999-07-06 | Orchid Bio Computer, Inc. | Attachment of unmodified nucleic acids to silanized solid phase surfaces |
EP1908832B1 (en) | 1997-07-07 | 2012-12-26 | Medical Research Council | A method for increasing the concentration of a nucleic acid molecule |
US6124120A (en) | 1997-10-08 | 2000-09-26 | Yale University | Multiple displacement amplification |
US6485944B1 (en) | 1997-10-10 | 2002-11-26 | President And Fellows Of Harvard College | Replica amplification of nucleic acid arrays |
AU737174B2 (en) | 1997-10-10 | 2001-08-09 | President & Fellows Of Harvard College | Replica amplification of nucleic acid arrays |
US6511803B1 (en) * | 1997-10-10 | 2003-01-28 | President And Fellows Of Harvard College | Replica amplification of nucleic acid arrays |
US5866473A (en) * | 1997-10-31 | 1999-02-02 | Advanced Micro Devices, Inc. | Method of manufacturing a polysilicon gate having a dimension below the photolithography limitation |
ATE291097T1 (en) | 1997-10-31 | 2005-04-15 | Affymetrix Inc A Delaware Corp | EXPRESSION PROFILES IN ADULT AND FETAL ORGANS |
US6322901B1 (en) | 1997-11-13 | 2001-11-27 | Massachusetts Institute Of Technology | Highly luminescent color-selective nano-crystalline materials |
US5990479A (en) | 1997-11-25 | 1999-11-23 | Regents Of The University Of California | Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes |
US6207392B1 (en) | 1997-11-25 | 2001-03-27 | The Regents Of The University Of California | Semiconductor nanocrystal probes for biological applications and process for making and using such probes |
US6087102A (en) | 1998-01-07 | 2000-07-11 | Clontech Laboratories, Inc. | Polymeric arrays and methods for their use in binding assays |
US6428752B1 (en) | 1998-05-14 | 2002-08-06 | Affymetrix, Inc. | Cleaning deposit devices that form microarrays and the like |
US6269846B1 (en) | 1998-01-13 | 2001-08-07 | Genetic Microsystems, Inc. | Depositing fluid specimens on substrates, resulting ordered arrays, techniques for deposition of arrays |
US6287776B1 (en) | 1998-02-02 | 2001-09-11 | Signature Bioscience, Inc. | Method for detecting and classifying nucleic acid hybridization |
JP2002502588A (en) | 1998-02-06 | 2002-01-29 | アフィメトリックス インコーポレイテッド | Quality control methods in the manufacturing process |
US6136537A (en) | 1998-02-23 | 2000-10-24 | Macevicz; Stephen C. | Gene expression analysis |
JP3944996B2 (en) | 1998-03-05 | 2007-07-18 | 株式会社日立製作所 | DNA probe array |
US6174687B1 (en) | 1999-02-26 | 2001-01-16 | The Burnham Institute | Methods of identifying lung homing molecules using membrane dipeptidase |
DE19812729A1 (en) | 1998-03-24 | 1999-09-30 | Bosch Gmbh Robert | Electric motor, in particular with a fan wheel to form an axial or radial fan |
DK1997909T3 (en) * | 1998-03-25 | 2012-04-23 | Olink Ab | Rolling circle replication of circularized target nucleic acid fragments |
US5936324A (en) | 1998-03-30 | 1999-08-10 | Genetic Microsystems Inc. | Moving magnet scanner |
US6004755A (en) * | 1998-04-07 | 1999-12-21 | Incyte Pharmaceuticals, Inc. | Quantitative microarray hybridizaton assays |
JP4262799B2 (en) | 1998-04-16 | 2009-05-13 | 平田機工株式会社 | Raw tire supply method |
US6270831B2 (en) | 1998-04-30 | 2001-08-07 | Medquest Products, Inc. | Method and apparatus for providing a conductive, amorphous non-stick coating |
US6255469B1 (en) | 1998-05-06 | 2001-07-03 | New York University | Periodic two and three dimensional nucleic acid structures |
US6031078A (en) | 1998-06-16 | 2000-02-29 | Millennium Pharmaceuticals, Inc. | MTbx protein and nucleic acid molecules and uses therefor |
US5980345A (en) | 1998-07-13 | 1999-11-09 | Alliedsignal Inc. | Spark plug electrode having iridium based sphere and method for manufacturing same |
US6316229B1 (en) * | 1998-07-20 | 2001-11-13 | Yale University | Single molecule analysis target-mediated ligation of bipartite primers |
GB0002310D0 (en) | 2000-02-01 | 2000-03-22 | Solexa Ltd | Polynucleotide sequencing |
US20040106110A1 (en) * | 1998-07-30 | 2004-06-03 | Solexa, Ltd. | Preparation of polynucleotide arrays |
US6787308B2 (en) | 1998-07-30 | 2004-09-07 | Solexa Ltd. | Arrayed biomolecules and their use in sequencing |
WO2000006770A1 (en) † | 1998-07-30 | 2000-02-10 | Solexa Ltd. | Arrayed biomolecules and their use in sequencing |
US6232067B1 (en) * | 1998-08-17 | 2001-05-15 | The Perkin-Elmer Corporation | Adapter directed expression analysis |
US6046039A (en) | 1998-08-19 | 2000-04-04 | Battelle Memorial Institute | Methods for producing partially digested restriction DNA fragments and for producing a partially modified PCR product |
US6653077B1 (en) * | 1998-09-04 | 2003-11-25 | Lynx Therapeutics, Inc. | Method of screening for genetic polymorphism |
EP1114184A2 (en) * | 1998-09-15 | 2001-07-11 | Yale University | Molecular cloning using rolling circle amplification |
US20020019007A1 (en) * | 1998-09-18 | 2002-02-14 | Jensen Wayne A. | PCR methods and materials |
US6251303B1 (en) | 1998-09-18 | 2001-06-26 | Massachusetts Institute Of Technology | Water-soluble fluorescent nanocrystals |
US6326144B1 (en) | 1998-09-18 | 2001-12-04 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
US6426513B1 (en) | 1998-09-18 | 2002-07-30 | Massachusetts Institute Of Technology | Water-soluble thiol-capped nanocrystals |
US6235502B1 (en) * | 1998-09-18 | 2001-05-22 | Molecular Staging Inc. | Methods for selectively isolating DNA using rolling circle amplification |
US6610492B1 (en) | 1998-10-01 | 2003-08-26 | Variagenics, Inc. | Base-modified nucleotides and cleavage of polynucleotides incorporating them |
US6277628B1 (en) | 1998-10-02 | 2001-08-21 | Incyte Genomics, Inc. | Linear microarrays |
US7272507B2 (en) * | 1999-10-26 | 2007-09-18 | Michael Paul Strathmann | Applications of parallel genomic analysis |
WO2000040755A2 (en) | 1999-01-06 | 2000-07-13 | Cornell Research Foundation, Inc. | Method for accelerating identification of single nucleotide polymorphisms and alignment of clones in genomic sequencing |
EP2145963A1 (en) | 1999-01-06 | 2010-01-20 | Callida Genomics, Inc. | Enhanced sequencing by hybridization using pools of probes |
GB9901475D0 (en) | 1999-01-22 | 1999-03-17 | Pyrosequencing Ab | A method of DNA sequencing |
US6514768B1 (en) | 1999-01-29 | 2003-02-04 | Surmodics, Inc. | Replicable probe array |
EP1147229A2 (en) * | 1999-02-02 | 2001-10-24 | Bernhard O. Palsson | Methods for identifying drug targets based on genomic sequence data |
EP1196554B1 (en) | 1999-03-18 | 2009-02-25 | Complete Genomics AS | Methods of cloning and producing fragment chains with readable information content |
WO2000056937A2 (en) | 1999-03-25 | 2000-09-28 | Hyseq, Inc. | Solution-based methods and materials for sequence analysis by hybridization |
EP1165839A2 (en) | 1999-03-26 | 2002-01-02 | Whitehead Institute For Biomedical Research | Universal arrays |
ATE553219T1 (en) | 1999-04-20 | 2012-04-15 | Illumina Inc | DETECTION OF NUCLEIC ACID REACTIONS ON BEAD ARRAYS |
US6355431B1 (en) | 1999-04-20 | 2002-03-12 | Illumina, Inc. | Detection of nucleic acid amplification reactions using bead arrays |
US6521428B1 (en) * | 1999-04-21 | 2003-02-18 | Genome Technologies, Llc | Shot-gun sequencing and amplification without cloning |
EP1179185B1 (en) | 1999-05-07 | 2009-08-12 | Life Technologies Corporation | A method of detecting an analyte using semiconductor nanocrystals |
WO2000075373A2 (en) * | 1999-05-20 | 2000-12-14 | Illumina, Inc. | Combinatorial decoding of random nucleic acid arrays |
US6544732B1 (en) | 1999-05-20 | 2003-04-08 | Illumina, Inc. | Encoding and decoding of array sensors utilizing nanocrystals |
ATE338273T1 (en) | 1999-05-20 | 2006-09-15 | Illumina Inc | DEVICE FOR HOLDING AND PRESENTING AT LEAST ONE MICRO SPHERE MATRIX FOR SOLUTIONS AND/OR OPTICAL IMAGING SYSTEMS |
US6573369B2 (en) * | 1999-05-21 | 2003-06-03 | Bioforce Nanosciences, Inc. | Method and apparatus for solid state molecular analysis |
US6326719B1 (en) | 1999-06-16 | 2001-12-04 | Alliedsignal Inc. | Spark plug shell having a bimetallic ground electrode spark plug incorporating the shell, and method of making same |
US6818395B1 (en) | 1999-06-28 | 2004-11-16 | California Institute Of Technology | Methods and apparatus for analyzing polynucleotide sequences |
US7501245B2 (en) | 1999-06-28 | 2009-03-10 | Helicos Biosciences Corp. | Methods and apparatuses for analyzing polynucleotide sequences |
AU6387000A (en) | 1999-07-29 | 2001-02-19 | Genzyme Corporation | Serial analysis of genetic alterations |
US6440706B1 (en) † | 1999-08-02 | 2002-08-27 | Johns Hopkins University | Digital amplification |
US6472156B1 (en) * | 1999-08-30 | 2002-10-29 | The University Of Utah | Homogeneous multiplex hybridization analysis by color and Tm |
US7211390B2 (en) | 1999-09-16 | 2007-05-01 | 454 Life Sciences Corporation | Method of sequencing a nucleic acid |
US6274320B1 (en) | 1999-09-16 | 2001-08-14 | Curagen Corporation | Method of sequencing a nucleic acid |
AU7537200A (en) | 1999-09-29 | 2001-04-30 | Solexa Ltd. | Polynucleotide sequencing |
EP1235932A2 (en) * | 1999-10-08 | 2002-09-04 | Protogene Laboratories, Inc. | Method and apparatus for performing large numbers of reactions using array assembly |
US6297016B1 (en) | 1999-10-08 | 2001-10-02 | Applera Corporation | Template-dependent ligation with PNA-DNA chimeric probes |
US6287778B1 (en) | 1999-10-19 | 2001-09-11 | Affymetrix, Inc. | Allele detection using primer extension with sequence-coded identity tags |
AU783841B2 (en) † | 1999-11-26 | 2005-12-15 | 454 Life Sciences Corporation | Nucleic acid probe arrays |
CA2360342A1 (en) * | 1999-12-02 | 2001-06-07 | Molecular Staging Inc. | Generation of single-strand circular dna from linear self-annealing segments |
US20030186256A1 (en) † | 1999-12-23 | 2003-10-02 | Achim Fischer | Method for carrying out the parallel sequencing of a nucleic acid mixture on a surface |
EP1255860A2 (en) | 1999-12-29 | 2002-11-13 | Mergen Ltd. | Methods for amplifying and detecting multiple polynucleotides on a solid phase support |
GB0002389D0 (en) | 2000-02-02 | 2000-03-22 | Solexa Ltd | Molecular arrays |
US6221603B1 (en) * | 2000-02-04 | 2001-04-24 | Molecular Dynamics, Inc. | Rolling circle amplification assay for nucleic acid analysis |
US6913884B2 (en) | 2001-08-16 | 2005-07-05 | Illumina, Inc. | Compositions and methods for repetitive use of genomic DNA |
DE60136166D1 (en) * | 2000-02-07 | 2008-11-27 | Illumina Inc | NUCLEIC ACID PROOF METHOD WITH UNIVERSAL PRIMING |
AU2001238067B2 (en) * | 2000-02-07 | 2007-01-25 | Illumina, Inc. | Nucleic acid detection methods using universal priming |
US6770441B2 (en) | 2000-02-10 | 2004-08-03 | Illumina, Inc. | Array compositions and methods of making same |
AU2001241723A1 (en) | 2000-02-25 | 2001-09-03 | Affymetrix, Inc. | Methods for multi-stage solid phase amplification of nucleic acids |
US20020004204A1 (en) | 2000-02-29 | 2002-01-10 | O'keefe Matthew T. | Microarray substrate with integrated photodetector and methods of use thereof |
US6413722B1 (en) * | 2000-03-22 | 2002-07-02 | Incyte Genomics, Inc. | Polymer coated surfaces for microarray applications |
AU2001253310A1 (en) * | 2000-04-10 | 2001-10-23 | Matthew Ashby | Methods for the survey and genetic analysis of populations |
WO2001090415A2 (en) | 2000-05-20 | 2001-11-29 | The Regents Of The University Of Michigan | Method of producing a dna library using positional amplification |
WO2001090821A1 (en) | 2000-05-25 | 2001-11-29 | Fujitsu Limited | Toner and image forming method |
DE10027651C2 (en) | 2000-06-03 | 2002-11-28 | Bosch Gmbh Robert | Electrode, method for its production and spark plug with such an electrode |
AU2001268468A1 (en) | 2000-06-13 | 2001-12-24 | The Trustees Of Boston University | Use of nucleotide analogs in the analysis of oligonucleotide mixtures and in highly multiplexed nucleic acid sequencing |
JP3930227B2 (en) * | 2000-06-14 | 2007-06-13 | ペンタックス株式会社 | Surveyor equipped with magnetic encoder and magnetic encoder |
JP2002085097A (en) | 2000-09-12 | 2002-03-26 | Hitachi Ltd | Method for determination of dna base sequence |
US6649138B2 (en) | 2000-10-13 | 2003-11-18 | Quantum Dot Corporation | Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media |
ATE380883T1 (en) | 2000-10-24 | 2007-12-15 | Univ Leland Stanford Junior | DIRECT MULTIPLEX CHARACTERIZATION OF GENOMIC DNA |
US20020055102A1 (en) * | 2000-10-24 | 2002-05-09 | David Stern | Apparatus and method for scanning multiple arrays of biological probes |
US6576291B2 (en) | 2000-12-08 | 2003-06-10 | Massachusetts Institute Of Technology | Preparation of nanocrystallites |
US20020074920A1 (en) | 2000-12-15 | 2002-06-20 | Chiu Randolph Kwok-Kin | High efficiency, extended life spark plug having improved firing tips |
AU2002239679A1 (en) * | 2000-12-20 | 2002-07-01 | The Regents Of The University Of California | Rolling circle amplification detection of rna and dna |
WO2002053732A2 (en) * | 2000-12-28 | 2002-07-11 | Pangenex | Methods for making polynucleotide libraries, polynucleotide arrays, and cell librraries for high-throughput genomics analysis |
ATE374259T1 (en) † | 2001-01-30 | 2007-10-15 | Solexa Ltd | PRODUCTION OF MATRICES FROM POLYNUCLEOTIDES |
WO2002061143A2 (en) * | 2001-01-31 | 2002-08-08 | Ambion, Inc. | Comparative analysis of nucleic acids using population tagging |
EP2465943A3 (en) * | 2001-03-16 | 2012-10-03 | Kalim Mir | Linear polymer display |
JP4171206B2 (en) | 2001-03-16 | 2008-10-22 | 株式会社デンソー | Spark plug and manufacturing method thereof |
US6777187B2 (en) | 2001-05-02 | 2004-08-17 | Rubicon Genomics, Inc. | Genome walking by selective amplification of nick-translate DNA library and amplification from complex mixtures of templates |
GB0114853D0 (en) * | 2001-06-18 | 2001-08-08 | Medical Res Council | Happier Mapping |
WO2003092043A2 (en) | 2001-07-20 | 2003-11-06 | Quantum Dot Corporation | Luminescent nanoparticles and methods for their preparation |
US7297778B2 (en) | 2001-07-25 | 2007-11-20 | Affymetrix, Inc. | Complexity management of genomic DNA |
AU2002322224A1 (en) | 2001-07-27 | 2003-02-17 | Mcgill University | Isp-1 and ctb-1 genes and uses thereof |
US6881579B2 (en) | 2001-07-30 | 2005-04-19 | Agilent Technologies, Inc. | Sample processing apparatus and methods |
GB2378245A (en) | 2001-08-03 | 2003-02-05 | Mats Nilsson | Nucleic acid amplification method |
WO2005040094A1 (en) * | 2003-10-24 | 2005-05-06 | Postech Foundation | Novel dendrimer compound and a biochip using the same |
US9201067B2 (en) * | 2003-03-05 | 2015-12-01 | Posco | Size-controlled macromolecule |
US6975943B2 (en) * | 2001-09-24 | 2005-12-13 | Seqwright, Inc. | Clone-array pooled shotgun strategy for nucleic acid sequencing |
US6617137B2 (en) | 2001-10-15 | 2003-09-09 | Molecular Staging Inc. | Method of amplifying whole genomes without subjecting the genome to denaturing conditions |
GB0126887D0 (en) | 2001-11-08 | 2002-01-02 | Univ London | Method for producing and identifying soluble protein domains |
WO2003044216A2 (en) | 2001-11-19 | 2003-05-30 | Parallele Bioscience, Inc. | Multiplex oligonucleotide addition and target amplification |
GB2382137A (en) | 2001-11-20 | 2003-05-21 | Mats Gullberg | Nucleic acid enrichment |
US7361310B1 (en) * | 2001-11-30 | 2008-04-22 | Northwestern University | Direct write nanolithographic deposition of nucleic acids from nanoscopic tips |
US7011945B2 (en) * | 2001-12-21 | 2006-03-14 | Eastman Kodak Company | Random array of micro-spheres for the analysis of nucleic acids |
US20040002090A1 (en) | 2002-03-05 | 2004-01-01 | Pascal Mayer | Methods for detecting genome-wide sequence variations associated with a phenotype |
WO2004011665A2 (en) | 2002-05-17 | 2004-02-05 | Nugen Technologies, Inc. | Methods for fragmentation, labeling and immobilization of nucleic acids |
AUPS298102A0 (en) | 2002-06-13 | 2002-07-04 | Nucleics Pty Ltd | Method for performing chemical reactions |
US20050019776A1 (en) | 2002-06-28 | 2005-01-27 | Callow Matthew James | Universal selective genome amplification and universal genotyping system |
US7046376B2 (en) | 2002-07-05 | 2006-05-16 | Therma-Wave, Inc. | Overlay targets with isolated, critical-dimension features and apparatus to measure overlay |
US6747331B2 (en) * | 2002-07-17 | 2004-06-08 | International Business Machines Corporation | Method and packaging structure for optimizing warpage of flip chip organic packages |
TW200403052A (en) | 2002-07-17 | 2004-03-01 | Novartis Ag | Use of organic compounds |
WO2004017376A2 (en) * | 2002-08-16 | 2004-02-26 | Miragene, Inc. | Integrated system for printing, processing, and imaging protein microarrays |
SI3587433T1 (en) | 2002-08-23 | 2020-08-31 | Illumina Cambridge Limited | Modified nucleotides |
AU2002348943A1 (en) | 2002-09-11 | 2004-04-30 | Moltech Invent S.A. | Non-carbon anodes for aluminium electrowinning and other oxidation resistant components with iron oxide-containing coatings |
EP1556506A1 (en) | 2002-09-19 | 2005-07-27 | The Chancellor, Masters And Scholars Of The University Of Oxford | Molecular arrays and single molecule detection |
AU2003279089A1 (en) | 2002-09-30 | 2004-04-19 | Parallele Bioscience, Inc. | Polynucleotide synthesis and labeling by kinetic sampling ligation |
US7459273B2 (en) | 2002-10-04 | 2008-12-02 | Affymetrix, Inc. | Methods for genotyping selected polymorphism |
US20040120861A1 (en) * | 2002-10-11 | 2004-06-24 | Affymetrix, Inc. | System and method for high-throughput processing of biological probe arrays |
US8859748B2 (en) | 2002-10-11 | 2014-10-14 | Jacobus Johannes Maria van Dongen | Nucleic acid amplification primers for PCR-based clonality studies |
US20040086892A1 (en) | 2002-11-06 | 2004-05-06 | Crothers Donald M. | Universal tag assay |
CA2510166A1 (en) | 2002-12-20 | 2004-09-30 | Caliper Life Sciences, Inc. | Single molecule amplification and detection of dna |
US6977153B2 (en) * | 2002-12-31 | 2005-12-20 | Qiagen Gmbh | Rolling circle amplification of RNA |
DE10300599A1 (en) | 2003-01-10 | 2004-07-22 | Jörg Dr. Sommer | Multi-hull ocean-going ship with movable float body wave power plant, converts float body movement relative to columns caused by wave motion to energy available on board, including for ship's drive |
EP2159285B1 (en) | 2003-01-29 | 2012-09-26 | 454 Life Sciences Corporation | Methods of amplifying and sequencing nucleic acids |
US7575865B2 (en) | 2003-01-29 | 2009-08-18 | 454 Life Sciences Corporation | Methods of amplifying and sequencing nucleic acids |
EP1592810A2 (en) | 2003-02-12 | 2005-11-09 | Genizon Svenska AB | Methods and means for nucleic acid sequencing |
EP1604040B1 (en) | 2003-03-07 | 2010-10-13 | Rubicon Genomics, Inc. | Amplification and analysis of whole genome and whole transcriptome libraries generated by a dna polymerization process |
FR2852605B1 (en) | 2003-03-18 | 2012-11-30 | Commissariat Energie Atomique | PROCESS FOR PREPARING DNA FRAGMENTS AND ITS APPLICATIONS |
CA2520811C (en) | 2003-03-28 | 2013-05-28 | Japan As Represented By Director General Of National Rehabilitation Center For Persons With Disabilities | Method of cdna synthesis |
WO2004092331A2 (en) * | 2003-04-08 | 2004-10-28 | Li-Cor, Inc. | Composition and method for nucleic acid sequencing |
US20050181394A1 (en) | 2003-06-20 | 2005-08-18 | Illumina, Inc. | Methods and compositions for whole genome amplification and genotyping |
US20040259118A1 (en) * | 2003-06-23 | 2004-12-23 | Macevicz Stephen C. | Methods and compositions for nucleic acid sequence analysis |
AU2003263632A1 (en) * | 2003-08-19 | 2005-03-07 | Posco | Novel dendrimer compound, a biochip using the same and a fabricating method thereof |
GB0320337D0 (en) | 2003-08-29 | 2003-10-01 | Syrris Ltd | A microfluidic system |
JP5171037B2 (en) | 2003-09-10 | 2013-03-27 | アルセア・ディーエックス,インク. | Expression profiling using microarrays |
AT501110A1 (en) * | 2003-09-16 | 2006-06-15 | Upper Austrian Res Gmbh | ARRAYS TO BIND MOLECULES |
US8222005B2 (en) * | 2003-09-17 | 2012-07-17 | Agency For Science, Technology And Research | Method for gene identification signature (GIS) analysis |
EP1685380A2 (en) | 2003-09-18 | 2006-08-02 | Parallele Bioscience, Inc. | System and methods for enhancing signal-to-noise ratios of microarray-based measurements |
GB0324456D0 (en) | 2003-10-20 | 2003-11-19 | Isis Innovation | Parallel DNA sequencing methods |
TWM245024U (en) * | 2003-10-30 | 2004-10-01 | Tranmax Machinery Co Ltd | Airtight structure for air passage of pneumatic tool |
EP1682680B2 (en) | 2003-10-31 | 2018-03-21 | AB Advanced Genetic Analysis Corporation | Methods for producing a paired tag from a nucleic acid sequence and methods of use thereof |
JP3796607B2 (en) | 2003-10-31 | 2006-07-12 | 株式会社リコー | Fixing device |
US7148361B2 (en) | 2003-10-31 | 2006-12-12 | North Carolina State University | Synthesis of phosphono-substituted porphyrin compounds for attachment to metal oxide surfaces |
US7169560B2 (en) | 2003-11-12 | 2007-01-30 | Helicos Biosciences Corporation | Short cycle methods for sequencing polynucleotides |
US7854108B2 (en) | 2003-12-12 | 2010-12-21 | Vision Robotics Corporation | Agricultural robot system and method |
US7972994B2 (en) * | 2003-12-17 | 2011-07-05 | Glaxosmithkline Llc | Methods for synthesis of encoded libraries |
US20050136414A1 (en) | 2003-12-23 | 2005-06-23 | Kevin Gunderson | Methods and compositions for making locus-specific arrays |
US20050208538A1 (en) | 2003-12-29 | 2005-09-22 | Nurith Kurn | Methods for analysis of nucleic acid methylation status and methods for fragmentation, labeling and immobilization of nucleic acids |
US20110059865A1 (en) * | 2004-01-07 | 2011-03-10 | Mark Edward Brennan Smith | Modified Molecular Arrays |
GB0400584D0 (en) * | 2004-01-12 | 2004-02-11 | Solexa Ltd | Nucleic acid chacterisation |
ES2432040T3 (en) | 2004-01-28 | 2013-11-29 | 454 Life Sciences Corporation | Nucleic acid amplification with continuous flow emulsion |
GB0402895D0 (en) | 2004-02-10 | 2004-03-17 | Solexa Ltd | Arrayed polynucleotides |
DE602005020421D1 (en) | 2004-02-19 | 2010-05-20 | Helicos Biosciences Corp | METHOD FOR THE ANALYSIS OF POLYNUCLEOTIDE SEQUENCES |
CN1950519A (en) | 2004-02-27 | 2007-04-18 | 哈佛大学的校长及成员们 | Polony fluorescent in situ sequencing beads |
KR100552706B1 (en) | 2004-03-12 | 2006-02-20 | 삼성전자주식회사 | Method and apparatus for nucleic acid amplification |
US20050214840A1 (en) | 2004-03-23 | 2005-09-29 | Xiangning Chen | Restriction enzyme mediated method of multiplex genotyping |
GB2413796B (en) * | 2004-03-25 | 2006-03-29 | Global Genomics Ab | Methods and means for nucleic acid sequencing |
EP1740719B1 (en) | 2004-04-09 | 2011-06-22 | Trustees of Boston University | Method for de novo detection of sequences in nucleic acids:target sequencing by fragmentation |
US20050260609A1 (en) | 2004-05-24 | 2005-11-24 | Lapidus Stanley N | Methods and devices for sequencing nucleic acids |
US7635562B2 (en) * | 2004-05-25 | 2009-12-22 | Helicos Biosciences Corporation | Methods and devices for nucleic acid sequence determination |
US20070117104A1 (en) | 2005-11-22 | 2007-05-24 | Buzby Philip R | Nucleotide analogs |
US7565346B2 (en) | 2004-05-31 | 2009-07-21 | International Business Machines Corporation | System and method for sequence-based subspace pattern clustering |
US20060024711A1 (en) | 2004-07-02 | 2006-02-02 | Helicos Biosciences Corporation | Methods for nucleic acid amplification and sequence determination |
US7276720B2 (en) | 2004-07-19 | 2007-10-02 | Helicos Biosciences Corporation | Apparatus and methods for analyzing samples |
US20060012793A1 (en) | 2004-07-19 | 2006-01-19 | Helicos Biosciences Corporation | Apparatus and methods for analyzing samples |
WO2006073504A2 (en) | 2004-08-04 | 2006-07-13 | President And Fellows Of Harvard College | Wobble sequencing |
US20060073506A1 (en) | 2004-09-17 | 2006-04-06 | Affymetrix, Inc. | Methods for identifying biological samples |
GB0422551D0 (en) | 2004-10-11 | 2004-11-10 | Univ Liverpool | Labelling and sequencing of nucleic acids |
US20060110764A1 (en) | 2004-10-25 | 2006-05-25 | Tom Tang | Large-scale parallelized DNA sequencing |
JP2008520975A (en) | 2004-11-16 | 2008-06-19 | ヘリコス バイオサイエンシーズ コーポレイション | TIRF single molecule analysis and method for sequencing nucleic acids |
CA2586228A1 (en) | 2004-11-17 | 2006-05-26 | The University Of Chicago | Histone deacetylase inhibitors and methods of use |
WO2006074351A2 (en) | 2005-01-05 | 2006-07-13 | Agencourt Personal Genomics | Reversible nucleotide terminators and uses thereof |
WO2006084132A2 (en) | 2005-02-01 | 2006-08-10 | Agencourt Bioscience Corp. | Reagents, methods, and libraries for bead-based squencing |
US7393665B2 (en) | 2005-02-10 | 2008-07-01 | Population Genetics Technologies Ltd | Methods and compositions for tagging and identifying polynucleotides |
US20060223122A1 (en) | 2005-03-08 | 2006-10-05 | Agnes Fogo | Classifying and predicting glomerulosclerosis using a proteomics approach |
US8110196B2 (en) | 2005-04-29 | 2012-02-07 | Polytopas LLC | Methods and compositions for polytopic vaccination |
US20060263789A1 (en) * | 2005-05-19 | 2006-11-23 | Robert Kincaid | Unique identifiers for indicating properties associated with entities to which they are attached, and methods for using |
EP2463386B1 (en) | 2005-06-15 | 2017-04-12 | Complete Genomics Inc. | Nucleic acid analysis by random mixtures of non-overlapping fragments |
CA2616433A1 (en) | 2005-07-28 | 2007-02-01 | Helicos Biosciences Corporation | Consecutive base single molecule sequencing |
US20090291419A1 (en) * | 2005-08-01 | 2009-11-26 | Kazuaki Uekawa | System of sound representaion and pronunciation techniques for english and other european languages |
EP1910688A4 (en) | 2005-08-04 | 2010-03-03 | Helicos Biosciences Corp | Multi-channel flow cells |
DK1915446T3 (en) | 2005-08-11 | 2017-09-11 | Synthetic Genomics Inc | IN VITRO RECOMBINATION PROCEDURE |
US7666593B2 (en) | 2005-08-26 | 2010-02-23 | Helicos Biosciences Corporation | Single molecule sequencing of captured nucleic acids |
CA2910861C (en) | 2005-09-29 | 2018-08-07 | Michael Josephus Theresia Van Eijk | High throughput screening of mutagenized populations |
AU2012216376B2 (en) | 2005-10-07 | 2015-08-13 | Complete Genomics, Inc. | High throughput genome sequencing on DNA arrays |
AU2013202990B2 (en) | 2005-10-07 | 2015-08-20 | Complete Genomics, Inc. | High throughput genome sequencing on DNA arrays |
US7960104B2 (en) | 2005-10-07 | 2011-06-14 | Callida Genomics, Inc. | Self-assembled single molecule arrays and uses thereof |
CA2624896C (en) | 2005-10-07 | 2017-11-07 | Callida Genomics, Inc. | Self-assembled single molecule arrays and uses thereof |
WO2007133831A2 (en) | 2006-02-24 | 2007-11-22 | Callida Genomics, Inc. | High throughput genome sequencing on dna arrays |
WO2007120208A2 (en) * | 2005-11-14 | 2007-10-25 | President And Fellows Of Harvard College | Nanogrid rolling circle dna sequencing |
WO2007087310A2 (en) * | 2006-01-23 | 2007-08-02 | Population Genetics Technologies Ltd. | Nucleic acid analysis using sequence tokens |
WO2007092538A2 (en) * | 2006-02-07 | 2007-08-16 | President And Fellows Of Harvard College | Methods for making nucleotide probes for sequencing and synthesis |
CN101415839B (en) | 2006-02-08 | 2012-06-27 | 亿明达剑桥有限公司 | Method for sequencing a polynucleotide template |
US8460879B2 (en) * | 2006-02-21 | 2013-06-11 | The Trustees Of Tufts College | Methods and arrays for target analyte detection and determination of target analyte concentration in solution |
SG10201405158QA (en) | 2006-02-24 | 2014-10-30 | Callida Genomics Inc | High throughput genome sequencing on dna arrays |
CA2647786A1 (en) * | 2006-03-14 | 2007-09-20 | Genizon Biosciences Inc. | Methods and means for nucleic acid sequencing |
DE102006015433A1 (en) | 2006-03-31 | 2007-10-04 | Reuver, Hermannus S.F. | Soil-processing of red mud comprises mixing the red mud with a soil substrate to form soil-mixture, spreading the mixture on a processing surface, adding soil processing worms into the mixture, and biologically processing by the worms |
US7359610B2 (en) | 2006-04-03 | 2008-04-15 | Adc Telecommunications, Inc. | Cable manager including nestable radius limiter |
US7569979B2 (en) | 2006-04-07 | 2009-08-04 | Federal-Mogul World Wide, Inc. | Spark plug having spark portion provided with a base material and a protective material |
US20090062129A1 (en) | 2006-04-19 | 2009-03-05 | Agencourt Personal Genomics, Inc. | Reagents, methods, and libraries for gel-free bead-based sequencing |
EP2047910B1 (en) | 2006-05-11 | 2012-01-11 | Raindance Technologies, Inc. | Microfluidic device and method |
WO2008070352A2 (en) | 2006-10-27 | 2008-06-12 | Complete Genomics, Inc. | Efficient arrays of amplified polynucleotides |
US20090111706A1 (en) | 2006-11-09 | 2009-04-30 | Complete Genomics, Inc. | Selection of dna adaptor orientation by amplification |
WO2008092155A2 (en) | 2007-01-26 | 2008-07-31 | Illumina, Inc. | Image data efficient genetic sequencing method and system |
JP5258760B2 (en) | 2007-06-08 | 2013-08-07 | 合同会社Bio−Dixam | Method for amplifying methylated or unmethylated nucleic acid |
EP2188386A2 (en) | 2007-09-17 | 2010-05-26 | Universite De Strasbourg | Method for detecting or quantifying a truncating mutation |
US8268564B2 (en) | 2007-09-26 | 2012-09-18 | President And Fellows Of Harvard College | Methods and applications for stitched DNA barcodes |
US7897344B2 (en) * | 2007-11-06 | 2011-03-01 | Complete Genomics, Inc. | Methods and oligonucleotide designs for insertion of multiple adaptors into library constructs |
US8518640B2 (en) | 2007-10-29 | 2013-08-27 | Complete Genomics, Inc. | Nucleic acid sequencing and process |
WO2009061840A1 (en) * | 2007-11-05 | 2009-05-14 | Complete Genomics, Inc. | Methods and oligonucleotide designs for insertion of multiple adaptors employing selective methylation |
US8592150B2 (en) | 2007-12-05 | 2013-11-26 | Complete Genomics, Inc. | Methods and compositions for long fragment read sequencing |
CN102016068A (en) | 2008-01-09 | 2011-04-13 | 生命科技公司 | Method of making a paired tag library for nucleic acid sequencing |
US20090298131A1 (en) | 2008-02-19 | 2009-12-03 | Intelligent Biosystems, Inc. | Non-Emulsion Methods And Masked Biomolecules |
CA2731219A1 (en) | 2008-07-18 | 2010-01-21 | Ideapaint, Inc. | Ambient cure solvent-based coatings for writable-erasable surfaces |
US8407554B2 (en) | 2009-02-03 | 2013-03-26 | Complete Genomics, Inc. | Method and apparatus for quantification of DNA sequencing quality and construction of a characterizable model system using Reed-Solomon codes |
US9524369B2 (en) * | 2009-06-15 | 2016-12-20 | Complete Genomics, Inc. | Processing and analysis of complex nucleic acid sequence data |
CN102725424B (en) | 2010-01-25 | 2014-07-09 | Rd生物科技公司 | Self-folding amplification of target nucleic acid |
US9506112B2 (en) | 2010-02-05 | 2016-11-29 | Siemens Healthcare Diagnostics Inc. | Increasing multiplex level by externalization of passive reference in polymerase chain reactions |
EP2363502B1 (en) | 2010-03-04 | 2017-02-15 | miacom Diagnostics GmbH | Enhanced multiplex FISH |
DE202011003570U1 (en) | 2010-03-06 | 2012-01-30 | Illumina, Inc. | Systems and apparatus for detecting optical signals from a sample |
WO2012098599A1 (en) | 2011-01-17 | 2012-07-26 | パナソニック株式会社 | Imaging device |
CN103843001B (en) * | 2011-04-14 | 2017-06-09 | 考利达基因组股份有限公司 | The treatment and analysis of complex nucleic acid sequence data |
WO2012162161A1 (en) | 2011-05-20 | 2012-11-29 | Phthisis Diagnostics | Microsporidia detection system and method |
US9006630B2 (en) | 2012-01-13 | 2015-04-14 | Altasens, Inc. | Quality of optically black reference pixels in CMOS iSoCs |
AU2013266394B2 (en) | 2012-05-21 | 2019-03-14 | The Scripps Research Institute | Methods of sample preparation |
US9146248B2 (en) | 2013-03-14 | 2015-09-29 | Intelligent Bio-Systems, Inc. | Apparatus and methods for purging flow cells in nucleic acid sequencing instruments |
-
2006
- 2006-06-13 EP EP12150825.3A patent/EP2463386B1/en active Active
- 2006-06-13 JP JP2008516994A patent/JP5331476B2/en active Active
- 2006-06-13 WO PCT/US2006/022950 patent/WO2006138284A2/en active Application Filing
- 2006-06-13 CN CN200680029826.4A patent/CN101466847B/en active Active
- 2006-06-13 US US11/451,692 patent/US7709197B2/en active Active
- 2006-06-13 EP EP06760745.7A patent/EP1907571B1/en active Active
- 2006-06-13 EP EP06784802.8A patent/EP1907583B2/en active Active
- 2006-06-13 CA CA2611743A patent/CA2611743C/en active Active
- 2006-06-13 AU AU2006259565A patent/AU2006259565B2/en active Active
- 2006-06-13 EP EP17167651.3A patent/EP3257949A1/en not_active Withdrawn
- 2006-06-13 WO PCT/US2006/022895 patent/WO2006138257A2/en active Application Filing
- 2006-06-13 DK DK12150825.3T patent/DK2463386T3/en active
- 2006-06-13 EP EP18202997.5A patent/EP3492602A1/en not_active Withdrawn
- 2006-06-13 CA CA2611671A patent/CA2611671C/en active Active
- 2006-06-13 US US11/451,691 patent/US8445194B2/en active Active
- 2006-06-13 SG SG201004212-5A patent/SG162795A1/en unknown
- 2006-06-13 DK DK12180882.8T patent/DK2620510T4/en active
- 2006-06-13 EP EP12180882.8A patent/EP2620510B2/en active Active
- 2006-06-13 EP EP20140198079 patent/EP2865766A1/en not_active Withdrawn
- 2006-06-13 DK DK06760745.7T patent/DK1907571T3/en active
- 2006-06-13 DK DK06784802.8T patent/DK1907583T4/en active
-
2007
- 2007-10-31 US US11/981,607 patent/US8133719B2/en active Active
- 2007-10-31 US US11/982,467 patent/US8445197B2/en active Active
- 2007-10-31 US US11/981,767 patent/US8445196B2/en active Active
- 2007-12-13 IL IL188142A patent/IL188142A/en active IP Right Grant
-
2008
- 2008-12-15 US US12/335,168 patent/US7901891B2/en active Active
-
2010
- 2010-09-15 US US12/882,880 patent/US20110071053A1/en not_active Abandoned
-
2011
- 2011-01-31 US US13/017,244 patent/US8765379B2/en active Active
- 2011-06-14 JP JP2011132349A patent/JP5965108B2/en active Active
-
2013
- 2013-07-30 US US13/954,778 patent/US8673562B2/en active Active
- 2013-08-08 US US13/962,893 patent/US8765375B2/en active Active
- 2013-08-20 US US13/971,797 patent/US10125392B2/en active Active
- 2013-08-20 US US13/971,806 patent/US9637785B2/en active Active
- 2013-08-20 US US13/971,801 patent/US9637784B2/en active Active
- 2013-08-23 US US13/975,223 patent/US8765382B2/en active Active
- 2013-08-23 US US13/975,234 patent/US8771958B2/en active Active
- 2013-08-23 US US13/975,215 patent/US8771957B2/en active Active
-
2014
- 2014-02-20 JP JP2014030924A patent/JP2014138597A/en active Pending
- 2014-12-24 US US14/583,010 patent/US20150159204A1/en not_active Abandoned
-
2015
- 2015-05-15 US US14/714,133 patent/US9650673B2/en active Active
- 2015-10-08 IL IL241986A patent/IL241986A0/en unknown
- 2015-10-26 HK HK15110524.7A patent/HK1209795A1/en unknown
-
2016
- 2016-04-15 JP JP2016082087A patent/JP2016174608A/en active Pending
-
2017
- 2017-02-06 US US15/425,791 patent/US9944984B2/en active Active
- 2017-02-25 US US15/442,659 patent/US10351909B2/en active Active
- 2017-09-26 US US15/716,314 patent/US20180051333A1/en not_active Abandoned
-
2019
- 2019-05-29 US US16/425,846 patent/US20200115748A1/en not_active Abandoned
- 2019-12-30 US US16/730,829 patent/US11414702B2/en active Active
-
2020
- 2020-08-14 US US16/994,343 patent/US20200392574A1/en not_active Abandoned
-
2021
- 2021-11-09 US US17/522,708 patent/US20220162694A1/en active Pending
-
2022
- 2022-07-14 US US17/864,913 patent/US20220411865A1/en active Pending
- 2022-07-14 US US17/864,916 patent/US20220411866A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020076716A1 (en) | 1998-04-09 | 2002-06-20 | Trustees Of Boston University | Nucleic acid arrays and methods of synthesis |
US6355419B1 (en) | 1998-04-27 | 2002-03-12 | Hyseq, Inc. | Preparation of pools of nucleic acids based on representation in a sample |
US20020012930A1 (en) | 1999-09-16 | 2002-01-31 | Rothberg Jonathan M. | Method of sequencing a nucleic acid |
WO2003102231A1 (en) | 2002-05-29 | 2003-12-11 | Axaron Bioscience Ag | Method for parallelly sequencing a nucleic acid mixture by using a continuous flow system |
WO2004076683A2 (en) | 2003-02-26 | 2004-09-10 | Callida Genomics, Inc. | Random array dna analysis by hybridization |
Non-Patent Citations (2)
Title |
---|
LADNER ET AL., LABORATORY INVESTIGATION, vol. 81, no. 8, August 2001 (2001-08-01), pages 1079 - 1086 |
See also references of EP1907583A4 |
Cited By (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7846733B2 (en) | 2000-06-26 | 2010-12-07 | Nugen Technologies, Inc. | Methods and compositions for transcription-based nucleic acid amplification |
US7771934B2 (en) | 2000-12-13 | 2010-08-10 | Nugen Technologies, Inc. | Methods and compositions for generation of multiple copies of nucleic acid sequences and methods of detection thereof |
US8334116B2 (en) | 2000-12-13 | 2012-12-18 | Nugen Technologies, Inc. | Methods and compositions for generation of multiple copies of nucleic acid sequences and methods of detection thereof |
US9181582B2 (en) | 2001-03-09 | 2015-11-10 | Nugen Technologies, Inc. | Compositions for amplification of RNA sequences using composite primers |
US8071311B2 (en) | 2001-03-09 | 2011-12-06 | Nugen Technologies, Inc. | Methods and compositions for amplification of RNA sequences |
US7771946B2 (en) | 2001-03-09 | 2010-08-10 | Nugen Technologies, Inc. | Methods, kits and compositions for single primer linear isothermal amplification of nucleic acid sequences |
US9175325B2 (en) | 2003-04-14 | 2015-11-03 | Nugen Technologies, Inc. | Global amplification using a randomly primed composite primer |
US8465950B2 (en) | 2003-04-14 | 2013-06-18 | Nugen Technologies, Inc. | Global amplification using a randomly primed composite primer |
US8765379B2 (en) | 2005-06-15 | 2014-07-01 | Callida Genomics, Inc. | Nucleic acid sequence analysis from combined mixtures of amplified fragments |
EP3492602A1 (en) | 2005-06-15 | 2019-06-05 | Complete Genomics, Inc. | Single molecule arrays for genetic and chemical analysis |
US9637784B2 (en) | 2005-06-15 | 2017-05-02 | Complete Genomics, Inc. | Methods for DNA sequencing and analysis using multiple tiers of aliquots |
US10351909B2 (en) | 2005-06-15 | 2019-07-16 | Complete Genomics, Inc. | DNA sequencing from high density DNA arrays using asynchronous reactions |
US9637785B2 (en) | 2005-06-15 | 2017-05-02 | Complete Genomics, Inc. | Tagged fragment library configured for genome or cDNA sequence analysis |
US8771958B2 (en) | 2005-06-15 | 2014-07-08 | Callida Genomics, Inc. | Nucleotide sequence from amplicon subfragments |
US9944984B2 (en) | 2005-06-15 | 2018-04-17 | Complete Genomics, Inc. | High density DNA array |
US10125392B2 (en) | 2005-06-15 | 2018-11-13 | Complete Genomics, Inc. | Preparing a DNA fragment library for sequencing using tagged primers |
US8771957B2 (en) | 2005-06-15 | 2014-07-08 | Callida Genomics, Inc. | Sequencing using a predetermined coverage amount of polynucleotide fragments |
US8765375B2 (en) | 2005-06-15 | 2014-07-01 | Callida Genomics, Inc. | Method for sequencing polynucleotides by forming separate fragment mixtures |
US8765382B2 (en) | 2005-06-15 | 2014-07-01 | Callida Genomics, Inc. | Genome sequence analysis using tagged amplicons |
US8673562B2 (en) | 2005-06-15 | 2014-03-18 | Callida Genomics, Inc. | Using non-overlapping fragments for nucleic acid sequencing |
US11414702B2 (en) | 2005-06-15 | 2022-08-16 | Complete Genomics, Inc. | Nucleic acid analysis by random mixtures of non-overlapping fragments |
EP2865766A1 (en) | 2005-06-15 | 2015-04-29 | Callida Genomics, Inc. | Single molecule arrays for genetic and chemical analysis |
EP2620510A1 (en) | 2005-06-15 | 2013-07-31 | Callida Genomics, Inc. | Single molecule arrays for genetic and chemical analysis |
US7939258B2 (en) | 2005-09-07 | 2011-05-10 | Nugen Technologies, Inc. | Nucleic acid amplification procedure using RNA and DNA composite primers |
US8852867B2 (en) | 2005-09-07 | 2014-10-07 | Nugen Technologies, Inc. | Nucleic acid amplification procedure using RNA and DNA composite primers |
EP2546360A1 (en) * | 2005-10-07 | 2013-01-16 | Callida Genomics, Inc. | Self-assembled single molecule arrays and uses thereof |
EP1994180A2 (en) * | 2006-02-24 | 2008-11-26 | Callida Genomics, Inc. | High throughput genome sequencing on dna arrays |
EP2495337A1 (en) * | 2006-02-24 | 2012-09-05 | Callida Genomics, Inc. | High throughput genome sequencing on DNA arrays |
EP1994180A4 (en) * | 2006-02-24 | 2009-11-25 | Callida Genomics Inc | High throughput genome sequencing on dna arrays |
WO2007124651A1 (en) * | 2006-04-26 | 2007-11-08 | Zuhong Lu | An array chip of multiple copies of unimolecular nucleic acids |
US9228228B2 (en) | 2006-10-27 | 2016-01-05 | Complete Genomics, Inc. | Efficient arrays of amplified polynucleotides |
US9334490B2 (en) | 2006-11-09 | 2016-05-10 | Complete Genomics, Inc. | Methods and compositions for large-scale analysis of nucleic acids using DNA deletions |
US9680163B2 (en) | 2007-07-26 | 2017-06-13 | Plansee Se | Fuel cell and method for production thereof |
WO2009034181A3 (en) * | 2007-09-14 | 2009-04-30 | Twof Inc | Methods for the preparation of dna microarrays with linear high density probes |
WO2009034181A2 (en) * | 2007-09-14 | 2009-03-19 | Twof, Inc. | Methods for the preparation of dna microarrays with linear high density probes |
AU2008307617B2 (en) * | 2007-09-28 | 2013-05-23 | Pacific Biosciences Of California, Inc. | Error-free amplification of DNA for clonal sequencing |
WO2009045344A2 (en) | 2007-09-28 | 2009-04-09 | Pacific Biosciences Of California, Inc. | Error-free amplification of dna for clonal sequencing |
EP2203566A4 (en) * | 2007-09-28 | 2011-02-09 | Pacific Biosciences California | Error-free amplification of dna for clonal sequencing |
US8003330B2 (en) | 2007-09-28 | 2011-08-23 | Pacific Biosciences Of California, Inc. | Error-free amplification of DNA for clonal sequencing |
EP2203566A2 (en) * | 2007-09-28 | 2010-07-07 | Pacific Biosciences of California, Inc. | Error-free amplification of dna for clonal sequencing |
US8951731B2 (en) | 2007-10-15 | 2015-02-10 | Complete Genomics, Inc. | Sequence analysis using decorated nucleic acids |
US9267172B2 (en) | 2007-11-05 | 2016-02-23 | Complete Genomics, Inc. | Efficient base determination in sequencing reactions |
US9238834B2 (en) | 2007-11-29 | 2016-01-19 | Complete Genomics, Inc. | Efficient shotgun sequencing methods |
CN103290106B (en) * | 2007-12-05 | 2015-07-29 | 考利达基因组股份有限公司 | In sequencing reaction, base effectively determines |
JP2011520420A (en) * | 2007-12-05 | 2011-07-21 | コンプリート・ジェノミックス・インコーポレイテッド | Efficient base determination in sequencing reactions |
US9499863B2 (en) | 2007-12-05 | 2016-11-22 | Complete Genomics, Inc. | Reducing GC bias in DNA sequencing using nucleotide analogs |
US11389779B2 (en) | 2007-12-05 | 2022-07-19 | Complete Genomics, Inc. | Methods of preparing a library of nucleic acid fragments tagged with oligonucleotide bar code sequences |
US11098356B2 (en) | 2008-01-28 | 2021-08-24 | Complete Genomics, Inc. | Methods and compositions for nucleic acid sequencing |
US10662473B2 (en) | 2008-01-28 | 2020-05-26 | Complete Genomics, Inc. | Methods and compositions for efficient base calling in sequencing reactions |
US11214832B2 (en) | 2008-01-28 | 2022-01-04 | Complete Genomics, Inc. | Methods and compositions for efficient base calling in sequencing reactions |
US9222132B2 (en) | 2008-01-28 | 2015-12-29 | Complete Genomics, Inc. | Methods and compositions for efficient base calling in sequencing reactions |
US9523125B2 (en) | 2008-01-28 | 2016-12-20 | Complete Genomics, Inc. | Methods and compositions for efficient base calling in sequencing reactions |
US8034568B2 (en) | 2008-02-12 | 2011-10-11 | Nugen Technologies, Inc. | Isothermal nucleic acid amplification methods and compositions |
US7846666B2 (en) | 2008-03-21 | 2010-12-07 | Nugen Technologies, Inc. | Methods of RNA amplification in the presence of DNA |
US20090270273A1 (en) * | 2008-04-21 | 2009-10-29 | Complete Genomics, Inc. | Array structures for nucleic acid detection |
US9524369B2 (en) | 2009-06-15 | 2016-12-20 | Complete Genomics, Inc. | Processing and analysis of complex nucleic acid sequence data |
WO2011123246A3 (en) * | 2010-04-01 | 2013-05-30 | Illumina, Inc. | Solid-phase clonal amplification and related methods |
US9574234B2 (en) | 2010-04-01 | 2017-02-21 | Illumina, Inc. | Solid-phase clonal amplification and related methods |
US8951940B2 (en) | 2010-04-01 | 2015-02-10 | Illumina, Inc. | Solid-phase clonal amplification and related methods |
US9359641B2 (en) | 2010-04-30 | 2016-06-07 | Complete Genomics, Inc. | Method and system for accurate alignment and registration of array for DNA sequencing |
US8725422B2 (en) | 2010-10-13 | 2014-05-13 | Complete Genomics, Inc. | Methods for estimating genome-wide copy number variations |
US9249460B2 (en) | 2011-09-09 | 2016-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for obtaining a sequence |
US9725765B2 (en) | 2011-09-09 | 2017-08-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for obtaining a sequence |
US11312992B2 (en) | 2011-10-14 | 2022-04-26 | President And Fellows Of Harvard College | Sequencing by structure assembly |
EP2774978A4 (en) * | 2011-10-31 | 2015-07-15 | Hitachi High Tech Corp | Nucleic acid amplification method, nucleic acid substrate, nucleic acid analysis method, and nucleic acid analysis device |
US11566276B2 (en) | 2011-12-22 | 2023-01-31 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11293052B2 (en) | 2011-12-22 | 2022-04-05 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11293054B2 (en) | 2011-12-22 | 2022-04-05 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11566277B2 (en) | 2011-12-22 | 2023-01-31 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11021737B2 (en) | 2011-12-22 | 2021-06-01 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11639518B2 (en) | 2011-12-22 | 2023-05-02 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11293051B2 (en) | 2011-12-22 | 2022-04-05 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11549136B2 (en) | 2011-12-22 | 2023-01-10 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US11111521B2 (en) | 2011-12-22 | 2021-09-07 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
WO2013166517A1 (en) | 2012-05-04 | 2013-11-07 | Complete Genomics, Inc. | Methods for determining absolute genome-wide copy number variations of complex tumors |
US11473139B2 (en) | 2012-06-05 | 2022-10-18 | President And Fellows Of Harvard College | Spatial sequencing of nucleic acids using DNA origami probes |
CN104969065A (en) * | 2013-02-07 | 2015-10-07 | 皇家飞利浦有限公司 | Processing of nucleotide sequences |
WO2014122548A3 (en) * | 2013-02-07 | 2014-11-20 | Koninklijke Philips N.V. | Processing of nucleotide sequences |
EP3603794A1 (en) * | 2013-02-26 | 2020-02-05 | Illumina, Inc. | Gel patterned surfaces |
US11173466B2 (en) | 2013-02-26 | 2021-11-16 | Illumina, Inc. | Gel patterned surfaces |
WO2014133905A1 (en) * | 2013-02-26 | 2014-09-04 | Illumina, Inc. | Gel patterned surfaces |
EP3834924A1 (en) * | 2013-02-26 | 2021-06-16 | Illumina Inc | Gel patterned surfaces |
US10668444B2 (en) | 2013-02-26 | 2020-06-02 | Illumina, Inc. | Gel patterned surfaces |
US9512422B2 (en) | 2013-02-26 | 2016-12-06 | Illumina, Inc. | Gel patterned surfaces |
US11078520B2 (en) | 2013-03-12 | 2021-08-03 | President And Fellows Of Harvard College | Method for generating a three-dimensional nucleic acid containing matrix |
US11299767B2 (en) | 2013-03-12 | 2022-04-12 | President And Fellows Of Harvard College | Method for generating a three-dimensional nucleic acid containing matrix |
US10960377B2 (en) | 2014-12-15 | 2021-03-30 | Illumina, Inc. | Compositions and methods for single molecular placement on a substrate |
US10350570B2 (en) | 2014-12-15 | 2019-07-16 | Illumina, Inc. | Compositions and methods for single molecular placement on a substrate |
WO2016100196A1 (en) * | 2014-12-15 | 2016-06-23 | Illumina, Inc. | Compositions and methods for single molecular placement on a substrate |
EP3882356A1 (en) * | 2014-12-15 | 2021-09-22 | Illumina, Inc. | Compositions and methods for single molecular placement on a substrate |
US11118220B2 (en) | 2015-11-03 | 2021-09-14 | President And Fellows Of Harvard College | Method and apparatus for volumetric imaging of a three-dimensional nucleic acid containing matrix |
US11542554B2 (en) | 2015-11-03 | 2023-01-03 | President And Fellows Of Harvard College | Method and apparatus for volumetric imaging |
GB2559526B (en) * | 2015-11-03 | 2021-02-17 | Harvard College | Method and apparatus for volumetric imaging of a three-dimensional nucleic acid containing matrix |
US11713485B2 (en) | 2016-04-25 | 2023-08-01 | President And Fellows Of Harvard College | Hybridization chain reaction methods for in situ molecular detection |
US11718874B2 (en) | 2016-04-25 | 2023-08-08 | President And Fellows Of Harvard College | Hybridization chain reaction methods for in situ molecular detection |
US11447807B2 (en) | 2016-08-31 | 2022-09-20 | President And Fellows Of Harvard College | Methods of combining the detection of biomolecules into a single assay using fluorescent in situ sequencing |
US11085072B2 (en) | 2016-08-31 | 2021-08-10 | President And Fellows Of Harvard College | Methods of generating libraries of nucleic acid sequences for detection via fluorescent in situ sequencing |
EP3818166A4 (en) * | 2018-07-05 | 2022-03-30 | AccuraGen Holdings Limited | Compositions and methods for digital polymerase chain reaction |
US11193163B2 (en) | 2018-07-30 | 2021-12-07 | Readcoor, Llc | Methods and systems for sample processing or analysis |
GB2613480A (en) * | 2018-11-15 | 2023-06-07 | Element Biosciences Inc | Methods for generating circular nucleic acid molecules |
GB2613480B (en) * | 2018-11-15 | 2023-11-22 | Element Biosciences Inc | Methods for generating circular nucleic acid molecules |
WO2022008931A1 (en) * | 2020-07-10 | 2022-01-13 | Vidya Holdings Ltd | Improvements in or relating to an apparatus for imaging |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10351909B2 (en) | DNA sequencing from high density DNA arrays using asynchronous reactions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680029826.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2611671 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 188142 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2008516994 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006259565 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2006784802 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006784802 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006259565 Country of ref document: AU Date of ref document: 20060613 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 241986 Country of ref document: IL |